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Abstract 
 
Reduced physical activity is an important feature of Chronic Obstructive Pulmonary Disease (COPD). 
This thesis explores the importance of technical, environmental and patient factors in physical activity 
in COPD.  
 
Activity monitors are integral in accurately measuring physical activity in COPD but, to date, 
commercially available monitors had not been satisfactorily validated in this patient group. The first 
study (Chapter 3) was a multicentre validation study of 6 different physical activity monitors in a 
laboratory setting in 40 COPD patients, against a gold standard of indirect calorimetry from a portable 
metabolic kit. Validity was assessed by correlation of each monitor output with indirect calorimetry 
during a standardised activity protocol (including slow and fast walking, sitting, standing, lifting and 
stair climbing). From this method, three triaxial accelerometers were found to be the most accurate 
activity monitors (SenseWear Armband, Actigraph GT3X and Dynaport MiniMod). The Dynaport 
MiniMod and Actigraph GT3X were best able to discriminate between different walking speeds. 
 
Chapter 4 describes a further validation study of 3 of the activity monitors used in Chapter 3, as well 
as a novel activity monitor (the Imperial eAR monitor) in a domestic setting in 20 UK-based patients. 
Monitor outputs were assessed against a gold standard of indirect calorimetry from the doubly 
labelled water method.  
 
Chapter 5 describes a multicentre longitudinal study of 236 COPD patients. Physical activity was 
measured at 3 different time points over 12 months with 2 triaxial monitors (Actigraph GT3X and 
Dynaport MiniMod) previously validated in the laboratory study (Chapter 3) with the aim to assess the 
effect of time, geographic location and climatic conditions on physical activity. There was a significant 
effect of time with a decline in physical activity over time. There was no effect of centre on activity 
despite differences in baseline characteristics. These changes were demonstrated with both activity 
monitors. There was also a significant effect of temperature and day length with lower levels of activity 
associated with lower temperatures and shorter day length, although the effect of day length was only 
demonstrated with the Actigraph device. This has implications for future studies in COPD using 
physical activity as an outcome measure, in terms of adjusting for climatic conditions in multicentre 
trials. In addition, a decline in physical activity over time across several European centres supports 
the importance of physical activity in the course of COPD and early intervention to attenuate its 
decline. 
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The breathing response to the initiation of exercise in COPD and its association with daily physical 
activity levels was investigated (Chapter 6). A rapid shallow pattern of breathing on exertion is 
commonly found in COPD, which worsens with disease severity. Dyspnoea is arguably the most 
important symptom that limits patients during exertion and behavioural adoption of this maladaptive 
breathing pattern early in exercise was hypothesised to be associated with lower levels of daily 
physical activity; however, this link was not found. Tackling the perception of dyspnoea during 
physical activity successfully may enable patients to be less symptomatic and therefore increase their 
daily activity levels, which could attenuate disease progression. This represents an important 
therapeutic target. 
 
Further work assessing a semi-automated coaching tool with a smart phone and pedometer in an 
interventional study to increase physical activity in COPD is ongoing, The use of devices in both 
research and clinical settings in both COPD as well as other patient groups to increase physical 
activity levels remains an exciting opportunity for future work.  
6 
 
Publications arising from this thesis 
 
Raste Y, Langer D, Burtin C, Louvaris Z, Giavedoni S, Costa F, Wilson F, Rabinovich R, Hopkinson 
N, Vogiatzis I, Peterson B, Troosters T. Validity of 6 activity monitors during standard physical 
activities in COPD – Comparison with indirect calorimetry Presented as a spoken session at the 
annual ERS Congress, Amsterdam 2011. 
 
Van Remoortel H & Raste Y, Louvaris Z, Giavedoni S, Burtin C, Langer D, Wilson F, Rabinovich R, 
Vogiatzis I, Hopkinson NS, Troosters T on behalf of the PROactive consortium. Validity of Six Activity 
Monitors in Chronic Obstructive Pulmonary Disease: A Comparison with Indirect Calorimetry. PLoS 
One. 7(6): p. e39198 
 
Rabinovich RA, Louvaris Z, Raste Y, Langer D, Van Remoortel D, Giavedoni, S, Burtin C, Regueiro 
E, Vogiatzis I, Hopkinson NS, Polkey MI, Wilson FJ, MacNee W, Westerterp KR, Troosters T on 
behalf of the PROactive consortium. Validity of physical activity monitors during daily life in patients 
with COPD. Eur Respir J, 2013. 42(5): p. 1205-15. 
 
Gimeno-Santos E, Raste Y, Demeyer H, Louvaris Z, de Jong C, Rabinovich RA, Hopkinson NS, 
Polkey MI, Vogiatzis I, Tabberer M, Dobbels, Ivanoff N, de Boer W, van der Molen T, Kulich K, Serra 
I, Basagana X, Troosters T, Karlsson & Garcia-Aymerich G on behalf of the PROactive consortium. 
The PROactive instruments to measure physical activity in patients with chronic obstructive 
pulmonary disease. Eur Respir J, 2015. 46(4): p. 988-1000. 
 
 
  
7 
 
Table of contents 
1 Introduction ........................................................................................................... 19 
1.1 Physical activity and COPD: summary .......................................................................... 19 
1.2 Physical activity ............................................................................................................... 21 
1.2.1 Patterns of physical activity………………………………………………………………… 21 
1.2.2 Physical activity: historical perspective…………………………………………………… 22 
1.2.3 Physical activity: the evidence……………………………………………………………... 24 
1.2.4 Physical activity: the benefits………………………………………………………………. 26 
 
1.3 Physical activity in COPD ............................................................................................... 28 
1.3.1 Pulmonary rehabilitation and the relationship with physical activity…………………… 29 
 
1.4 COPD pathophysiology ................................................................................................... 31 
1.4.1 Main pathological features of COPD……………………………………………………… 31 
1.4.2 Disease mechanisms………………………………………………………………………. 32 
1.4.3 COPD as a systemic disease……………………………………………………………… 34 
 
1.5 Mechanisms of exercise limitation in COPD ................................................................. 38 
1.5.1 Ventilatory factors…………………………………………………………………………… 38 
1.5.2 Other factors…………………………………………………………………………………. 40 
 
1.6 Measuring physical activity ............................................................................................ 41 
1.6.1 Physical activity questionnaires……………………………………………………………. 41 
1.6.2 Physical activity monitors…………………………………………………………………… 44 
1.6.3 Energy expenditure and physical activity………………………………………………… 45 
 
1.7 Physical activity and exercise capacity ......................................................................... 47 
1.7.1 The Borg scale of perceived exertion……………………………………………………... 48 
1.7.2 Cardiopulmonary exercise testing………………………………………………………… 48 
1.7.3 Field exercise capacity tests……………………………………………………………….. 51 
 
1.8 Physical activity: behaviour versus physiology? ......................................................... 54 
1.8.1 Barriers to physical activity…………………………………………………………………. 54 
 
8 
 
1.8.2 The effect of weather on physical activity………………………………………………… 55 
 
1.9 The PROactive project ..................................................................................................... 56 
1.10 Thesis aims ...................................................................................................................... 58 
2 Methods ................................................................................................................. 59 
2.1 Ethical approval ............................................................................................................... 59 
2.2 Statistical analysis ........................................................................................................... 59 
2.3 Study subjects ................................................................................................................. 59 
2.4 Pulmonary Function Testing .......................................................................................... 60 
2.5 Exercise testing ............................................................................................................... 60 
2.5.1 The Borg scale of perceived exertion…………………………………………………….. 60 
2.5.2 Six minute walking test (6MWT)…………………………………………………………… 61 
2.5.3 Cardiopulmonary exercise testing………………………………………………………… 62 
 
2.6 Indirect calorimetry.......................................................................................................... 64 
2.6.1 Indirect calorimetry: doubly labelled water (DLW) method……………………………… 64. 
2.6.2 Indirect calorimetry: ventilated hood method…………………………………………….. .64 
 
2.7 Measurement of muscle strength ................................................................................... 65 
2.8 Body composition analysis ............................................................................................ 65 
2.8.1 Bioelectrical impedence analysis (BIA)…………………………………………………… 65 
2.8.2 Dual energy x-ray absorptiometry (DEXA) scanning ……………………………………..66 
 
2.9 Health-related quality of life questionnaires ................................................................. 66 
2.9.1 The Medical Research Council Dyspnoea Scale………………………………………… 66 
2.9.2 The Chronic Respiratory Diseases Questionnaire (CRQ)……………………………… 67 
2.9.3 The St. George’s Respiratory Questionnaire (SGRQ)………………………………….. 67 
2.9.4 The COPD Assessment Test (CAT)………………………………………………………. 67 
2.9.5 The Clinical COPD Questionnaire (CCQ)………………………………………………… 68 
 
3 Laboratory validation of six activity monitors in COPD: a comparison with 
indirect calorimetry ..................................................................................................... 69 
9 
 
3.1 Introduction ...................................................................................................................... 69 
3.2 Materials and Methods .................................................................................................... 69 
3.2.1 Study subjects……………………………………………………………………………….. 69 
3.2.2 Study design…………………………………………………………………………………. 70 
3.2.3 Expired gases method of indirect calorimetry……………………………………………. 72 
 
3.3 Statistical analysis ........................................................................................................... 75 
3.3.1 Primary outcomes …………………………………………………………………………..76 
3.3.2 Secondary outcomes………………………………………………………………………. 76 
3.4 Results .............................................................................................................................. 76 
3.5 Discussion ........................................................................................................................ 83 
3.5.1 Significance of the findings ………………………………………………………………….83 
3.5.2 Critique of the method………………………………………………………………………. 84 
 
4 Domestic validation study of physical activity monitors in COPD in daily 
life ................................................................................................................................. 86 
4.1 Introduction ...................................................................................................................... 86 
4.1.1 The Imperial College eAR monitor………………………………………………………… 88 
 
4.2 Materials and methods .................................................................................................... 90 
4.2.1 Study subjects……………………………………………………………………………….. 90 
4.2.2 Study design…………………………………………………………………………………. 90 
4.2.3 Doubly labelled water method of indirect calorimetry…………………………………… 91 
4.2.4 Measurement of resting energy expenditure…………………………………………….. 91 
 
4.3 Statistical analysis ........................................................................................................... 92 
4.3.1 Primary outcomes …………………………………………………………………………....92 
4.3.2 Secondary outcomes……………………………………………………………………….. 92 
 
4.4 Results .............................................................................................................................. 93 
4.5 Discussion ...................................................................................................................... 100 
4.5.1 Significance of the findings ………………………………………………………………….100 
4.5.2 Critique of the method……………………………………………………………............... 101 
10 
 
5 Change in physical activity with time and climate in COPD ....................... 104 
5.1 Introduction .................................................................................................................... 104 
5.2 Materials and methods .................................................................................................. 106 
5.2.1 Study subjects……………………………………………………………………………….. 106 
5.2.2 Physical activity monitoring………………………………………………………………… 108 
5.2.3 Weather data………………………………………………………………………………… 108 
 
5.3 Data handling and statistical analysis ......................................................................... 108 
5.4 Results ............................................................................................................................ 110 
5.5 Discussion ...................................................................................................................... 121 
5.5.1 Significance of findings……………………………………………………………………... 121 
5.5.2 Limitations …………………………………………………………………………………….123 
 
5.6 Conclusion ..................................................................................................................... 124 
 
6 Changes in early exercise in patients with COPD and their association with 
daily physical activity ............................................................................................... 126 
6.1 Introduction .................................................................................................................... 126 
6.2 Methods .......................................................................................................................... 129 
6.2.1 Cardiopulmonary exercise testing………………………………………………………… 129 
6.2.2 Six minute walk tests………………………………………………………………………... 130 
6.2.3 Physical activity monitoring………………………………………………………………… 131 
 
6.3 Data analysis .................................................................................................................. 131 
6.3.1 Exercise data………………………………………………………………………………… 131 
6.3.2 Six minute walks…………………………………………………………………………….. 132 
6.3.3 Physical activity data………………………………………………………………………... 132 
 
6.4 Results ............................................................................................................................ 132 
6.4.1 Cardiopulmonary exercise testing………………………………………………………… 132 
6.4.2 Six minute walk tests………………………………………………………………………... 135 
 
6.5 Discussion ...................................................................................................................... 137 
11 
 
6.5.1 Significance of findings…………………………………………………………………….. 137 
6.5.2 Critique of the method……………………………………………………………………… 138 
6.5.3 Conclusions…………………………………………………………………………………. 140 
 
7 Conclusions and future work ........................................................................... 141 
7.1 Laboratory validation of six activity monitors in COPD: a comparison with indirect 
calorimetry. ................................................................................................................................. 141 
7.1.1 Summary of findings………………………………………………………………………… 141 
7.1.2 Limitations …………………………………………………………………………………….143 
7.1.3 Future work………………………………………………………………………………….. 143 
 
7.2 Domestic validation study of physical activity monitors in COPD in daily life ........ 145 
7.2.1 Summary of findings………………………………………………………………………… 145 
7.2.2 Limitations …………………………………………………………………………………….146 
7.2.3 Future work…………………………………………………………………………………... 148 
 
7.3 Change in physical activity with time and climate in COPD ...................................... 148 
7.3.1 Summary of findings………………………………………………………………………… 149 
7.3.2 Limitations …………………………………………………………………………………….150 
7.3.3 Future work…………………………………………………………………………………... 151 
 
7.4 Changes in early exercise in patients with COPD and their association with daily 
physical activity .......................................................................................................................... 152 
7.4.1 Summary of findings………………………………………………………………………… 152 
7.4.2 Limitations …………………………………………………………………………………….152 
 
7.5 Future research .............................................................................................................. 154 
7.5.1 Change in PRO over time………………………………………………………………….. 154 
7.5.2 Physical activity as an interventional therapy……………………………………………. 154 
7.5.3 Wider use of activity monitors – implications in public health …………………………...155 
7.5.4 Further study of the ventilator response to exercise in COPD…………………………. 156 
 
8 References .......................................................................................................... 158 
 
 
12 
 
List of figures 
Figure 3.1 Position of the activity monitors and metabolic kit .............................................................. 71 
Figure 1.1  Example of one patient’s experiment, showing indirect calorimetry data from the Oxycon 
Mobile (METs) plotted against the different activity monitor outputs………………………………….….77 
Figure 1.2  Minute-by-minute correlations (R) between activity monitor outputs and metabolic 
equivalents of task (METs) per patient………………………………………………………………………78 
Figure 3.4  Bland-Altman plot showing comparisons of manual step counts with Sensewear, Dynaport 
Minimod and Video step counts. ......................................................................................................... 79 
Figure 3.5  Bland Altman plot showing comparison of manual step count with Sensewear an Dynaport 
Minimod monitors for slow and fast paced walking ............................................................................. 80 
Figure 3.6  Mean correlations of each activity monitor output with indirect calorimetry (METs). ......... 81 
Figure 3.7  Bland regression analysis for each activity monitor output versus indirect calorimetry (IC).
 ............................................................................................................................................................ 82 
Figure 4.1  Imperial eAR monitor ........................................................................................................ 88 
Figure 4.2  Example of data from eAR monitor. .................................................................................. 89 
Figure 4.3  Coefficient of variation for each patient for each activity monitor. ..................................... 94 
Figure 4.4  Percentage difference in mean activity between weekday and weekend for activity monitor 
output (with maximum and minimum difference plotted on error bars) ............................................... 94 
Figure 4.5  Correlations between activity monitor outputs and 6 minute walk distance. ..................... 96 
Figure 4.6  Correlations between activity monitor outputs and active energy expenditure measured 
with doubly labelled water (AEE .......................................................................................................... 97 
Figure 4.7  Correlations between monitor outputs and AEE as calculated by the Weir method using 
measured REE values from the ventilated hood.. ............................................................................... 98 
Figure 4.8  Bland-Altman plot of Sensewear (SW) and RT3 energy expenditure (EE) versus total 
energy expenditure (TEE) as measured by the doubly labelled water method. .................................. 99 
Figure 4.9  Correlations between eAR activity index and other activity monitor outputs (significant 
correlations shown). .......................................................................................................................... 100 
Figure 5.1  WP4 study design . ......................................................................................................... 107 
Figure 6.1  Lung compliance as a function of respiratory rate in an emphysema patient  ................. 129 
Figure 6.2  Relationship of steps per day with FEV1, RV/TLC ratio, six minute walk distance and TLco
 .......................................................................................................................................................... 133 
Figure 6.3  Example from one patient: Area under curve for tidal volume (VT) and respiratory rate 
(RR) for first minute of loaded cycling. .............................................................................................. 134 
Figure 6.4  Graphs showing linear regression for area under curve for VT, RR and VT/RR ............. 134 
13 
 
Figure 6.5  Linear regression of K values for all patients plotted against time periods of 1 minute for 
rest, unloaded cycling, 10W, 20W and at peak exercise. .................................................................. 135 
Figure 6.6  Area under curve for VT and RR against steps per day for slow and fast walks. ............ 136 
Figure 6.7  AUC VT to AUC RR for slow and fast walks during the first minute of exercise. ............ 136 
Figure 6.8  Linear regression of k values against steps per day for slow and fast walks. ................. 137 
 
  
14 
 
List of tables 
Table 3.1  Patient characteristics ........................................................................................................ 73 
Table 3.2  Details of type, location and output of the six activity monitors .......................................... 74 
Table 3.3  Schedule of physical activities in the standardised protocol. .............................................. 75 
Table 4.1  Patient characteristics ........................................................................................................ 92 
Table 1.1  Baseline characteristics of all patients at Visit 1……………………………………………...111 
Table 5.2  Baseline characteristics by centre & ANOVA ................................................................... 113 
Table 5.3  Results of repeated measures ANOVA ............................................................................ 115 
Table 5.4  AG mvpa ln……………………………………………………………………………………….116 
Table 5.5  AG VMU ln ....................................................................................................................... 117 
Table 5.6  AG steps ln……………………………………………………………………………………….117 
Table 5.7  MMwalktime ln ................................................................................................................. 118 
Table 5.8  MMintensity ln .................................................................................................................. 118 
Table 5.9  MMsteps ln ....................................................................................................................... 118 
Table 5.10  MM VMU ln .................................................................................................................... 119 
Table 5.11  Baseline characteristics in dropout subjects vs non-dropout subjects............................ 120 
Table 6.1  Patient characteristics – cardiopulmonary exercise testing………………………………..130 
Table 6.2  Patient characteristics – six minute walk distance............................................................ 130 
 
  
15 
 
Abbreviations 
 
AC      activity count  
AEE      active energy expenditure 
AG     Actigraph activity monitor 
ANOVA     analysis of variance 
AP-1      activator protein-1 
AU      arbitrary unit 
AUC     area under the curve 
BIA      bioelectrical impedence analysis 
BMI     body mass index 
BP      blood pressure 
bpm      beats per minute 
CaO2      oxygen concentration of arterial blood 
CAT     COPD assessment test 
CCQ      Clinical COPD Questionnaire 
CD      compact disc 
CD8
+     
cluster of differentiation  
CF      cystic fibrosis
 
CHAMPS     Community Healthy Activities Model Program for Seniors 
COPD     chronic obstructive pulmonary disease 
CPET      cardiopulmonary exercise test 
CRP     c-reactive protein 
CRQ      Chronic Respiratory Questionnaire 
CSA     cross-sectional area 
CvO2      oxygen concentration of venous blood 
DEXA     dual energy x-ray absorptiometry 
16 
 
DLW      doubly labelled water 
Δt      sampling interval 
ECG     electrocardiogram 
EE      energy expenditure 
EELV      end expiratory lung volume 
EFL      expiratory flow limitation 
EILV      end inspiratory lung volume 
EU      European Union 
FFM     fat free mass 
FFMI     fat free mass index 
FECO2      fractional instantaneous concentration of expired CO2 
FEO2      fractional instantaneous concentration of expired O2 
FEV1     forced expiratory volume in 1 second 
FIO2      fractional instantaneous concentration of inspired O2 
FVC     forced vital capacity 
GP     general practitioner 
GOLD     Global initiative for chronic Obstructive Lung Disease 
HAD A      Hospital anxiety and depression scale – anxiety score 
HAD D      Hospital anxiety and depression scale – depression score 
HDL      high density lipoprotein 
hs-CRP     high sensitivity c-reactive protein 
IGF-1     insulin-like growth factor-1 
IL-6     interleukin-6 
ILD      interstitial lung disease 
IPAQ      International Physical Activity Questionnaire  
ISWT     incremental shuttle walk test 
K2      rate of elimination of deuterium 
17 
 
K18      rate of elimination of 18-oxygen 
kCal     kilocalories 
kDa     kilo Dalton 
LC3B      light chain 3B 
Ln      natural logarithm 
MET     metabolic equivalent of task 
MM     Minimod activity monitor 
mmHg     millimetres of mercury 
MMP-2     metalloproteinase-2 
MMP-9      metalloproteinase-9 
Mol      moles 
MRC      Medical Research Council 
6MWD     six minute walk distance 
NF-κB     nuclear factor kappa B  
NT-BNP    N-terminal pro-B-type natriuretic peptide 
OEP      opto-electronic plethysmography 
PaO2      partial pressure of arterial oxygen 
PEEPi      intrinsic positive end expiratory pressure 
PF     pulmonary fibrosis 
PM10     particulate matter 10  
ppm     parts per million 
PR     pulmonary rehabilitation 
PRO      patient reported outcome 
Q      cardiac output 
QMVC     quadriceps maximal voluntary contraction 
rco2      rate of co2 production  
REE     resting energy expenditure 
18 
 
rpm     revolutions per minute 
ROC      receiver operator curve 
ROS     reactive oxygen species 
RR     respiratory rate 
RV     residual volume 
SGRQ     St George’s Respiratory Questionnaire 
SMP-30     senescence marker protein-30 
Te      expiratory time 
TEE      total energy expenditure 
Ti      inspiratory time 
TLC     total lung capacity 
TLCOc     corrected transfer factor of lung for carbon monoxide 
TNF-α     tumour necrosis factor-α 
TORCH     Towards a Revolution in COPD Health 
TwQ     twitch quadriceps force 
VC     vital capacity 
VCO2     carbon dioxide output 
VE     minute ventilation 
VMU      vector magnitude units 
VO2 max     maximal oxygen uptake  
VO2peak      peak oxygen uptake 
VQ     ventilation perfusion 
W      watts 
WHO     World Health Organisation 
WR      work rate  
19 
 
1 Introduction 
1.1 Physical activity and COPD: summary 
 
Physical activity is defined as any bodily movement produced by the contraction of skeletal muscle 
that increases energy expenditure above a basal level [1], thus encompassing both formal exercise as 
well as many activities of daily living. Adequate levels of physical activity are vital for health and well-
being in all populations; physical inactivity is one of the most prevalent modifiable risk factor in a 
number of non-communicable diseases including chronic obstructive pulmonary disease, COPD [2-6]. 
 
COPD is a chronic progressive condition caused by inhalation of noxious particles, such as cigarette 
smoke or biomass fumes. It is a major worldwide health problem, with global prevalence estimated at 
around 10% of the adult population [7]. Prevalence continues to increase, particularly in the 
developing world, largely due to the increase in tobacco use and it is now the third largest cause of 
death globally [8]. COPD is characterised by poorly reversible airflow limitation and destruction of lung 
parenchyma. Loss of lung elastic recoil leads to gas trapping, resulting in hyperinflation. Ventilatory 
capacity is reduced and patients experience breathlessness and exercise limitation.  
 
The significance of physical inactivity in COPD is well established, not only as a consequence of 
exercise limitation and dyspnoea which has a direct effect on patients’ quality of life, but as an 
important factor in disease progression at an early stage, even perhaps before onset of other 
symptoms [9]. In fact, recent worldwide epidemiological studies have highlighted physical inactivity as 
a leading contributor to morbidity and mortality in non-communicable diseases, estimated to have 
caused 9% of worldwide mortality in 2008 alone [10].  
 
Increasing physical activity in COPD should therefore be a cornerstone of treatment in COPD. 
Pulmonary rehabilitation has been proven to be the most cost effective intervention in COPD, over 
and above any pharmacological therapy including inhaled bronchodilators [11]. Exercise training 
forms an integral part of pulmonary rehabilitation, with the aim of increasing participants’ exercise 
capacity. This, along with the education provided to patients to enable them to be more autonomous 
in managing their condition, should promote increased daily physical activity. Those patients who are 
able to complete pulmonary rehabilitation do show improvements in exercise capacity, dyspnoea and 
quality of life measures. There is also good evidence to show it is a safe and effective intervention to 
reduce hospital admission, morbidity and mortality in patients who have recently suffered an 
exacerbation of COPD [12].However, the effects on daily physical activity are less clear; a recent 
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review by Spruit et al have highlighted the difficulties with translating the benefits experienced from 
pulmonary rehabilitation, in terms of exercise capacity and quality of life, to ‘real life’ improvements in 
daily physical activity [13], with only some studies showing an increase in levels of physical activity 
after completion of a pulmonary rehabilitation programme. [14-16]. For example, Walker et al 
evaluated the effect of a standard 8 week programme in 24 patients with moderate to very severe 
COPD using an accelerometer and found an increase in time spent mobile, mean activity score and 
mean activity intensity, as well as improvements in exercise capacity, health related quality of life 
measures and lower limb function. Conversely, other studies have found no increase in physical 
activity following pulmonary rehabilitation [17-19]. For example, Saunders et al looked at the effect of 
7 pulmonary rehabilitation programmes, both community and hospital based, on daily physical activity 
in 294 COPD patients, as measured by a pedometer. There was no change in daily steps after 
completion of rehabilitation [19].    
 
Despite the clear benefits, only around a third of patients referred for pulmonary rehabilitation actually 
complete a course with a third never actually even starting [20]. In addition, the beneficial effects of 
pulmonary rehabilitation are short-lived, lasting approximately 6 months for a typical programme of 8 
to 12 weeks [21]. This, along with the mixed outcomes from studies looking at levels of daily physical 
activity following pulmonary rehabilitation, suggests that COPD patients find it difficult to make lifestyle 
changes necessary to increase daily physical activity and thus sustain the benefits that are gained in 
the short term through pulmonary rehabilitation.  
 
Being able to measure daily physical activity levels in COPD accurately could make it easier for 
clinicians to facilitate patients to increase their daily physical activity, either following a course of 
pulmonary rehabilitation, or as an alternative if patients were unable to access a course. This could 
potentially improve both effectiveness and cost-effectiveness of COPD management, as well as 
encouraging patient autonomy. A number of sophisticated physical activity monitors are now available 
and this has made objective measurement of physical activity in COPD patients possible in a number 
of circumstances, such as in the community, during rehabilitation programmes [18], during 
exacerbation and hospital admission [22], and in response to pharmacotherapy [23]. Most of the 
monitors currently available have been validated in healthy subjects, but not necessarily in patients 
with chronic diseases. As such patients, including those with COPD, are less physically active and 
move more slowly than healthy subjects [24], the validity of these monitors to detect movement in 
these patients needs to be evaluated. 
 
In addition, other factors which determine patients’ ability to be physically active need to be clearly 
understood, if they are to be influenced in a positive manner by clinicians. These include 
environmental factors such as weather and climate, geographical location and accessibility to 
21 
 
rehabilitation programmes; and personal factors such as other co-morbidities, personal motivation 
and disease factors which may be specific to that individual such as perception of breathlessness. A 
comprehensive understanding of all determinants of physical activity in COPD will enable more 
effective interventions to be delivered in this population. 
 
1.2 Physical activity 
 
Physical activity is defined as ‘any bodily movement produced by the contraction of skeletal muscle 
that increases energy expenditure above a basal level’ [1]; thus it incorporates not only formal 
exercise but also movements a patient must undertake whilst performing many activities of daily 
living. In contrast, exercise
1
 is a subset of physical activity that is planned, structured, and repetitive 
and has as a final or an intermediate objective of the improvement or maintenance of physical fitness 
[25].The World Health Organisation recommends that healthy adults aged 18 to 64 years should do at 
least 150 minutes of moderate to vigorous intensity aerobic physical activity, in at least 10 minute 
bouts, (which roughly equates to 30 minutes five times a week), as well as muscle strengthening 
exercise at least twice a week [26]. The importance of physical activity in healthy populations is well 
established; it is one of the most prevalent modifiable risk factors for a number of chronic diseases 
such as cardiovascular disease, diabetes, osteoporosis, cancer, obesity and depression [2-6].  
 
1.2.1 Patterns of physical activity 
1.2.1.1 Aerobic or endurance activity 
This involves movement of the large muscle groups, such as walking, running or cycling, and 
increases oxygen consumption from resting levels. Repeated aerobic activity improves cardiovascular 
fitness, that is, the ability of the heart to deliver oxygen to the muscles for use, and how efficiently that 
process occurs.  
 
1.2.1.2 Resistance activity 
Resistance training is any exercise that causes the muscles to contract against an external 
resistance, such as weight training, sprinting or resistance cycling. This improves muscle condition as 
well as bone strength.  
 
                                                     
1
 Exercise and physical activity as terms are often used interchangeably but are not synonymous; exercise is a subset of 
physical activity. 
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1.2.1.3 Flexibility activity 
Stretching improves joint flexibility and stretches muscles, improving range of motion, thereby 
reducing risk of injury.  
 
1.2.1.4 Frequency and amount of activity 
Frequency refers to the number of times per week the activity is carried out. As mentioned above, 
WHO recommendations are for a total of 150 minutes per week, but ideally at least 30 minutes 5 
times per week.  
 
Amount can be described in terms of duration i.e. the number of minutes the activity is performed; and 
intensity, that is, the energy expended per minute as compared to resting energy expenditure levels. 
A common expression of intensity is the MET, or Metabolic equivalent of Task, defined as 3.5 ml 
O2·kg
−1·min−1, or 1 MET. This value is typically considered to be resting metabolic rate. Light intensity 
is classified as less than 3 METS (such as slow walking), moderate 3 to 6 METS (such as light cycling 
or fast walking) and vigorous above 6 METS (such as jogging).  
 
 
1.2.2 Physical activity: historical perspective 
 
“Lack of activity destroys the good condition of every human being, while movement and methodical 
physical exercise save it and preserve it.” – Plato (427-347 BC) 
 
The benefits of physical activity in the general population have long been established; there are 
records of exercise being prescribed for health and well-being in the ancient civilisations of China, 
Greece and India [27, 28].  
 
Over two thousand years ago, in 600 BC, Susruta, an ancient Indian physician, was the first recorded 
physician to prescribe exercise for health, stating that “it should be taken every day” but “only to half 
extent of his capacity” as otherwise “may prove fatal” and was “absolutely conducive to a better 
preservation of health”. He advised consideration of the age and strength of the patient beforehand. He 
prescribed diet and exercise to cure diabetes, and also observed that exercise ‘made the body stout, 
strong, firm, compact, and light, enhanced the growth of limbs and muscles, improved digestion and 
complexion, prevented laziness, and reduced senility’ [29]. 
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Hippocrates, widely considered to be the father of modern medicine, wrote on the importance of diet 
and exercise: ‘eating alone will not keep a man well; he must also take exercise. For food and 
exercise work together to produce health’. In his work ‘Regimen in Acute Diseases’, he gives a 
detailed account of the personalisation of exercise, gymnastics and diet according to that person’s 
individual nature. He suggested modification to diet and exercise that should be made according to 
season. He recognised that exercise should not be excessive as that would also have detrimental 
effects, for example regarding horseriding: ‘‘Horse riding causes chronic arthritis because the legs are 
always suspended. In serious cases, the cohesion of the tissues on the ischium totally loosens up and 
the horsemen are lamed...’ He also advised on how exercise should take place, for example ‘walks 
after gymnastics..., running with the clothes on ….’ and ‘….the holding of the breath...’[30] 
 
500 years after Hippocrates, Galen emerged as one of the most influential physicians of the ancient 
period. He began studying medicine at the age of 16 and was physician to the gladiators. His theories 
were heavily influenced by Hippocrates’ humoral theory which taught that an imbalance of the humors 
caused disease. He developed his own medical theory based on the ‘natural’ or physiological factors, 
‘non-natural’ or external factors such as exercise and diet and the pathological or disease factors. 
Exercise was prescribed for several illnesses such as gout, dyspepsia, arthritis and depression. He 
specified that the activity had to be vigorous enough to cause laboured breathing [31]. 
 
After Galen, during the Renaissance period and further, integral to the historical development of 
medicine as a discipline was the study of anatomy and physiology of exercise as well as of health and 
illness. For example, Andreas Vesalius (1541-64) was a Dutch physician and anatomist who 
produced high quality anatomical drawings. He tried to connect form to functions, that is, that nerves 
controlled muscle movement. This was an important development in the evolution of medicine as a 
modern science. Lavoisier (1743-94) was the first person to conduct experiments on human 
respiration and supervised the first physiology experiment during which the subject breathed through 
a copper pipe and oxygen consumption and heart rate were measured in response to increasing the 
work of depressing a foot pedal. William Prout (1785-1850), the English chemist and physician, 
measured expired CO2 when exercising to exhaustion and found it to increase in fatiguing exercise. 
The first formal exercise physiology laboratory was established in Harvard University in 1891. This 
was followed by the Harvard Fatigue Laboratory in 1927 which specialised in experimental 
physiology. Its importance emerged with the outbreak of the Second World War as it had the only 
experimental altitude chamber, valuable to the US Air Force, as well as hot and cold chambers, which 
were valuable in assessing the physiological effects of extreme climates on soldiers.  
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1.2.3 Physical activity: the evidence 
 
Despite the historical roots of exercise prescription for health and treatment of disease in the ancient 
civilisations of Greece and India, as far back as ancient Greece, the importance of physical activity in 
the primary prevention of disease has come to prominence in modern medicine only more recently, 
since the work of Jerry Morris in the 1950s.  
 
Morris and his colleagues were the first to describe the link between physical activity and coronary 
artery disease, specifically the protective effects of physical activity in cardiovascular disease, through 
large epidemiological studies. It had long been observed that, for example, bus drivers seemed to 
have a higher incidence of cardiovascular disease than bus conductors, raising the possibility that 
those in physically demanding jobs were more protected from cardiovascular disease than their 
sedentary peers; this was formally demonstrated in Morris’ landmark 1953 study [32]. It was the first 
large scale study showing the long term health benefits associated with physical activity. In a 
subsequent study looking at post mortem data on cause of death in nearly 4000 patients, they found 
an almost threefold increase in incidence of large healed myocardial infarcts in those occupied in light 
work [33]. 
 
Similar work from a US group led by Paffenbarger in over 6000 Californian longshoreman followed 
and supported these findings, that is, the more physically active longshoreman had lower all-cause 
mortality rates [34]. Over 30 years after Morris’ original study, similar results were reported in 
Pafferbarger’s Harvard alumini study. Nearly 20000 Harvard alumini were followed over 16 years; 
again, all-cause mortality was better for those individuals who were more physically active. In this 
particular study physical activity was self-reported via questionnaire [35].  
 
Another landmark study, the Whitehall study, was initiated by Professor DD Reid in 1967, and was so 
dubbed because its subjects were male civil servants based in London. It was ground-breaking in 
terms of the scale of the study, and its analysis of the implications of the social gradient on health. 
Confining the study to the London civil service minimised the number of confounding variables, thus 
strengthening its findings. Of the 18403 participants recruited from 1967 to 1969, 17530 were 
included in the final analysis of mortality and morbidity by Professor Sir Michael Marmot in 1978 [36]. 
As well as measuring parameters such as pulse, blood pressure and BMI, questionnaires were used 
to gather information on leisure activities including physical activity. The main findings were that 
workers in higher grades had lower mortality compared to those in lower grades. They also had lower 
blood pressure and smoking rates, as well as higher physical activity levels, albeit self-reported.  
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The Whitehall II study was set up in 1985 by Marmot and investigated the effects of the work and 
home environment on long term health outcomes in over 10000 civil servants[37], this time in both 
male (6900) and female subjects (3414) aged between 33 and 55 years. The findings were similar, in 
that moderate or vigorous exercise was less common in those in lower grade jobs.  
 
In a follow up phase of Whitehall II, physical activity (self-reported via a questionnaire) and 
inflammatory markers (high sensitivity C-reactive protein, hs-CRP; and interleukin-6, IL-6) were 
measured in 4289 men and women (mean age 49.2 years). 49% were found to adhere to the 
guideline of 2.5 hours of moderate or vigorous physical activity per week. Those who were more 
physically active had lower levels of inflammatory markers at baseline and these remained stable over 
10 years. This suggests that physical activity may be important in preventing the pro-inflammatory 
state which accompanies ageing and that may lie behind the development of chronic diseases [38]. 
Logically the counter hypothesis would of course be that an inflammatory condition (of whatever 
cause) reduced patients’ physical activity. 
 
Several subsequent large meta-analyses have found a lower relative risk of death for those men and 
women who reported increased levels of physical activity and fitness. Nocon et al performed a 
systematic review and meta-analysis of 33 studies with 883,372 subjects [39]. The studies were 
prospective in nature and had to have a minimum of 5000 participants from a general, healthy 
population. Follow up ranged from 4 to 20 years. They found reductions in cardiovascular and all-
cause mortality of 35% and 33% respectively between the least active and most active subjects. 
However there was great heterogeneity in the risk reductions found, from 16 to 57%, which they 
attributed to the method of recording activity. Larger risk reductions were found where fitness tests 
were used. Participants may have tended to overestimate their activity in a self-reported 
questionnaire, thereby reducing the beneficial effect of activity. Interestingly, in the subgroup analysis, 
lower reductions of mortality were found where questionnaires rather than objective measures (e.g. 
fitness test) were used to assess physical activity levels. However the authors acknowledge that there 
may be publication bias in favour of positive studies. Samitz et al conducted a similar analysis of 80 
studies with 1338143 participants, but studies with at least 2 years follow up were included [40]. They 
classified outcomes according to intensity (low, moderate and vigorous) and domain of activity (sports 
and exercise, occupational and daily living). They found both the domain and intensity to be 
important; risk reduction was greatest for vigorous activity and for occupational and sports activity. 
They also found that studies which used complex questionnaires showed a lower risk reduction, 
perhaps due to difficulties administering the questionnaires, as did those studies with longer follow up 
(greater than 11 years), which could be explained by under-powering from loss of subjects to follow 
up.   
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The difficulty with any such analysis is that it is observational and therefore prone to bias. There is 
great heterogeneity when analysing such a large number of studies, which may cause confounding. It 
is also unclear whether it is the intensity rather than duration of activity or total energy expended that 
is important in mortality reduction. This can only be established in a prospective randomised 
interventional study. 
 
However, the evidence supporting physical activity in overall health is such that the World Health 
Organisation has recognised physical inactivity as one of the most important risk factors threatening 
global health [26]. In fact, it could be argued that there is now a pandemic of physical inactivity, with 
an estimated 31% of the world’s population not meeting minimum recommendations for physical 
activity [41]. 6-10% of all non-communicable diseases are attributable to physical inactivity; this rises 
to around 30% in ischaemic heart disease [7]. The economic cost of morbidity due to physical 
inactivity is a substantial burden on health systems and society as a whole. Reduced physical activity 
is associated with urbanisation and modernisation; there has been a definitive shift in morbidity from 
communicable diseases to non-communicable diseases in countries which have undergone recent 
rapid modernisation and industrialisation, such as China and India [42]. With improved survival rates 
due to improved medical care, as well as falling birth rates, in both the developed world and the newly 
industrialised countries, the health burden of an ageing population is a more prescient concern. 
People over the age of 65 years make up one of the fastest growing population segments in 
industrialised countries; they carry the greatest proportion of the chronic disease burden, disability 
and health utilisation. They are also the most sedentary and physically inactive [43]. However, of 
growing concern is the lack of physical activity in adult populations as a whole, resulting in these 
diseases, traditionally associated with advanced age, manifesting at an earlier age [44].  
 
 
1.2.4 Physical activity: the benefits 
 
The benefits of physical activity have been demonstrated in a number of chronic diseases. 
 
1.2.4.1 Cardiovascular disease 
Cardiovascular disease, including coronary artery disease and cerebrovascular disease, is the most 
prevalent chronic disease accounting for approximately 50% of deaths worldwide [45]. Physical 
inactivity is one of several modifiable risk factors, as well as hypertension, hyperlipidaemia, smoking, 
obesity and elevated blood glucose levels. With regard to exercise based interventions, several 
studies have shown a reduction in cardiovascular mortality in myocardial infarction patients who have 
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participated in cardiac rehabilitation which includes physical activity and exercise [46].A meta-analysis 
by O’Connor et al of 22 randomised controlled trials of cardiac rehabilitation with over 4000 patients 
demonstrated a 20% mortality reduction at 1 year [47].  However, a similar problem to that of 
pulmonary rehabilitation exists, in that it is difficult to sustain the benefits gained from an initial course 
of cardiac rehabilitation.  A subanalysis of two randomised controlled trials of exercise based cardiac 
rehabilitation by Ribeiro et al in 50 patients following myocardial infarction showed that physical 
activity levels measured with an accelerometer were increased immediately after rehabilitation [48]. 
However, Ayabe et al showed that physical activity levels in patients on days that they were not 
attending cardiac rehabilitation were significantly lower than on rehabilitation days [49]. Butler et al 
showed that physical activity levels were only sustained at 6 months following rehabilitation if patients 
were given a pedometer based intervention [50]. Nevertheless, other benefits of exercise based 
cardiac rehabilitation also include improved muscle strength and aerobic capacity; and reduced blood 
pressure, submaximal heart rate, inflammatory markers, and HDL cholesterol [51].  
 
1.2.4.2 Type 2 diabetes 
The worldwide incidence of type 2 diabetes is increasing with UK prevalence approximately 7.4% or 
3.2 million adults [52]. There is also an increased incidence of impaired glucose tolerance which 
confers a 10% risk of subsequently developing type 2 diabetes [53]. Type 2 diabetes is strongly 
associated with physical inactivity, so increasing physical activity is a key intervention in both primary 
and secondary prevention [54]. Aerobic exercise has been shown to improve insulin sensitivity [55]. A 
review of several exercise programmes targeted at diabetic patients has shown that one week of at 
least moderate intensity exercise can improve insulin sensitivity [56]. Other benefits include weight 
loss, lowering of systolic blood pressure and improved lipid profile which in turn has positive effects on 
the known associated increased cardiovascular risk [57].  
 
1.2.4.3 Cancer 
Cancer is the second leading cause of death worldwide, causing around 15% of all deaths. There is 
evidence to support the association of physical inactivity with certain malignancies such as breast, 
prostate and colon cancer [58]. Moreover, studies have demonstrated improved survival in patients 
previously diagnosed with cancer who are more physically active. For example, Holmes et al followed 
approximately 3000 women diagnosed with breast cancer between 1984 and 1998 until 2002 or 
death. They categorised their physical activity levels according to MET-hours per week and found that 
survival rates were better in those women who had an average of the equivalent of walking 3 to 5 
hours a day have an adjusted relative risk of 0.5 of mortality during follow up compared to those who 
were less active [59]. Whilst this evidence is compelling, it is difficult to know whether this is 
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confounded by disease severity rather than a true effect of physical activity. However it may be 
beneficial to incorporate exercise into the management plans of patients with diagnosed with cancer.   
 
1.2.4.4 Osteoporosis 
Osteoporosis is a chronic degenerative multifactorial metabolic disease of bone. It results in reduced 
bone density and increased propensity to fractures and associated pain. Physical activity stimulates 
bone formation through weightbearing and improved associated muscle strength, and is important in 
disease prevention [60]. In patients with established osteoporosis, exercise is still a valuable therapy 
once pain is controlled, as it can improve balance and muscle strength and reduce falls risk [61]. 
 
 
1.3 Physical activity in COPD 
 
Given the significance of physical activity in the general population, it would come as no surprise that 
it is also an important factor is COPD and there is a growing body of work to support this. In one of 
the first studies to confirm the finding that had only been previously demonstrable from questionnaire 
data - that patients with chronic respiratory disease are less physically active in day to day life than 
healthy controls - Schonhofer et al [62] used simple pedometers to quantify physical activity 
objectively in COPD patients compared to controls. This was, in the main, a feasibility study to show 
that it was possible to carry out this kind of measurement in this patient group. A later study by Pitta et 
al used a more sophisticated monitor to show that indeed COPD patients are less physically active 
than aged-matched healthy subjects; they spend less time walking or standing and more time lying or 
sitting, and when they are moving, they are doing so at a much lower intensity compared to healthy 
subjects [24, 62]. Time spent walking also correlates strongly with measures of functional exercise 
capacity such as six minute walking distance.  
 
However, it is in day-to-day life that COPD has its greatest impact; patients report being unable to 
complete activities of daily living (such as dressing, shopping, household tasks), due to physical 
limitation [63, 64]. Exercise capacity and quality of life measures are often impaired disproportionately 
to lung function [65]. There is increasing evidence, mainly epidemiological, that reduced physical 
activity is not only a manifestation of disease severity in COPD, but is intrinsic to disease progression. 
A large population based cohort study by Garcia-Aymerich et al 2007 assessed a random population 
sample of nearly 7000 adults that had been previously recruited into the Copenhagen City Heart 
Study and followed up over a ten year period. Physical activity was assessed by questionnaires on 
occupational and spare time work originally devised by Saltin and Grimby in 1968, and then 
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categorised into low, medium and high activity levels. They found that healthy smokers with increased 
levels of physical activity show a slower decline in lung function compared to healthy but less active 
smokers, as well as a lower risk of developing COPD [9]. There also seems to be a dose-response 
relationship – the higher the levels of activity amongst smokers, the lower the decline in lung function 
and therefore incidence of COPD.  
 
In another study, a subset of the same cohort (2386 subjects) who had been diagnosed with COPD, 
were followed over a mean 12 year period. Using similar physical activity data, it was found that those 
who reported some regular physical activity (low, moderate or high levels) had a reduced risk of both 
hospital admission and mortality compared to those who reported very low levels of physical activity 
[66]. The importance of physical activity in hospital admission is further supported by the finding  that 
patients with COPD and low reported physical activity levels also have an increased risk of 
readmission after a severe exacerbation [67]. 
 
The results of these large cohort studies are compelling, but could be criticised for the way the activity 
data was collected – questionnaires as opposed to objective measurement – as there is scope for 
recall bias and inaccuracy of self-reporting in terms of under or overestimating amount of activity 
undertaken. There is also the potential problem of survival bias; those surviving being more physically 
active, causing an underestimation of the effect of physical activity. These drawbacks seem to 
necessitate a more reliable method of measuring physical activity in not only this group of patients, 
but in the general population.  
 
1.3.1 Pulmonary rehabilitation and the relationship with physical activity 
 
This is a multidisciplinary programme of care for patients with chronic respiratory impairment, 
including COPD,  that is individually tailored and designed to optimise physical and social 
performance and autonomy [68].  The fundamental  components are a structured and regular 
exercise programme and an education programme, giving advice on nutrition, medication, and social 
aspects of the disease (e.g. available financial support) [69]. The aim of pulmonary rehabilitation is 
not to reverse the disease process, but to reduce the symptoms experienced, and therefore the 
distress caused; and also to encourage patients to be more independent and able to self-manage 
their disease as far as possible. Exercise is essential to this process; the patients are supervised 
during the classes and taught how to manage their dyspnoea to eventually enable them to increase 
their exercise capacity, and therefore their daily physically activity once they have finished the 
programme.  
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Notwithstanding the heterogeneity of rehabilitation programmes, specifically with respect to exercising 
training intensity, a Cochrane meta-analysis of numerous studies involving pulmonary rehabilitation in 
COPD has found both short and long term benefits. Pulmonary rehabilitation improves exercise 
capacity, muscle endurance, dyspnoea and quality of life-related outcome measures. There is also 
evidence to show that pulmonary rehabilitation is highly effective and safe intervention to reduce 
hospital admission, mortality and health-related quality of life in patients who have recently suffered 
an exacerbation of COPD [70, 71]. 
 
Despite the clear benefits of pulmonary rehabilitation, one of the main shortcomings is that the effects 
are short-lived, and this seems to be inherent to the way that most programmes are delivered. The 
majority are between 8 to 12 weeks in duration; the beneficial effects in terms of improved exercise 
capacity and quality of life measures tend to decline after 6 months. However, these effects are 
greater and more sustained if programmes are longer. For example, a study comparing 3 months 
versus 18 months rehabilitation showed a greater increase in six minute walk distance and health-
related quality of life after the longer programme. Another study showed the effects of 6 months of 
rehabilitation were sustained up to 18 months after completion [72]. However, even with these longer 
programmes, effects do seem to eventually wane [21]. Long term maintenance strategies that have 
been tried include prescribed structured home exercise programmes, or monthly maintenance classes 
with weekly telephone contact. These have been shown to maintain the benefits gained from 
rehabilitation compared to those who did not have such input [73].  
 
Thus it follows that if pulmonary rehabilitation were truly successful in effecting behaviour change in 
COPD, then one would expect to find increased levels of physical activity well after completion. 
Although there is improvement in measures of exercise capacity such as six minute walk distance, 
when it comes to daily physical activity levels as an outcome measure, the results are less 
convincing. A meta-analysis by Cindy Ng et al [74] looked at studies which investigated the effect of 
exercise training, of at least 4 weeks, on physical activity levels measured with an activity monitor. 
Only 7 studies (with a total number of 472 subjects) met their criteria, none of which were randomised 
controlled trials. There was great heterogeneity amongst the studies; some included pulmonary 
rehabilitation as the intervention, while others just used a general exercise programme with or without 
counselling; sample size also varied greatly. Overall only a very small positive effect on physical 
activity levels was found as a result of pulmonary rehabilitation of formal exercise training. A more 
recent review by Spruit et al [13] echoes the previous systematic review; they cite 12 studies 
(including 6 studies not reviewed by Cindy Ng et al) which evaluated the effect of pulmonary 
rehabilitation on physical activity in COPD. Results were inconsistent: 3 studies showed increased 
activity levels (measured with an activity monitor) immediately after a standard 8 week programme in 
both inpatient and outpatient settings [14-16]; 5 studies had negative findings with no increase in 
physical activity immediately after pulmonary rehabilitation [17-19, 75, 76]; the remaining 3 studies 
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showed mixed results with some measures improving (such as daily step count) and others not (such 
as movement intensity [77-79]. However whether any positive effect is maintained over a longer 
period of time is unknown. 
 
Currently, pulmonary rehabilitation is the best ‘weapon’ in the clinician’s armoury in terms of dealing 
with physical deconditioning and exertional dyspnoea in COPD, but it is far from perfect in dealing 
with physical inactivity in the long term. The benefits of physical activity on morbidity and mortality are 
undisputed. However, the evidence so far illustrates that it is much more difficult for patients to make 
lifestyle changes in order to sustain the physical benefits that are undoubtedly achievable in the short 
term. Therein lies the key to not only the long term success of pulmonary rehabilitation, but also the 
management of COPD as a whole.  
 
 
1.4 COPD pathophysiology 
 
COPD is essentially a chronic inflammatory disorder triggered by inhalation of noxious particles. How 
the cellular and molecular mechanisms link to the pathological findings, abnormal physiology and 
symptoms is still not fully understood. This is compounded by the considerable heterogeneity of the 
disease; patients with similar smoking backgrounds can have vastly differing disease phenotypes, 
ranging from widespread emphysema, to predominant airways disease with chronic bronchitis, to a 
mixture of both to a varying degree. Indeed, only around a quarter of all smokers will go on to develop 
COPD (although up to half may have abnormal spirometry without symptoms) [80], and of these, 
some will have a more rapid progression in disease than others, emphasising the importance of 
genetic susceptibility and other host factors in its pathogenesis. 
 
1.4.1 Main pathological features of COPD 
 
1.4.1.1 Chronic bronchitis 
Cigarette smoke triggers infiltration of the bronchial wall with inflammatory cells, predominantly 
macrophages and CD8
+
 lymphocytes, with increased number of fibroblasts [81]. Damage to the 
bronchial wall endothelium impairs the mucociliary response, which causes mucous secretions to 
accumulate in the airway, resulting in obstruction. Chronic inflammation leads to goblet cell 
metaplasia, smooth muscle hyperplasia and peribronchial fibrosis. The airway is deformed with 
luminal narrowing, causing further airway obstruction [82].  
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1.4.1.2 Emphysema 
This is defined as permanent enlargement of the airspaces distal to the terminal bronchioles. The 
pattern of emphysema typically seen in COPD is centriacinar (focal destruction limited to the 
respiratory bronchioles and the central portions of the acini), and is usually most severe in the upper 
lobes [83]. The result is a marked decline in alveolar surface area available for gas exchange. Loss of 
alveoli and supporting structures leads to reduced elastic recoil of the lung; airways collapse more 
easily, resulting in airflow limitation.  
 
1.4.1.3 Hyperinflation 
Reduced lung recoil means that equilibrium with the pressure exerted by the chest wall occurs at 
higher lung volumes, causing static hyperinflation. Dynamic hyperinflation can also occur, 
independent of or in addition to static hyperinflation. It results from air being trapped within the lungs 
after each breath due to a disequilibrium between the volumes inhaled and exhaled. The ability to fully 
exhale depends on the degree of airflow limitation and the time available for exhalation. Each of these 
can vary, causing greater hyperinflation for example during exacerbations or exercise. Both static and 
dynamic hyperinflation contribute significantly to the degree of breathlessness perceived by patients 
with COPD [84, 85]. 
 
1.4.2 Disease mechanisms 
 
1.4.2.1 Abnormal inflammation 
Cigarette smoke and other noxious substances trigger an abnormal and exaggerated inflammatory 
response in the lungs. The macrophage (which is activated by cigarette smoking) is perhaps the most 
important inflammatory cell in this response. In patients with COPD compared to normal smokers, 
macrophages seem to be more pro-inflammatory and this is further increased by exposure to 
cigarette smoke. There are increased numbers (5-10 times) of macrophages in the airways, sputum, 
bronchoalveolar lavage and parenchyma of patients with COPD [86]. They release inflammatory 
mediators such as TNFα, IL-8 and other chemokines, secrete elastases including matrix 
metalloproteinases 2 and 9 (MMP-2, MMP-9) and neutrophils elastases, and generate reactive 
oxygen species (ROS) [87].There are also increased numbers of other inflammatory cells, such as 
neutrophils and CD8+ T lymphocytes [88], but their role in the development of COPD is not as clear. 
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1.4.2.2 Oxidative stress 
Oxidative stress is the cellular and molecular damage that occurs as a result of cumulative exposure 
to reactive oxidative species (ROS). Oxidative changes affect protein conformation, trafficking and 
DNA interaction. Cigarette smoke is an important exogenous source of ROS. Chronic smoking 
exposes the respiratory tree to ROS, either directly, or by stimulating their production, causing 
oxidative stress and injury [89, 90]. ROS activate NF-ĸB and AP-1, which switch on multiple 
inflammatory genes resulting in amplification of the inflammatory response [91]. Population studies 
have shown that genetic polymorphisms in antioxidant genes (e.g. superoxide dismutase 3), with the 
resulting reduced antioxidant levels, are associated with an increased susceptibility to emphysema in 
smokers [92]. It is therefore possible that smokers who go on to develop COPD are less able to deal 
with oxidative stress than normal smokers, providing a possible link between smoking and cellular 
mechanisms. 
 
1.4.2.3 COPD: a disease of the ageing lung 
Ageing is a natural process consisting of a progressive functional impairment and reduced capacity to 
respond appropriately to environmental stimuli and injury. For example, lung function declines with 
age in normal subjects; however, this decline is accelerated in COPD [93]. As the incidence of COPD 
increases with age, it is possible that abnormalities in the normal ageing process could contribute to 
the pathogenesis of COPD. Mechanisms of ageing are as follows: 
 
Increased oxidative stress 
As already discussed, oxidative stress has a role in the pathogenesis of COPD, and this may 
represent accelerated or abnormal ageing. Neutrophils, monocytes and macrophages show 
enhanced ROS production in mice models of ageing [94]. Telomere shortening (see below) has been 
shown to be enhanced by ROS in vitro and in vivo there is a strong correlation between telomere 
length and vascular dementia, typically a disease of ageing [95].  
 
Changes in regulation of telomere length 
Telomeres are the regions at each end of the chromosome containing a 1 to 5 kDa sequence of 
specific base pair repeats which protect the chromosome during cell division. Telomere shortening is 
a natural consequence of ageing, but length is also affected by cumulative oxidative stress and 
chronic inflammation. The telomeres of alveolar type II cells and endothelial cells of COPD patients 
have been found to be significantly shorter than those in age matched asymptomatic non smokers 
[96] and there is a dose-dependent relationship between smoking history and telomere length [97].   
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Cellular senescence 
Cell death or senescence occurs once telomere shortening reaches a critical level, and is part of the 
normal ageing process. However increased senescence has been found in COPD. Exposure of lung 
fibroblasts and human alveolar epithelial cells to cigarette smoke in vitro results in senescence [98]. 
Patients with emphysema have increased expression of senescence markers in type II alveolar cells, 
[96, 99]. There is also a strong relationship between senescence and proinflammatory mediators such 
as NFkB. Telomerase deficient mice were found to have shorter telomeres in lung cells as well as 
higher levels of inflammatory markers in the lungs, which could result in protease release and 
therefore progression of emphysema [100].  
 
Changes in anti-ageing molecules 
Anti-ageing molecules may also have a role in the pathogenesis of COPD. Senescence marker 
protein-30 (SMP-30) levels increase in early life and decline with age. SMP-30 knockout mice develop 
changes in the lung consistent with emphysema and if these mice are exposed to cigarette smoke, 
they develop a greater degree of emphysema than wild type mice [101, 102]. Klotho is an important 
protein in cell senescence. It is a transmembrane protein that, amongst other effects, modulates 
insulin sensitivity, although its mechanism of action is not completely understood. Genetic variants in 
klotho are associated with human ageing and circulating serum klotho levels have been found to 
decline with age [103]. Klotho deficient mice have a shortened life span and display features of ageing 
such as thinned skin, accelerated atherosclerosis, osteoporosis and emphysema [104-107].  
 
Apoptosis  
Apoptosis is programmed cell death and serves to eliminate damaged or infected cells. There is 
evidence for a disruption in the balance between apoptosis and cell proliferation in COPD. Various 
studies have found increased apoptosis in alveolar and airway epithelial cells and interstitial cells of 
patients with COPD [99, 108]. There is also increased expression of autophagic proteins in 
emphysematous lungs [109]; autophagy is an important part of cell apoptosis. Ryter et al found 
increased autophagy in COPD lung specimens, both morphologically and with increased levels of 
autophagic regulator proteins such as beclin-1 and LC3B [110].  
 
 
1.4.3 COPD as a systemic disease 
 
COPD is no longer regarded exclusively as a disease of the lungs, but as a systemic disease with 
several extrapulmonary sequelae: skeletal muscle wasting, cachexia, low-grade systemic 
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inflammation, increased cardiovascular risk and metabolic disturbance (e.g. insulin resistance) [111, 
112]. In fact, indices of airflow limitation, such as decline in FEV1, correlate poorly with survival [113]. 
Other factors, such as exercise intolerance, dyspnoea, skeletal muscle wasting and weakness, and 
physical inactivity are better predictors of mortality [114, 115]. The pathophysiological mechanisms 
have not yet been fully elucidated, but many factors, including genetic susceptibility and local and 
systemic inflammation are involved.  
 
1.4.3.1 Skeletal muscle in COPD 
Peripheral skeletal muscle dysfunction, with loss of both strength and endurance, is a well recognised 
feature of COPD, with the lower limbs affected to a greater degree than the upper limbs, and has a 
significant role in exercise limitation and thus, reduced quality of life [116, 117].  
 
The quadriceps muscle group is a major muscle of locomotion and dysfunction is common in COPD. 
Killian et al first described COPD patients reporting leg fatigue to be as limiting as breathlessness 
during a cycle cardiopulmonary exercise test [118]. Gosselink et al showed quadriceps strength 
(measured by maximal volitional contraction) correlated strongly with exercise capacity as measured 
by distance achieved in the six minute walk test [116]. Bernard et al found that COPD patients were 
around 30% weaker than controls [119]. They also found that although the cross-sectional area (CSA) 
of the quadriceps muscle group was smaller in COPD patients (on computed tomography), the ratio of 
strength to CSA was similar to that in controls, suggesting weakness was due to atrophy. In addition, 
the quadriceps muscles were proportionally weaker than the shoulder girdle muscles in COPD. 
Previous work in this group by Man et al has shown the type of activity to be important in terms of 
symptoms reported, with more patients reporting leg fatigue during cycling than whilst walking [120].  
 
Endurance is defined as the capacity of the muscle to maintain a certain force over time; quadriceps 
endurance is also attenuated in COPD. Studies of quadriceps endurance have shown a reduction in 
endurance time compared to healthy controls, and also increased fatigue at equivalent workloads 
[121, 122]. Work in our lab by Swallow et al demonstrated increased quadriceps fatigue in COPD 
using repetitive magnetic stimulation of the femoral nerve [121].    
 
It should be noted that quadriceps dysfunction in COPD is independent of airflow limitation; 
quadriceps weakness can be found in COPD patients with mild disease and yet be absent in those 
with severe airflow limitation [123, 124]. Analysis of the quadriceps muscle at the microscopic level is 
most commonly done through biopsies of the vastus lateralis which is the most easily accessible. A 
hallmark feature in COPD patients is a change in muscle fibre composition.  In healthy elderly 
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subjects, muscle biopsy shows approximately 50% type I fibres (oxidative) and 50% type II fibres 
(type IIx glycolytic and type IIa intermediate oxidative/glyolytic fibres) and a minimal number of hybrid 
fibres. In contrast, COPD patients show an increase in type II fibres with more hybrid fibres, i.e. fibre 
shift [125]. Fibre atrophy has also been reported in some studies [126]. However, this morphology has 
recently been shown to be heterogeneous amongst COPD patients. Again, through work done in our 
lab, Natanek et al.analysed the quadriceps biopsies of 114 COPD patients and 30 controls with a 
range of findings in the patients compared to controls: isolated fibre shift in 31%, fibre atrophy alone in 
20%, both fibre shift and atrophy in 25% and normal morphology in 24%. The findings correlated 
poorly to clinical parameters including lung function.  
  
In contrast, there seems to be relative preservation of other muscle groups, such as the adductor 
pollicis and elbow flexors [127, 128]. The diaphragm is also preserved, perhaps even augmented; 
although transdiaphragmatic pressure is reduced in COPD, this is a result of hyperinflation which puts 
the diaphragm at a mechanical disadvantage, and is mitigated by correcting for lung volume [129, 
130]. Biopsies of the diaphragm have shown a shift to fatigue resistant type I fibres, which is probably 
due to training of the muscle from increased work of breathing [131], Indeed, the accessory muscles 
of breathing have also shown a similar pattern in COPD [132].  
 
Skeletal muscle dysfunction in COPD is clinically significant, both prognostically and from a treatment 
perspective. Quadriceps weakness is a better predictor of mortality in COPD than FEV1. In fact, once 
FEV1 has dropped below 50% predicted, it has no further influence on mortality [114]. Despite double 
lung transplantation restoring lung function, peak exercise capacity does not improve to the same 
degree and remains at 50% predicted at up to 2 years follow-up after surgery [133]. Furthermore, 
pulmonary rehabilitation, which improves exercise capacity, muscle function and quality of life, does 
not improve lung function [134]. Thus, muscle dysfunction represents an important treatment target in 
COPD. 
 
1.4.3.2 Cachexia 
Related to muscle dysfunction is cachexia, which encompasses weight loss, muscle atrophy, 
weakness, fatigue and loss of appetite. As loss of fat free mass is important, a definition for cachexia 
of fat free mass less than 16 kg/m
2
 (men) and 15 kg/m
2
 (women) has been proposed [135]. 20 to 40% 
of COPD patients will develop cachexia [136, 137], and it is associated with a 50% reduction in 
median survival [135].  
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1.4.3.3 Cardiovascular disease 
There is a significant burden of cardiovascular disease amongst COPD patients; in fact, it is the cause 
of mortality in the majority of these patients, rather than lung failure [138]. In the TORCH study 
(Towards a Revolution in COPD Health), a multicentre randomised controlled study looking at all 
cause mortality in around 6000 COPD patients treated with either salmeterol/fluticasone propionate, 
salmeterol alone, fluticasone proprionate alone or placebo for 3 years [139], 25% of patients died from 
cardiovascular events [140]. The risk of cardiovascular events seems to be highest after 
exacerbations of COPD; Donaldson et al reported a 2.3 fold increase in myocardial infarction 1 to 5 
days after an exacerbation [141], and exacerbation is also associated with an increase in biochemical 
markers such as NT-proBNP and troponin T [142]. Again, systemic inflammation is likely to play a 
significant role; its role in the development of atherosclerosis is well characterised [143]. Compared to 
age-matched controls, patients with stable COPD have increased levels of circulating platelet-
monocyte aggregates, which are a sensitive marker of platelet activation, and are also raised in 
patients with acute coronary syndrome. These levels increase after an exacerbation [144], proving a 
potential pathological link between COPD exacerbations and cardiovascular events. Fibrinogen, an 
acute phase protein, has also been shown to be a useful biomarker in COPD, since fibrinogen levels 
are not only increased in COPD patients as compared to controls, but also because fibrinogen levels 
also correspond with frequency and severity of exacerbations [145]. Fibrinogen is also associated 
with cardiovascular mortality [146]. Pulse wave velocity, a measure of arterial stiffness, and thus 
cardiovascular disease has been shown to be increased in patients with COPD.[147]. In addition, it 
has been recently demonstrated that COPD patients who exacerbate frequently have increased 
arterial stiffness as measured by pulse wave velocity. These increases are slow to recover and are 
related to airway inflammation, which again lends weight to the argument that inflammation 
contributes significantly to cardiovascular disease in COPD [148]. 
 
There is also a significant incidence of cardiac dysfunction, both left and right sided, in patients with 
COPD. Cor pulmonale can develop in any chronic respiratory disease, including COPD and ILD, and 
is associated with increased pulmonary vascular resistance and right heart failure. CT scanning 
studies have shown a linear relationship between the extent of emphysema and airflow obstruction 
and degree of left ventricular filling impairment, whilst ejection fraction remains relatively preserved, 
indicating that subclinical haemodynamic changes do occur even in mild disease [149, 150].  
 
1.4.3.4 Metabolic disease 
Metabolic syndrome is characterised clinically by abdominal obesity, elevated triglycerides, 
dyslipidaemia, insulin resistance and/or high blood glucose and hypertension. It is associated with a 
pro-inflammatory and pro-thrombotic state [151, 152]. Bolton et al found an increased incidence of 
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insulin resistance and circulating inflammatory mediators in COPD patients, in the absence of 
diabetes [153].  
 
1.4.3.5 Osteoporosis 
Osteoporosis is characterised by a decrease in bone density and deterioration in bone 
microarchitecture, and is defined by the World Health Organisation as bone mineral density 2 
standard deviations or more below the mean peak bone mass (average of young, healthy adults) as 
measured by dual-energy X-ray absorptiometry (DEXA) [154]. Patients with COPD have an increased 
risk of developing osteoporosis and the proportion increases with disease severity. Causative factors 
include smoking, low BMI, immobility and skeletal muscle dysfunction, glucocorticoid use and vitamin 
D deficiency. It is a significant cause of morbidity in these patients, with vertebral fractures affecting 
lung function and hip fractures resulting in decreased mobility [155].  
 
 
1.5 Mechanisms of exercise limitation in COPD 
 
As explained earlier, exertional dyspnoea is one of the cardinal features of COPD and is responsible 
for exercise limitation in the majority of patients of all disease severities, compared to their healthy 
counterparts [156]. Exercise limitation itself is a measure of poor health status in COPD [157]; 
measures of exercise performance, such as six minute walk distance or maximal oxygen uptake (VO2 
max) on cardiopulmonary exercise testing, predict poor prognosis [158, 159]. Ventilatory limitation is 
the most common factor in these patients because of an inability to increase ventilation in response to 
the increased metabolic demands of exercise, although other factors such as cardiac and metabolic 
dysfunction also contribute to a greater or lesser extent [160, 161].  
 
1.5.1 Ventilatory factors 
 
1.5.1.1 Expiratory flow limitation and dynamic hyperinflation 
Expiratory flow limitation is defined as the attainment of the maximal expiratory flow during tidal 
expiration and occurs when a further increase in transpulmonary pressure does not result in a further 
increase in expiratory flow [162]. It results from the pathological changes seen in COPD, namely 
airway narrowing from chronic inflammation and airway wall thickening, and parenchymal destruction 
leading to reduced elastic recoil and static hyperinflation, which causes early airway closure [163]. 
Expiratory flow limitation can be present during exercise alone, or in more advanced disease at rest 
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as well [164]. Patients with severe COPD often exhale along the same flow-volume curve during quiet 
breathing as during a forced expiratory vital capacity manoeuvre. Others may only reach this during 
exercise, in contrast to healthy individuals who do not reach this threshold on the flow volume curve 
even at maximal exercise [165, 166].  
 
One of the consequences of EFL is dynamic hyperinflation; there is no way for flow limited patients to 
increase ventilation with the increasing metabolic demands of exercise other than to increase lung 
volumes. However, as respiratory rate increases, expiratory time falls, resulting in gas trapping, an 
increase in end expiratory lung volume (EELV) and a consequent reduction in inspiratory capacity. 
This means that end inspiratory lung volume (EILV) becomes positioned close to total lung capacity 
(TLC), and a further increase in tidal volume is not possible.  Conversely in healthy individuals, there 
is often a fall in EELV and tidal volume never reaches TLC, even at maximum exercise [167]. 
 
1.5.1.2 Diaphragm and inspiratory muscle dysfunction 
Both static and dynamic hyperinflation lead to inspiratory muscle impairment in some COPD patients 
through a number of mechanisms. Static hyperinflation causes diaphragm flattening and shortening of 
its fibres, reducing its force generating potential [168]. It is also unable to produce as much lateral 
expansion of the rib cage during inspiration. In severe dynamic hyperinflation, diaphragm contraction 
causes indrawing of the lateral rib cage as its fibres are orientated radially rather than axially. In 
addition, inward lateral recoil of chest wall means the inspiratory muscles need to work against this as 
well as lung elastic recoil and therefore need to generate more force to overcome PEEPi and 
increased elastic load.  
 
1.5.1.3 VQ mismatch  
Emphysema results in increased ventilation of poorly perfused areas due to parenchymal destruction 
of alveolar capillaries i.e. increased dead space. Conversely, chronic bronchitis leads to alveolar 
hypoperfusion and perfusion of underventilated areas i.e. physiological shunt. Both are measurable in 
even mild COPD, but become more prominent with increasing disease severity. On exercise, 
hypoxaemia may actually improve in milder COPD patients due to improved VQ matching [169]. 
 
However in severe disease, there is increased peripheral oxygen extraction and VQ mismatch [170]; 
dynamic hyperinflation, alveolar hypoventilation and worsening hypoxia [171]. Alveolar hypoxia and 
hypoxaemia increase respiratory neural drive with a subsequent increase in tidal volume and 
respiratory rate. However, an increased respiratory rate increases both dynamic elastance of the lung 
as well as dynamic hyperinflation, contributing to increased work of breathing [172].  
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1.5.1.4 Increased work of breathing 
The work of breathing is that required from the respiratory muscles to overcome elastic forces (lung 
elastic recoil, thoracic cage displacement) and frictional forces (airway resistance). This is increased 
in COPD, as explained above, and in fact, during exercise, up to 50% of the metabolic cost of 
exercise can be due to this increased workload.  
 
 
1.5.2 Other factors 
 
1.5.2.1 Cardiac dysfunction  
Hypoxia contributes to the development of pulmonary hypertension in COPD [173], although there is 
some evidence for pulmonary vascular remodelling in normoxic patients, perhaps as a result of low 
grade systemic inflammation [174]. In addition, evidence of right ventricular dysfunction has been 
found in both mildly hypoxic and normoxic COPD [175]. This right ventricular dysfunction can be 
exacerbated on exercise, resulting in a lower stroke volume and cardiac output [176].  
 
Hyperinflation itself causes cardiac dysfunction due to intrathoracic pressure changes. MRI analysis 
of ventricular size in severe emphysema patients has shown reduced end diastolic volumes and 
stroke volume compared to healthy controls. In addition, decreased biventricular preload and relative 
intrathoracic hypovolaemia was attributed to hyperinflation [177]. On exercise, dynamic hyperinflation 
have been shown to be negatively correlated with the oxygen pulse (r=0.48), a surrogate for cardiac 
output [160].  Intrathoracic pressure swings limit stroke volume; the high intrathoracic pressures 
generated in severe airflow limitation impede venous return, so cardiac output falls. 
 
COPD patients are also known to have excess risk for cardiovascular disease [178], which in itself 
could contribute to exercise limitation, for example as a result of ischaemia or heart failure.   
 
1.5.2.2 Skeletal muscle dysfunction 
As discussed earlier, skeletal muscle dysfunction is well recognised in COPD as a cause of exercise 
limitation [116]; patients are often equally limited by leg fatigue as by dyspnoea [118]. In particular, the 
muscles of the lower extremities seem to be more susceptible to changes associated with muscle 
dysfunction, namely reduced strength and endurance, and fatigability.  
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1.5.2.3 Deconditioning  
Deconditioning is defined as a loss of physiological function as a result of reduction of training 
intensity and affects healthy subjects as well as those with chronic disease. COPD patients are much 
less physically active than their healthy counterparts, leading to the theory that deconditioning causes 
muscle dysfunction; However deconditioning affects all systems. Cardiovascular effects include 
reduction in maximal oxygen uptake capacity, an increase in resting heart rate and increased heart 
rate recovery time and a reduction in stroke volume [179]. Other metabolic effects include change in 
lipid profile towards less high density lipoproteins, reduction in muscle oxidative capacity and muscle 
fibre atrophy [180]. However, it is difficult to distinguish changes due to deconditioning and general 
lack of fitness from other changes in the muscle thought to be specific to COPD itself and not seen in 
other patient populations.  
 
 
1.6 Measuring physical activity  
 
1.6.1 Physical activity questionnaires 
 
In order to change behaviour with a view to increasing patients’ physical activity in day to day life, it is 
necessary to establish baseline levels of activity, but accurately measuring this remains challenging. 
When studying small numbers of subjects, direct methods of recording physical activity such as 
motion detectors or heart rate monitors can be used. However, this is simply not feasible when 
studying physical activity patterns at the population level. Where occupation had originally been used 
to classify levels of activity (such as in the Morris and Paffenberger studies), the changing and varied 
patterns of modern working life make this unreliable. Questionnaires are therefore the only practical 
alternative. Numerous questionnaires or surveys on physical activity (e.g. IPAQ [181], Yale physical 
activity questionnaire [182], CHAMPS [183], Harvard alumni questionnaire [184], Minnesota leisure 
time physical activity questionnaire [185]), have been used over the last few decadesin 
epidemiological studies, all measuring different factors over time periods of day to years. Whilst they 
are cheap, usually easy to administer and often the only feasible way to measure physical activity at a 
population level, there are several problems associated with their use. 
 
1.6.1.1 Type of physical activity 
Physical activity as an entity is not uniform or one-dimensional (such as measuring blood pressure or 
heart rate for example), which makes it challenging to be assessed accurately by questionnaires. 
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Activity itself can mean several things, as discussed earlier; anything from formal exercise to 
housework. Intensity, frequency, duration, aerobic and resistance activity are all different facets of 
physical activity, and questionnaires must be able capture all these aspects to truly reflect an 
individual’s activity. For example, a common classification of intensity is to use METs with light 
exercise anything below 3 METs, to vigorous exercise above 6 METs. However, this classification is 
mainly based on values in young adults; thus what may be classed as light intensity for a 20 year old 
may actually constitute vigorous activity for a 50 year old, but a questionnaire may not be able to 
make this distinction if simply asking patients to list their activities.  
 
1.6.1.2 Reliability 
This is the ability of a questionnaire to give the same result on re-testing the same factor. (Measures 
of reliability include Chi squared statistics, the coefficient of repeatability and test/retest intraclass -
correlation coefficients). Any changes on re-testing either represent true change from the subject or 
errors of subject reporting. In addition, if the test in administered by an observer, inter- and intra-
observer errors can add to the inaccuracy. 
 
Reliability is also compromised due to differing perceptions between individuals regarding perception 
of intensity or duration of exercise. As already mentioned, an activity which may constitute light 
exercise to one person may be vigorous to another and a questionnaire may not be able to assess 
this.  
 
Reliability of response deteriorates the greater the interval between test and retest. For example, 
test/retest correlation coefficient on the college alumnus questionnaire found r values of 0.72 at one 
month, but only 0.3 to 0.4 at 12 months[186]. Similar findings were observed with other 
questionnaires, such as the CHAMPS questionnaire (r=0.58-0.67 at 6 months)[183].  
 
Another reason for poor reliability is recall bias. This is a systematic error that occurs due to 
inaccuracies in the recollections retrieved. This is a particular problem in retrospective studies, 
particularly if the questionnaire is administered after a long time period after the activity to be 
measured. 
 
Other sources of error include cultural or social pressures to respond in a certain, e.g. over-reporting 
amount of activity; or lack of awareness about what constitutes activity (such as under-reporting 
housework).  
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1.6.1.3 Validity 
This is an important aspect of questionnaire design and refers to how well the questionnaire 
measures what it says it is measuring i.e. physical activity. Although there are many components of 
validity, criterion validity is the most relevant; that is, assessing the questionnaire against another 
related measure, such as energy expenditure as recorded by an activity monitor. For example, the 
Minnesota leisure time physical activity questionnaire was validated with a waist mounted activity 
monitor, resulting in a correlation coefficient of 0.69, although this fell to 0.43 when the monitor was to 
the leg [187]. The doubly labelled water method of measuring energy expenditure, although 
expensive and technically challenging, has also been used to validate questionnaires (this method is 
discussed later), for example, to assess the Baecke total activity index, giving a correlation coefficient 
of 0.68 [188].  
 
1.6.1.4 Sensitivity 
This refers to the ability of a questionnaire to detect change in the factor being measured, such as 
amount of activity. In one study, activity was measured with monitors and questionnaires in patients 
with peripheral arterial disease compared to controls. Activity monitor data suggested the patients’ 
energy expenditure was only 46% of the controls, whereas the Stanford 7 day activity recall 
suggested it was much higher at 98% [189].  
 
Floor effects are common and occur when the questionnaire is not sensitive to discriminate activity at 
lower levels. This is a major weakness in severe COPD patients who typically have low levels of 
activity and have poor repeatability and sensitivity [190].  
 
The number of physical activity questionnaires is vast, all measuring physical activity in a different 
way, but very few have been tested for reliability, validity or sensitivity. For example, a systematic 
review by van Poppel et al [191] tested the measurement properties of 85 different physical activity 
questionnaires. Properties such as validity, responsiveness (i.e. does the questionnaire score change 
to reflect changes in the factor being measured?) and reliability were investigated. Validity was also 
assessed in 76 of these questionnaires using accelerometer or metabolic data. 51 were tested for 
reliability. Overall, few questionnaires had sufficient reliability and validity. They also found lack of 
standardisation of questionnaires, leading to many variations in questionnaires. They didn’t find any 
questionnaire to be better than others and suggested more care when assessing the measurement 
properties of questionnaires in order to develop more reliable tools.  
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These problems have predicated the need for more accurate ways to measure physical activity, in 
order to not only study its effects, but also to implement changes to improve health. 
 
 
1.6.2 Physical activity monitors  
 
Physical activity monitors are devices which are increasingly used to provide objective measures of 
daily physical activity levels in both healthy subjects and patients. A wide variety of activity monitors 
are currently available, and they continue to grow in number, but they all have the common feature of 
piezoelectric accelerometers. The piezo
2
electric effect was first demonstrated in 1880 by the Curie 
brothers Pierre and Jacques, and is the property of certain crystals to exhibit electrical change under 
mechanical loading. (Examples include quartz, topaz and lead zirconate titanate).  
 
Accelerometers are able to use the piezoelectric effect to transduce forces of movement, usually in 
two or three axes, into an electrical signal. Accelerations of the human body are usually less than 
10Hz and between -6 to 6g (although higher forces occur during impacts and landings). Therefore the 
raw accelerometer signals require filtering to accurately reflect human movement. High pass filters 
remove low frequency signals such as normal gravitational force; this allows monitors to record zero 
acceleration when a person is stationary. Conversely, low pass filters remove high frequency 
accelerations and electrical interference (typically at around 20Hz in order to capture the full range of 
human movement). 
 
These signals can then be transformed into a measure of energy expenditure using one of a number 
of algorithms, or summarised as activity counts or vector magnitude units (reflecting acceleration of 
the body in different planes). With the information obtained in the vertical plane or through pattern 
recognition, steps or walking time can also be derived by some monitors. 
 
Due to their very nature, accelerometers are not perfect in their measurement of movement. Sources 
of error include detection of gravitational acceleration, external vibration or jolting of the sensor due to 
incorrect fastening, all of which are not attributable to actual physical activity. Positioning of activity 
monitors is important to consider. The manufacturers of several monitors indicate their preference of 
position to be at the hip, as this position will capture walking but is perhaps less obtrusive than a thigh 
or ankle worn device. However, wrist and arm worn devices are also available. Lower limb-positioned 
                                                     
2
 Piezo from the Greek piezin, meaning to press or squeeze 
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monitors may capture walking and running activities more accurately than arm or wrist worn monitors, 
but upper limb devices may better capture activities such as lifting. However, Bouten et al have found 
very little difference in prediction of energy expenditure during physical activity from monitors placed 
in different positions on the body, despite positional differences in absolute movement detected; 
change in movement, and therefore acceleration, from baseline was more important [192].  
 
A well-known limitation of activity monitors is their inability to accurately detect incline walking, which 
requires more effort but with relatively unchanged accelerometry compared to walking on the flat 
[193]. There is on the whole an underestimation of energy expenditure for activities with a large 
force:displacement ratio (such as stair climbing or knee bends), versus an overestimation with 
activities such as running or jumping with a low force:displacement ratio [194].  
 
 
1.6.3 Energy expenditure and physical activity 
 
As previously discussed, energy expenditure has long been accepted as the reference measure of 
physical activity. Early studies have shown a linear relationship between body acceleration and 
energy expenditure during physical activity [195, 196]. Most of the validation studies of contemporary 
physical activity monitors have been done against some form of energy expenditure measurement, 
known as calorimetry.  
 
1.6.3.1 Whole body direct calorimetry 
Energy released from metabolism results in heat production, which can be measured directly in a 
human calorimetry chamber. This is a well-insulated, adequately ventilated chamber, above which are 
a series of coils through which water flows, absorbing the heat released from the room. The difference 
in temperature of the water at the start and end of the circuit can be used to calculate energy 
expenditure. Air circulation is also carefully controlled to avoid heat loss from expired gases. Although 
highly accurate, this method is expensive and not widely available, requires a great deal of technical 
expertise, and is not suitable for field studies. 
 
1.6.3.2 Indirect calorimetry 
Indirect calorimetry uses the principle that, in order to produce energy from food, the body must use 
oxygen and produces carbon dioxide as a waste product. There are a number of accepted methods, 
depending on the time scale over which measurements are to be made, described below. Resting 
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energy expenditure, REE, that is, the amount of energy required by the body during a 24 hour period 
in resting conditions, can thus be estimated according to the abbreviated Weir equation: 
 
REE per day (kcal) = [3.9 (VO2 ml/min) + 1.1(VCO2 ml/min)] x 1.44  
 
This takes into account certain assumptions about the composition of the ‘fuel’ or dietary intake of 
carbohydrates, fat and protein; all are metabolised using oxygen to produce energy, water and carbon 
dioxide, although protein is usually only metabolised during periods of negative energy balance e.g. 
starvation. The respiratory quotient (RQ) is the ratio of carbon dioxide produced to oxygen consumed. 
The RQ for carbohydrate metabolism is 1; for fat it is 0.7; for an equal mixture it is 0.85. 
 
Indirect calorimetry: expired gases method 
This can be measured directly, using the ventilated hood method [197]. Patients are instructed to lie 
still under a canopy after an overnight fast. The canopy is connected to an analyser and the changes 
in oxygen and carbon dioxide concentrations are measured over a 30 minute period. Resting energy 
expenditure can be calculated using the Weir equation as described above. Similarly, expired gases 
analysis during cardiopulmonary exercise testing can also be used to calculate energy expenditure at 
rest and during exercise. Both methods are useful when making measurements over minutes or 
hours. 
 
Indirect calorimetry: doubly labelled water method 
This method can be used for measurements over longer time periods. The technique is based on the 
administration of water containing a known quantity of two stable isotopes of water, 
2
H2O and H2
18
O. 
The water equilibrates throughout the body. Labelled hydrogen will leave the body as water (urine, 
sweat), whereas labelled oxygen will leave as both water and carbon dioxide. The difference between 
the levels of the two isotopes can be measured in the urine, indicating the amount of carbon dioxide 
produced. This represents the amount of energy expended since carbon dioxide is a waste product of 
metabolism. Urine samples are typically collected over a two week period, so the end result is total 
energy expenditure (TEE) over that time period, i.e. the total amount of energy (in calories or joules) 
expended at rest and during physical activity per day. Active energy expenditure can be calculated by 
subtracting resting energy expenditure from this total. Again, energy expenditure is calculated using 
the abbreviated Weir equation [198]. 
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Estimating energy expenditure 
Predicted resting energy expenditure (REE) can also be estimated using the Harris Benedict 
equations [199], which predict values for individuals based on age, sex, weight (in kilograms) and 
height (in metres).   
 
Male: (66.5 + 13.8 x weight) + (5.0 x height) - (6.8 x age) 
 
Female: (665.1 + 9.6 x weight) + (1.8 x height) - (4.7 x age)   
 
Active energy expenditure (AEE) is calculated as (0.9 × TEE) − REE, assuming diet-induced 
thermogenesis to be 10% of total energy expenditure (TEE).  
 
It is important to note that these predicted values apply to healthy subjects, and are not necessarily 
accurate for all COPD patients. It is known that COPD patients have higher resting energy 
requirements, reportedly around 10% higher than demographically matched healthy subjects [200]. 
Fat free mass is the main determinant of resting energy expenditure, but when cachectic COPD 
patients are compared to non-COPD patients with cachexia, they have higher resting energy 
expenditure levels [201].  A number of mechanisms have been postulated. Hypoxia itself causes 
sympathetic activation, which leads to up-regulation of the mitochondrial enzyme, cytochrome 
oxidase, and increased oxygen consumption [202, 203]. Increased work of breathing is more ‘energy 
expensive’, as is poor mechanical efficiency [204, 205]. Muscle fibre shift itself may be responsible, as 
type II fibres consume more oxygen per unit than type I fibres [206]. The role of systemic inflammation 
as a driver for increased energy expenditure is less clear; some studies have found an association 
with TNFα, a marker of inflammation; others have not [207, 208]. Medications such as theophyllines 
and beta agonists have also been shown to increase resting energy expenditure in COPD [209, 210]. 
Regardless of the mechanism, this phenomenon needs to be taken into account when estimating 
active energy expenditure values for COPD patients, particularly when validating physical activity 
monitors against this so-called ‘gold standard’. 
 
 
1.7 Physical activity and exercise capacity 
 
Exercise capacity and physical activity are two distinct concepts but are often erroneously used 
interchangeably. Exercise capacity is a measure of an individual’s maximum ability to do work and 
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can be measured in a number of ways, including walking or cycling tests, whereas physical activity is 
the amount of activity of any type that a person actually does that raises energy expenditure above a 
basal level, as explained earlier.  
 
Exercise testing is useful to assess functional capacity, degree of disability, prognosis for survival, 
limitations such as exercise-induced hypoxaemia and response to interventions. Exercise testing can 
be divided into field tests, such as the six-minute walk test and incremental and endurance shuttle 
tests; and cardiopulmonary exercise testing which is carried out on either a treadmill or braked 
bicycle, with measurement of metabolic data via expired gases analysis, cardiac monitoring via ECG 
and perceived exertion with the Borg scale. 
 
1.7.1 The Borg scale of perceived exertion 
 
Gunnar Borg first described the perception of exertion as a ‘gestalt’ of numerous stimuli from the 
heart, lungs, muscles, joints, as well as perceptions of pain, anxiety, heat and resistance to movement 
(e.g. whilst pedalling, or walking uphill) [211]. Thus, the Borg scale was developed in order to better 
understand an individual’s perceived exertion whilst undertaking physical activity. The 15 point scale 
from 6 (none) to 20 (maximum) was originally designed in this way to be directly scalable to heart rate 
(by a factor of 10); there are good correlations between Borg score and heart rate during exercise 
[177]. A modified 11 point version (0 to 10) with ratio properties (see p 55) was subsequently 
developed to be easier to use (i.e. if 4 is ‘light’, then 2 will be half as much exertion etc.) The scale 
can be applied to both breathlessness and leg fatigue, and scores for both factors are recorded 
before and immediately after any exercise test. 
 
1.7.2 Cardiopulmonary exercise testing 
 
The gold standard of assessment of exercise capacity is cardiopulmonary exercise testing, during 
which several cardiovascular, respiratory and metabolic variables can be collected for a dynamic, 
global assessment of the integrated physiological response to exercise which cannot be assessed by 
measuring the function of individual organ systems alone. Usually this test is carried out on either a 
treadmill or a static bike. Both submaximal and peak exercise responses can be assessed, and well 
as giving information on functional exercise capacity and impairment, CPET aids evaluation of 
undiagnosed exercise-induced dyspnoea, and preoperative assessment of patients with 
cardiopulmonary disease [212]. 
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1.7.2.1 Principles of CPET testing 
The metabolic response to exercise is determined through measurement of a number of variables. 
The subject wears either a tightly fitting mask or mouthpiece with a nose clip to prevent air leaks. 
Airflow is measured either with a pneumotachograph or a turbine flow transducer. Expired oxygen and 
carbon dioxide are measured during the test with a gas analyser. Breath by breath analysis was used 
in these studies to calculate the rate of oxygen uptake, VO2, and carbon dioxide output, VCO2 per 
minute: 
VO2 = Σ (FIO2 – FEO2) x VE x Δt 
VCO2 = Σ (FECO2 x VE x Δt) 
 
VE = Expired airflow rate 
FIO2, FEO2, and FECO2 are the fractional concentrations of expired O2, and expired CO2, 
respectively. 
Δt – sampling interval 
 
Oxygen uptake, VO2, is determined by cellular oxygen demand and can be calculated from blood flow 
as expressed by the Fick equation:  
 
VO2 = Q (CaO2 - CvO2) 
 
Q = cardiac output 
CaO2 = oxygen concentration of arterial blood 
CvO2 = oxygen concentration of venous blood 
 
Heart rate is monitored continuously with a 12 lead ECG which gives information regarding 
arrhythmias and ischaemic changes during exercise. Heart rate response to exercise is important to 
record; the normal response to exercise is an immediate increase in heart rate due to decreased 
vagal tone and increased sympathetic drive. Heart rate increases linearly with increasing workload but 
the rate of increase and the maximum heart rate achieved is determined by several factors including 
age and comorbidities. Medications are also important; beta-blockers will blunt the chronotropic 
response whereas beta agonist treatment has been shown to cause a significant increase in heart 
rate during exercise in healthy subjects compared to placebo, [213] so must be considered in patients 
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with COPD who are usually prescribed long acting beta agonist inhaled therapy. Cardiac output 
monitoring is rarely done in the clinical setting as it is an invasive procedure. Oxygen saturation is 
also monitored with an oximeter. In these studies, patients’ blood pressure was measured at the start 
and end of exercise. 
 
Factors affecting oxygen availability include haemoglobin concentration, oxygen saturation, cardiac 
function (stroke volume and heart rate), peripheral blood flow to tissues and tissue extraction of 
oxygen (mitochondrial density and function, capillary density and tissue diffusion). 
 
VO2 increases in proportion to work rate until one of its determinants reaches its limit, when the 
VO2/WR slope begins to plateau, giving a good indication of VO2max. However a clear plateau may not 
be reached if increased symptoms (breathlessness, leg fatigue) cause termination of the test before 
this point; the result is measurement of VO2peak, which is used as an approximation of VO2max. 
 
Ventilation increases in response to exercise to meet metabolic oxygen demand, but also serves to 
modulate acid-base changes that occur due to increased muscle activity. Minute ventilation, VE, tidal 
breathing and breathing frequency are all measured during CPET. Breathing depth and frequency 
increase in exercise and in healthy subjects at higher work rates, there is both a decrease in end 
expiratory lung volume (EELV) and an increase in end inspiratory lung volume (EILV). Ventilation 
increases linearly with VO2 until anaerobic threshold, where VCO2 and VE increase more than VO2. 
The point at which this happens is a good indicator of the anaerobic threshold, i.e the onset of lactic 
acidosis in the exercising muscles. In healthy subjects, this usually occurs at around 50 to 60% of 
VO2max. A lower value may indicate a problem with oxygen delivery to the muscles, be it cardiac, 
pulmonary or metabolic in the muscle itself.  
 
The ventilatory response to exercise is particularly important in COPD, as it is this factor that most 
limits patients during exercise. CPET has demonstrated the problems these patients encounter with 
dynamic hyperinflation. As ventilatory demands increase during exercise, there is progressive gas 
trapping due to airflow obstruction. This results in a paradoxical increase in EELV and reduction in 
inspiratory capacity, which limits the degree to which tidal volume can increase. There is a greater 
mechanical load on the respiratory system causing increased work of breathing, dyspnoea at lower 
workloads and a lower peak VO2 [84]. CPET has proved to be more sensitive in detecting 
improvements in exercise performance due to medication than the 6MWT [214]. CPET has also 
demonstrated that COPD patients experience an early-onset metabolic acidosis, which is associated 
with skeletal muscle dysfunction [215]. 
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1.7.2.2 Incremental CPET 
A CPET protocol in which the work rate increases at a constant rate enables rapid acquisition of data. 
Cycle ergometry permits increments of 5 to 20 watts per minute by increasing resistance to pedaling  
and subjects are encouraged to continue to exhaustion. Such an approach enables assessment of 
the integrated response of cardiovascular, respiratory and metabolic systems at peak exercise, 
through parameters such as VO2, lactate threshold, O2 pulse, CO2 production and minute ventilation. 
This can also be used as a diagnostic tool to detect pathology within one or more of these systems as 
the cause for exercise limitation or dyspnoea. 
 
1.7.2.3 Endurance CPET 
An endurance or steady state test is usually based upon the results of a maximal test, by taking a 
percentage of the maximum work load achieved (e.g.75%) and applying this as a constant work rate. 
During a steady state test, the period of dynamic adjustment to the constant work rate provides 
information regarding the dynamic behaviour of lung function, haemodynamics and tissue O2 
utilisation. Such a protocol may be more useful in establishing response to an intervention such as 
bronchodilator therapy or lung volume reduction surgery.  
 
 
1.7.3 Field exercise capacity tests 
 
Clearly, cardiopulmonary exercise testing requires complex equipment in the form of either a 
stationary bike or treadmill, together with a ‘metabolic cart’ which includes expired gas analysis, ECG 
monitoring and even blood gas analysis, as well as specialist training to both carry out the test and 
analyse the results. Hence, other measures of exercise capacity have been developed which are 
simpler to perform and require much less equipment and training. These include the six minute walk 
(6MWT) and incremental shuttle walk tests.  
 
1.7.3.1 Incremental shuttle walk test (ISWT) 
This test was developed by Professor Sally Singh to simulate a cardiopulmonary exercise test using a 
field walking test [216]. The patient is asked to walk between two cones, 10 metres apart, in time to a 
set of auditory beeps played on a CD. The speed of the beeps gradually increases each minute and 
patients walk as long as they are able to keep up with the beeps or until symptoms (dyspnoea, leg 
fatigue) no longer allow. Borg scores are recorded before and immediately afterwards. The number of 
shuttles (distance between the cones represents one shuttle) is recorded. Standardisation of the test 
is important; the ISWT should be performed twice to account for a learning effect.  
52 
 
 
The result of the ISWT can be used to prescribe exercise, as well as to evaluate efficacy of this 
exercise as in a pulmonary rehabilitation programme. According to Singh et al, an improvement of 
47.5 metres in ISWT distance indicates that patients with COPD are ‘slightly better’; an improvement 
of 78.7 metres represents ‘better’ [217].  
 
1.7.3.2 Six minute walk test 
This is a simple exercise test which only requires a minimum 30 metre flat straight walking course with 
markings every 3 metres to aid measurement. The strongest indication for the 6MWT is to measure 
the response to medical interventions in patients with moderate to severe heart or lung disease. It has 
also been used as a measure of functional status of patients, as well as a predictor of morbidity and 
mortality [218, 219]. 
 
There several sources of variation which influence the distance walked, including height, age, sex, 
and comorbidities (presence of musculoskeletal disorders such as arthritis, cognitive impairment), as 
well as technical factors such as using a shorter corridor necessitating more turning or degree of 
encouragement given during the test. However, it has been shown that while distance walked 
increases with practice indicating a training effect, performance plateaus after two tests [220], so 
patients should perform the test twice, with at least 30 minutes rest in between if on the same day but 
no more than a week apart, if they have never performed the test before.   
 
However, rather than absolute values, change with time or after a particular intervention is a more 
useful measure. Polkey et al have recently showed in a cohort of over 2000 patients with COPD that a 
mean decline in six minute walk distance over 1 year of at least 30m confers an increased risk of 
mortality (hazard ratio 1.93, 95% confidence interval, 1.29–2.90; p = 0.001) [221], establishing a 
minimal clinically important difference in this population.  
 
As the test is self paced and patients can stop and rest when they feel they need to, the test is 
submaximal in nature, when compared to cardiopulmonary exercise testing with subjects reaching 
around 80% of peak VO2 during a six minute walk test compared to an incremental CPET [222]. 
However it is for this reason that the six minute walk test is perhaps a more useful indicator of 
functional capacity and symptoms experienced, as patients will tend to perform their normal daily 
activities also at a submaximal level.  
 
These field exercise tests do not give any information regarding oxygen uptake during exercise, and it 
is suggested that they should complementary to CPET, rather than a substitute. However, the VO2 
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obtained on the ISWT has been shown to have a strong correlation (r=0.88) with VO2 obtained on a 
CPET on a treadmill [223]. 
 
Good correlations have been reported between the outcome of the 6MWT and CPET VO2max (r=0.73). 
Although both tests are effort dependent to an extent, the 6MWT is perhaps more so as patients pace 
themselves rather than having to meet an external pacing requirement, such as revolutions per 
minute on a stationary bike. It is perhaps why the 6MWT has been shown to correlate better than 
VO2max with patients’ ability to perform daily activities. Pitta et al 2005  studied 50 patients with COPD 
and found a weak correlation between daily physical activity levels as recorded with a physical activity 
monitor and VO2max achieved on an incremental CPET (r=0.33), compared to 6 minute walk distance 
(r=0.76). 
 
But how good is the 6MWT? Eliason et al [224] found positive associations of mean physical activity 
and time spent in moderate to vigorous physical activity, MVPA (as measured with the Actigraph a 
triaxial accelerometer) with 6MWD in 44 COPD patients. There was no association between exercise 
capacity and time spent sedentary, suggesting a role for at least moderate physical activity in 
contributing to exercise capacity. 
 
However, a recent study looked at the power of the 6MWT, as well as other functional measures (sit 
to stand test, hand grip strength) and a physical activity questionnaire, to predict daily physical activity 
in 70 COPD patients, as measured by a multisensor accelerometer [225]. They found that whilst there 
was a good correlation between the 6MWD and the steps per day measured by the activity monitor 
(r=0.69), the area under the curve on a subsequent receiver-operator curve was only 0.68, indicating 
moderate predictive power only, with a distance of 425m having positive and negative predictive value 
of 0.46 and 0.65 respectively. Interestingly, there were only weak correlations within variables of the 
activity monitor itself, namely both energy expenditure and average METs with steps/per day, which 
perhaps illustrates further the difficulties of accurately representing physical activity in this largely 
inactive patient group. However the ROC analysis with 6MWD was not done with either METs or EE. 
Nevertheless, the results of this study do suggest a significant behavioural component to physical 
activity levels in this population which are difficult to capture with objective measures such as activity 
monitoring or exercise capacity.  
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1.8 Physical activity: behaviour versus physiology? 
 
Despite the well-established benefits of physical activity in adults and children alike, nearly a third of 
the adult population worldwide are inactive. In order to improve this statistic, not only is it important to 
be able to accurately measure physical activity, as described earlier, but to also identify the barriers to 
increasing physical activity, particularly those which are potentially modifiable.  
 
1.8.1 Barriers to physical activity 
 
It is well recognised that the determinants of physical activity interact in a complex way, in that there 
may be several pathways to change in behaviour [226]; interventions may have different effects 
according to individual, cultural and social influences; and may also differ at initiation, maintenance 
and cessation of activity [227]. Broadly speaking, these determinants can be divided into personal and 
environmental factors [228]. 
 
Personal factors include health, motivation level, time constraints and previous exercise experience. 
Older adults often cite poor health as a barrier to being active [229]. Gender differences have also 
been found, with women more likely to be inactive than men, and this gap widens with age [230]. 
Previous experience of activity in childhood may have a carry over into adulthood in a positive way if it 
was enjoyed, but could also be a negative influence, for example if forced to do sports by parents. 
Socio-economic factors also influence barriers; for example, lack of time has been found to correlate 
positively with socio-economic status, whereas lack of money or transport correlated negatively [231].  
 
Environmental factors cited include weather, transportation, access to resources, safety concerns 
about the locality or suitability of the local area, for example, availability of parks and pavements for 
walking, and social factors such as lack of social support or other people to exercise with [232]. 
 
Adults over 65 have the highest prevalence of inactivity; 66% of those over 75 do not engage in any 
regular physical activity [233]. This is relevant to COPD as incidence of this disease increases with 
age [234].  Of those older adults who are active, adherence is poor, with only 30% of men and 15% of 
women participating in regular sustained activity. Physical activity is particularly important in this age 
group; as well as reducing risk factors associated with specific diseases such as cardiovascular 
disease it also improves overall quality of life, for example through promoting independence and 
preserving functional ability. In older adults, it is difficult to promote adherence to activity programmes 
– up to 50% drop out inside 6 months. It may be that changing attitudes to exercise in this group is 
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important – exercise should be seen not as a recreational activity, but a necessary medical treatment. 
In addition, older adults including those with chronic diseases such as COPD may need specific 
guidelines, rather than general advice to ‘be more active’, especially as they might perceive 
symptoms associated with exercise such as breathlessness, sweating and muscle fatigue as 
negative.  
 
1.8.2 The effect of weather on physical activity 
 
One potential environmental barrier to physical activity, weather, and seasonal differences in weather 
and climate, in the context of COPD will be discussed in this thesis in more detail in Chapter 5. The 
effect of weather and climate on physical activity levels in the general population has been recently 
examined in more depth. A systematic review by Tucker et al [235] looked at 37 studies published 
over a 26 year period, with nearly 30000 subjects across 8 countries.  Physical activity was measured 
either through questionnaires or with activity monitors. They found that in most studies, physical 
activity was found to peak in summer months and was significantly lower during winter. This decline 
was attributed to poor weather conditions and shorter day length [236]. However, one study carried 
out in Texas found physical activity to be lower in the summer [237]. This was attributed to extreme 
heat acting as a deterrent to outdoor activity – the average temperature for July was 29°C. 
Interestingly, an Australian study of 1754 healthy adults participating in a 5 year study on the effect of 
urban design on physical activity [238] found very little effect of weather on physical activity levels as 
measured with both a questionnaire and a pedometer. However the authors commented that weather 
conditions were fairly constant throughout the study and only explained up to 6% of the variance in 
physical activity.  
 
There is little data looking at the effect of weather and season on physical activity in COPD. O’Shea et 
al [239] interviewed 22 patients with COPD who were enrolled in a 12 week progressive resistance 
exercise programme, with the aim of identifying factors that would affect adherence. They found 
several barriers, in keeping with the themes already discussed (environmental, personal). Weather 
was the most commonly stated major environmental barrier to activity, but nevertheless was only 
cited by 7 participants. This was a mainly qualitative study with no objective physical activity 
measurement or systematic recording of weather conditions, and largely supported what is already 
known – that there is a complex interaction between personal and environmental factors in both short 
and long-term adherence. Other studies in healthy populations have shown the weather to be less of 
a barrier in those who are more physically active and enjoyed being so [240]. However, a recent study 
in another disease population, adults with arthritis, did find an objective effect of weather on physical 
activity levels as measured with an accelerometer. 214 patients were monitored over 3 years 
throughout the year to capture activity data throughout the year. Temperature, daylight hours, rain 
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and snowfall data was also collected. They found heavy rain to be associated with a 12% fall in 
activity and shorter day length characteristic of winter associated with a 14% fall in activity. On 
average, patients had a 38% lower activity level in winter compared to summer.  
 
A smaller study with direct measurement of physical activity in COPD by Sewell et al examined the 
effect of season in 95 patients participating in a pulmonary rehabilitation programme [241]. The 
patients were split into 4 groups according to when they enrolled in the programme. Physical activity 
was measured using a uniaxial accelerometer. They found that those starting pulmonary rehabilitation 
in the winter had lower physical activity levels at baseline but also improved the most. However, there 
was no effect of season on the other outcome measures before and after rehabilitation, namely 
incremental shuttle walk distance or quality of life measures. In addition, the number of patients in 
each group was relatively small (n=18 to 34) and the same patients were not followed up throughout 
the seasons. 
 
If it could be shown that there is a significant difference in physical activity due to season within the 
same subject, this would have to be taken account in terms of choosing when to monitor patients as 
well as for how long, as this may influence outcomes in not only interventional studies in clinical 
settings such as pulmonary rehabilitation. Optimisation of clinical resources in a financially restrained 
environment is vital for all stakeholders. Geographical location becomes more pertinent in multicentre 
studies where patients are being recruited from different countries, and inter-centre differences in 
results would also have to be accounted for. These potential variations could act as confounders for 
any effect that was being investigated. This question is addressed in more detail in Chapter 5.  
 
 
1.9 The PROactive project 
 
Much of the work of this thesis was carried out as part of the PROactive initiative. This is an EU wide 
multicentre project spanning 6 years and funded by the Innovative Medicines Agency. As has already 
been discussed, the importance of physical activity in COPD is undisputed. Patients struggle with 
simple activities of daily living which involve physical exertion. However, to date, there is no measure 
of physical activity that accurately captures the patient’s experience of physical activity and any 
difficulties associated with it as a result of COPD. This represents an important therapeutic target from 
the patient’s perspective, over and above traditional outcome measures such as FEV1. Thus, the main 
aim of this project is to develop a patient reported outcome tool, incorporating items from a 
questionnaire with data collected from a physical activity monitor (such as step count for an objective 
measure of amount of physical activity) to accurately record this experience of physical activity. Going 
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forward, this tool could then be used to measure physical activity as an outcome measure in 
randomised controlled trials, particularly for labelling purposes in pharmaceutical trials.  
 
The PROactive project is guided by a consortium of 19 partners including academic institutions, 8 
major pharmaceutical companies and patient organisations. The studies are implemented by research 
teams across Europe; in addition, there is an academic board which provide independent peer review 
of the work of the project. 
 
The process of developing this tool has taken several steps, firstly with a systematic review of the 
literature regarding activity monitors that have been previously used and validated in chronic diseases 
[242]. This review enabled selection of the activity monitors that were used in the validation studies 
presented in this thesis. A further systematic review set out to look at the determinants of physical 
activity, to give a better understanding of this concept, which would help plan interventions, guide 
research and manage COPD more effectively [243]. The main findings were that the overall quality of 
evidence regarding determinants of physical activity in COPD is low, but consistent evidence for the 
effect of physical activity on COPD exacerbations and mortality. Very few interventions on 
determinants of physical activity have been tested, with inconsistent results.  
 
As well as the findings of the systematic review, further information was gained from a study involving 
patient interviews and focus groups with COPD patients [244]. 116 patients from 4 different European 
countries participated in 3 consecutive qualitative studies; firstly, one to one interviews about how 
they experienced physical activity; secondly, focus groups where patients shared and compared their 
experiences; and thirdly, cognitive debriefings where patients were encouraged to think about the 
meanings of questions about physical activity initially derived from the first 2 studies. What patients 
actually said enabled the development of draft items for the patient reported outcome tool.   
 
In addition, this study, as well as the systematic review, enabled the development of a conceptual 
model of physical activity in COPD, comprising sociodemographic, environmental, lifestyle, clinical 
and functional determinants; and outcomes such as FEV1, dyspnoea and quality of life measures. . 
This is in accordance with guidelines set out by the US Food and Drugs Agency, which state that 
development of PROs must be based on a conceptual framework. The European Medicines 
Association defines a PRO as “any outcome directly evaluated by the patient and based on the 
patient’s perception of a disease and its treatment(s)”. Clearly, for pharmaceutical labelling purposes, 
adherence to these guidelines was a major consideration in the PROactive project as a whole.  
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Two versions of the draft questionnaire were developed – a daily PRO for use over a 1 to 2 week 
period; and a clinic PRO for use in an outpatient setting to reflect the previous 7 days’ experience of 
physical activity. These were used in an item reduction study, which is discussed further in Chapter 5 
[245], and provided data for the work presented in this chapter. The culmination of the project will be 
to use the final versions of the PROs in randomised controlled trials. These studies are ongoing at 
date of print.  
 
 
1.10 Thesis aims 
 
This thesis will explore the importance of technical, environmental and patient factors in physical 
activity in COPD. Much of the work of this thesis was carried out as part of the PROactive initiative. 
The first two studies are validation experiments of a number of physical activity monitors in COPD 
patients in laboratory and domestic settings for suitability as part of the PROactive tool.  
 
The third study explores the changes in physical activity over time, and how this varies according to 
season and climate. Physical activity was measured with monitors validated for use in COPD patients 
from the first two studies. Again, these patients were studied under the PROactive project, but as an 
additional study to the project’s primary objective, which was the formulation of the questionnaire part 
of the PRO tool. One of the aims of the PROactive tool is to use it as a secondary outcome measure 
in pharmacological and other interventional studies. As these studies are often multicentre and 
multinational in nature, how geographical location and climate might affect physical activity are factors 
which may require consideration in future studies, where physical activity is used as an outcome 
measure. 
 
The fourth study examines the influence of behavioural over physiological factors on daily physical 
activity in COPD, the hypothesis being that physiological factors contributing to dyspnoea at the 
beginning of any physical activity may drive behaviour in COPD of all severities and deter patients 
from persisting with activity, thus causing inactivity. The relationship of measured daily physical 
activity in COPD with the early physiological response to exercise is tested. The aim is to validate the 
analysis of this response and to test the hypothesis that the early response is better related to and 
more representative of daily physical activity in COPD patients than other measures of maximal 
exercise capacity. 
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2 Methods 
 
2.1 Ethical approval 
 
For the studies in Chapters 3 and 4 (laboratory and field validation studies), ethical approval was 
given for the UK by the Lothian Ethical committee (ethics number 10/S1102/37). For the study 
comprising Chapter 5, approval for the UK was granted by the London Bloomsbury Ethical committee 
(ethics number 11/LO/07111). Further approval for all studies was given by the Research and 
Development department of the Royal Brompton & Harefield NHS Trust. All subjects gave their 
written informed consent. 
 
2.2 Statistical analysis 
 
Analyses were carried out using SPSS Statistics 19 (IBM Corporation, New York, USA) and 
GraphPad Prism 5.0 (GraphPad Software Inc., CA, USA). GraphPad Prism was also used to 
construct the graphs. Specific analyses used in each study are described in more detail in the 
relevant chapters. A p-value <0.05 was taken to be significant (this takes into account corrections for 
multiple comparisons).  
 
2.3 Study subjects 
 
Most of the patients used were recruited from the COPD database, which included patients who 
attended the outpatients department in the Royal Brompton Hospital, as well as those from other 
trusts who had volunteered to participate in research. Only patients with COPD were recruited. 
Diagnosis was confirmed according to the GOLD guidelines [246], i.e. patients with predominantly 
irreversible airflow limitation with FEV1<80% predicted and/or an FEV1/FVC ratio<70% and a clinical 
history consistent with the diagnosis (symptoms of exertional dyspnoea, chronic cough, wheeze and 
regular sputum production with a significant smoking history). Patients with other primary respiratory 
conditions (such as asthma, bronchiectasis or pulmonary fibrosis) were excluded. Patients were also 
excluded if they had significant co-morbidities, including active malignancy, chronic heart failure, 
dementia, physical disability and other neurological and rheumatological conditions (e.g. Parkinson’s 
disease, severe arthritis) which prevented them being physically active for reasons other than COPD.  
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An exacerbation of COPD was defined as an episode of worsening in respiratory symptoms, which 
could be any of the following: increased breathlessness/wheeze, cough, increased sputum 
production/change in colour; requiring systemic glucocorticosteroids and/or antibiotics [247].  
 
 
2.4 Pulmonary Function Testing 
 
All pulmonary function measurements were performed with standardised equipment which was 
calibrated daily. Spirometry was obtained using a pneumotachograph and after administration of a 
bronchodilator. Diffusing capacity of the lung was determined by the single breath carbon monoxide 
gas transfer method. Lung volumes were measured using whole body plethysmography. Blood gas 
levels were measured using arterialised earlobe capillary samples. Patients who were on 
supplementary oxygen were asked to do the tests after a washout period of 30 minutes without 
oxygen, if symptoms allowed. All variables are given as absolute values expressed as percent 
predicted of reference values [248, 249]. In this thesis, these tests were carried out by respiratory 
physiologists in the Lung Function department of the Royal Brompton Hospital, according to American 
Thoracic Society and European Respiratory Society guidelines [250]. 
 
 
2.5 Exercise testing 
 
Exercise tests were used to assess the patients’ functional capacity; the six minute walk test and 
cardiopulmonary exercise test were used.  
 
 
2.5.1 The Borg scale of perceived exertion 
A Borg score was obtained before any exercise test, at rest, and immediately on cessation of 
exercise. A score for dyspnoea and leg fatigue were obtained using the scale below:  
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Borg score 
0 Nothing at all 
0.5 Just noticeable 
1 Very slight 
2 Slight 
3 Moderate 
4 Somewhat severe 
5 Severe 
6  
7 Very severe 
8  
9 Very very severe 
10 Maximal 
 
 
2.5.2 Six minute walking test (6MWT) 
 
This test was used to assess patients’ functional exercise capacity. As described earlier, two tests 
were performed to account for the learning effect, with at least 30 minutes rest in between if on the 
same day but no more than a week apart, if they had never performed the test before. The greater of 
the two results was used. This was performed in a marked 30 metre course.  
In a subset of patients studied for the third study in this thesis, the mean difference between the two 
walks was 12.8m (standard deviation 25.8m), well below the minimal clinically important difference 
described in the previous chapter [221]. Most of these patients had previously performed six minute 
walk tests either in previous studies or for clinical reasons, thereby accounting for any training effect.  
Absolute contraindications were unstable angina or myocardial infarction one month prior to the test. 
Relative contraindications were resting heart rate > 120 bpm, systolic blood pressure > 180mmHg 
and diastolic BP >120mmHg. Prior to the test, patients’ resting blood pressure, heart rate and oxygen 
saturation were recorded, as well as Borg scores for breathlessness and leg fatigue. Patients who 
required ambulatory oxygen were given supplementary oxygen (which was carried for them) during 
the test and the flow rate was noted. Patients were then instructed to walk as far as they can in six 
minutes and given standardised encouragement [218]. They were allowed to stop if they need to at 
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any time during the test and asked to resume walking as soon as they felt able to. If they did stop, the 
total length of time spent resting was noted. The clinician supervising the test did not walk with the 
patient to avoid pace setting. The test was stopped in the event of intolerable dyspnoea or leg fatigue, 
angina-like chest pain, light-headedness or any other appropriate clinical reason. Blood pressure, 
heart rate, oxygen saturation and Borg scores were recorded immediately at the end of the test.   
 
 
2.5.3 Cardiopulmonary exercise testing 
 
Cardiopulmonary exercise testing was carried out using a magnetically braked exercise bicycle. This 
was chosen over a treadmill as it provides a more stable platform than a moving treadmill which is 
better for some of the more severe and frailer COPD patients. (Although the peak VO2 reached in 
healthy subjects on the bike is around 10% lower than that achieved on the treadmill in walking or 
running, this is not the case in COPD [251]). The resistance on the pedals was adjusted to give a 
stable workload regardless of speed of pedalling, although patients were instructed to pedal at around 
60 rpm.  
 
 
Absolute contraindications to exercise testing are: 
Aortic Aneurysm 
Current viral illness / acute infection 
Unstable angina / acute ECG changes of ischaemia / acute cardiac event 
Myocardial infarction within the last 4 weeks 
Severe hypertension (systolic >240 mmHg; diastolic >120 mmHg) 
Poorly controlled heart failure 
Myocarditis / Endocarditis 
Exacerbation of asthma 
Severe aortic stenosis 
Acute pulmonary embolus / thrombus / venous thromboembolic disorders 
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In the presence of relative contraindications, testing was carried out at my discretion: 
Gross arrhythmias 
Resting tachycardia >120 beats/min. 
Electrolyte disturbance 
Epilepsy / Cerebrovascular disease 
Resting PaO2 < 7.0kPa. 
Pulmonary hypertension. 
Uncontrolled metabolic disorders 
Advanced or complicated pregnancy 
 
Subjects wore a mouthpiece within which was a turbine unit. An electronic sensor detects rotation of 
the vane inside the turbine; the number of pulses per unit time is equal to flow. It was important to get 
a good seal around the mouthpiece to avoid air leak and thus inaccurate airflow measurements. A 
gas analyser tube was attached to the mouthpiece and connected to the gas analyser unit, which 
comprised an O2 fuel cell analyser and a CO2 thermal conductivity analyser. Both volume and gas 
calibrations were carried out prior to testing.  
 
Subjects were seated on the bike and saddle height was adjusted accordingly. They were asked to 
wear the mouthpiece ensuring a good seal and ECG leads were connected. They started with a 2 
minute rest period to allow adjustment to the mouthpiece, followed by 1 minute of unloaded pedalling. 
This enabled patients to become accustomed to pedaling, whilst also allowing for the lag time 
between increment in workload and VE, VO2 and VCO2. They were given standardised 
encouragement throughout the test. Borg scores were recorded in rest and immediately on cessation 
of exercise. The test was terminated if the patient could not continue due to exhaustion, was unable to 
maintain a cadence of pedalling of 60 rpm despite verbal encouragement, exceeded 85% of their 
maximum predicted heart rate, desaturated significantly or if ECG abnormalities were seen. 
 
 
2.5.3.1 Incremental CPET 
After the 2 minute rest period followed by 1 minute unloaded cycling, loaded pedaling began with 
increments every minute. Work load increment was determined by disease severity; those with MRC 
dyspnoea scores of 4 or 5 did a 5W increment protocol, whereas less severe patients did a 10 or 20W 
increment protocol. Patients continued the test until exhaustion or unless the test was terminated for 
reasons listed above. The majority did not reach VO2max so their peak VO2 was used. 
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2.5.3.2 Endurance CPET 
The patients performed a constant rate protocol based on 75% of the maximum workload achieved in 
the incremental CPET. Again, patients cycled until exhaustion after similar periods of rest and 
unloaded cycling, but were asked to perform inspiratory capacity manoeuvres at rest and every 2 
minutes during the test. When instructed to, they were asked to inspire maximally from the end of 
expiration. This enabled the measurement of inspiratory capacity and EELV, and thus the degree of 
dynamic hyperinflation with progressive exertion.  
 
 
2.6 Indirect calorimetry 
 
2.6.1 Indirect calorimetry: doubly labelled water (DLW) method 
 
As previously described, this technique is based on the administration water containing a known 
quantity of two stable isotopes of water, 
2
H2O and H2
18
O. Each patient was instructed to completely 
void his bladder and a sample from this was taken as a background sample. The patient’s weight was 
measured. The patient then ingested a known volume of DLW and the time noted (this was usually 
done in the morning). A urine sample was taken from the second voiding after ingesting the DLW 
(usually at least 6 hours after) to enable the isotopes to equilibrate throughout the body. Samples 
were immediately stored in the fridge overnight and subsequently frozen at -20°C. Further urine 
samples were obtained on the mornings of days 2, 7 and 14 and the evening of days 6 and 13 and 
stored in a similar way, accurately noting the time each sample was obtained. The difference in 
elimination rates of 
2
H and 
18
O were calculated as a measure of carbon dioxide production and 
therefore total energy expenditure over the two week monitoring period. Active energy expenditure 
was calculated by subtracting resting energy expenditure from this total, as measured below.   
 
2.6.2 Indirect calorimetry: ventilated hood method 
 
This method was used to calculate resting energy expenditure in the second study. Patients were 
instructed to fast overnight and the measurements were taken first thing in the morning. Each patient 
was asked to lie in a supine position (as far as dyspnoea would allow) under a canopy which was 
connected to a gas analyser. They were asked to remain as still as possible to minimise energy 
expenditure through movement, but not to fall asleep, as this rate of energy expenditure would 
actually have been lower than whilst awake at rest. Once the readings of VCO2 had stabilised (usually 
after around 10 minutes), the changes in O2 and CO2 concentrations were measured over about a 30 
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minute period. Resting energy expenditure was calculated using the Weir equation as described 
above. 
 
The measurement was carried out on two separate occasions and the mean of the two 
measurements was taken. Measurements were not made if the patient was experiencing an 
exacerbation as this is known to increase resting energy expenditure [252].  
 
 
2.7 Measurement of muscle strength 
 
Isometric quadriceps maximal voluntary contraction (QMVC) in kg, defined as the highest mean force 
that could be sustained over 1 second, was measured in the right leg. Patients were seated on a 
couch at 90° and with the knee joint flexed at 90°. The ankle was placed in a strap attached to a strain 
gauge (Strainstall UK Ltd, Cowes, UK; range 0-100kg). Patients were instructed to make a maximal 
voluntary leg extension effort with standardised encouragement and asked to sustain this for 1 
second. This force was converted to a digital signal with Labview software (National Instruments, 
USA). The highest value of 5 efforts was accepted [253]. Each value was expressed as %predicted 
according to prediction equations from our group, based on gender, age and fat-free mass[123]. 
 
 
2.8 Body composition analysis 
 
Body weight (in kilograms) and height (in metres, measured with a stadiometer) were measured.  
 
2.8.1 Bioelectrical impedence analysis (BIA) 
 
This method of body composition measurement uses the principle that if a small electrical current is 
applied to the body, the extent to which it will be impede or resisted will depend upon the type and 
amount of tissues present. Fat almost completely blocks any current and is therefore an excellent 
resistor. Tissues with high water content (e.g. blood, extracellular fluid, muscle) have very low 
resistance. Other tissues merely impede, i.e., slow down the current. Cell membranes act as resistors 
at very low frequencies (<50Hz), but above this, act as capacitors, impeding the current. Using 
currents at different frequencies, it is possible to measure intracellular fluid, as well as fat mass, fat 
free mass and total body water content. Bioelectrical impedance as a measure of body composition 
[254] was assessed using the Bodystat Quadscan 4000 (Bodystat Ltd, Douglas, Isle of Man). This 
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uses four electrodes (two to pass the current and two to sense it). As factors such as hydration, 
distribution of body water and orientation of tissue affects the measurement, it was done after the 
patient had been lying for 5 to 10 minutes (and long longer to avoid ‘settling’ of water), and 2 hours 
after eating and 8 to 12 hours after exercise or drinking alcohol. Socks were removed, along with any 
metallic objects. Their legs were positioned so that the thighs were not touching and the ankles were 
about 20cm apart. The skin on the top of the right hand and foot was cleaned with alcohol to ensure 
the electrodes adhered properly. Electrodes were placed proximal to the metacarpophalangeal joints 
and just proximal to the lateral malleolus of the wrist on the right hand, and similarly on the right foot 
(metatarsal joints and lateral malleolus of the ankle). Fat free mass and total body water 
measurements were noted. 
 
 
2.8.2 Dual energy x-ray absorptiometry (DEXA) scanning 
 
This method uses a very low dose of radiation to measure body composition. Two x-ray beams of 
different energy levels are aimed at the patient’s body. The differences in absorption occur due to 
differences in regional content of fat, muscle and bone. These differences are used to calculate trunk 
and limb fat and muscle content. Some patients also underwent this test as well as BIA to assess 
body composition.  
 
 
2.9 Health-related quality of life questionnaires 
 
2.9.1 The Medical Research Council Dyspnoea Scale 
 
Breathlessness is a complex and subjective sensation, and perhaps the most important symptom 
experienced in COPD. Fletcher et al first developed a numerical scale of breathlessness when 
working with coal miners in the Medical Research Council (MRC) Pneumoconiosis unit in the 1940s 
[255]. The MRC dyspnoea scale rates the type and magnitude of dyspnoea according to five grades 
of increasing severity [256], encompassing the whole range of respiratory disability (from none to 
almost complete incapacity). It can be self-administered and the score is the number that best fits the 
patient's level of activity. All the questions relate to everyday activities and are generally easily 
understood by patients. A score can usually be obtained in a few seconds. The MRC scale doesn’t 
quantify breathlessness itself, but the disability associated with physical activity. 
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2.9.2 The Chronic Respiratory Diseases Questionnaire (CRQ) 
 
This is an investigator administered 20 item questionnaire which measures both the physical and 
emotional aspects of chronic respiratory disease. It takes 15 to 25 minutes to complete. There are 4 
domains – dyspnoea, fatigue, emotional function and mastery. A higher total score indicates better 
quality of life. The minimal clinically important difference in score is 0.5, with a change of 1.5 
indicating a major change [257]. Good internal consistency reliability has been shown for all domains 
apart from dyspnoea in COPD patients [68].  
 
 
2.9.3 The St. George’s Respiratory Questionnaire (SGRQ)  
 
The SGRQ is a self-administered index designed to measure health status in patients with chronic 
airflow limitation.  It comprises 2 parts with 3 components and a total of 50 items. Part 1 gathers 
information on ‘Symptoms’ (frequency and severity) with 1, 3 or 12 month recall. Part 2 focuses on 
‘Activities’ that cause breathlessness or are limited by it. The third ‘Impacts’ component examines 
social functioning and psychological disturbances resulting from airways disease and refers to the 
current state as the recall. Scores range from 0 (no impairment) to 100 (worst possible) [258]. There 
is very good test-retest reliability with intra-class correlations reported from 0.795 to 0.900. Significant 
correlations have also been reported between total score and presence of cough, sputum, and 
wheeze; and between the activity and impact domains and other measures of disease activity (such 
as FEV1, FVC, SaO2 at rest, 6MWD, MRC dyspnoea grade and anxiety and depression scores) [258, 
259].  
 
 
2.9.4 The COPD Assessment Test (CAT)  
 
This was developed as a shorter questionnaire tool which would be easier and quicker to complete 
and therefore more applicable in clinical settings. It is a self-administered questionnaire with eight 
items (cough, phlegm, chest tightness, breathlessness, going up hills/stairs, activity limitations at 
home, confidence leaving home, sleep and energy) and takes less than 5 minutes to complete. Each 
item is scored from 0 to 5 giving a total score range from 0 to 40, corresponding to the best and worst 
health status in patients with COPD, respectively [260].In terms of reliability, an intra-class correlation 
coefficient of 0.8 has been reported. A strong correlation with the SGRQ across 7 European countries 
has also been reported [261]. 
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2.9.5 The Clinical COPD Questionnaire (CCQ) 
 
This questionnaire was also developed as a shorter, easier to use tool in the clinical setting, which 
also reflected the patient’s activity limitation and emotional response to the disease, as well as 
physical symptoms. There are 10 questions, reflecting symptoms, functional state and mental, with 
each item answered on a Likert scale (0 to 6) with a maximum score of 15, indicating severe 
disability. It takes around 10 minutes to complete. Good intra-class correlations with the SGRQ have 
been reported, regardless of COPD severity [262]. 
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3 Laboratory validation of six activity monitors in COPD: a 
comparison with indirect calorimetry 
 
3.1 Introduction 
 
The importance of physical activity in COPD is clear, not only due to prognostic implications, but also 
as it may be intrinsic to disease progression itself. Therefore, accurately measuring physical activity in 
COPD enables stratification of patients at baseline prior to intervention, such as pulmonary 
rehabilitation, and monitoring for change in response to such interventions. Independent activity 
monitoring using physical activity monitors is desirable due to the objectivity of the measurements 
obtained, as compared to the information obtained from questionnaires or from patient reported 
diaries, which are both prone to inaccuracies. However, commercial devices are all developed in 
healthy subjects and need validation for use in COPD, in particular because these patients tend to 
move more slowly than healthy age-matched subjects. The aim of this study was to validate six 
physical activity monitors in COPD patients, against a gold standard of indirect calorimetry in the form 
of VO2 data from a portable metabolic system under controlled laboratory conditions. Triaxial 
accelerometers have previously been reported as more accurately estimating energy expenditure and 
therefore physical activity levels than uniaxial accelerometers (transducing the body’s acceleration in 
three axes and one axis respectively) [263].  
 
Therefore, the hypothesis to be tested was that triaxial activity monitors would more faithfully reflect 
metabolic activity as assessed by indirect calorimetry than uniaxial activity monitors. Both the minute-
by-minute correlations of the activity monitor outputs, as well as an overall correlation over the study 
period, with indirect calorimetry were used as measures to validate them. The ability of these various 
monitors to detect differences in walking speed was also investigated. 
 
 
3.2 Materials and Methods  
 
3.2.1 Study subjects 
 
39 (25 male) patients from 4 centres across Europe were studied (London and Edinburgh in the UK, 
Athens in Greece and Leuven in Belgium). The number of patients was pre-determined by the 
PROactive consortium. 40 patients, that is, 10 from each participating study centre. A specific sample 
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size calculation was not undertaken as this was a validation study assessing the accuracy of monitors 
against a pre-set threshold (see analysis section below); the number was decided as being a 
workable number for each centre as the study protocol was complex.  Unfortunately one patient’s 
data had to be excluded due to technical difficulties (inaccurate metabolic data which was only picked 
up during the data analysis stage). All patients were diagnosed with COPD with a severity ranging 
from mild to very severe according to the Global Initiative for Chronic Obstructive Lung Disease (or 
GOLD) (stages I to IV) [246]. Patients were phenotyped as described in Chapter 2; their 
characteristics are shown in Table 3.1 They were clinically stable and free of exacerbations for at 
least 4 weeks prior to the study. Patients were excluded if they had other co-morbidities which 
restricted their physical activity other than COPD (e.g. arthritis), or if they were on long term or 
ambulatory oxygen therapy, as they were unable to have supplemental oxygen whilst wearing the 
metabolic equipment. Patients provided written informed consent. In the UK, the study had ethical 
approval from the Lothian Regional Ethics Committee (Edinburgh, United Kingdom) and local site 
specific approval from the Research and Development department of the Royal Brompton Hospital. In 
Greece, ethical approval was given by University Hospital Ethics Committee "Sotiria" hospital Athens. 
In Belgium, approval was from the UZ Leuven Medical Ethics Committee.  
   
 
3.2.2 Study design 
 
Each patient wore 6 activity monitors simultaneously, which were selected as a result of a systematic 
review of the literature as having been previously validated in chronic disease [242, 264]. This set out 
to identify monitors which had been validated in both healthy adults and those with chronic disease in 
whom inactivity is an important therapeutic target, but where mobility is preserved (i.e. studies in 
patients with conditions such as arthritis had to be excluded). All studies that used any commercially 
available accelerometer, pedometer or multisensory device were included. In addition, the validity of 
the device had to be tested against a criterion method such as indirect calorimetry (either using a 
metabolic cart or doubly labelled water). Validity was measured using coefficients of correlation with 
the criterion method between total and active energy expenditure measured with the monitor 
compared to the same measured by the metabolic cart or doubly labelled water.  
 
The following monitors were selected (i.e. those with good correlations with the criterion method): two 
uniaxial activity monitors; Kenz Lifecorder (Kenz), Actiwatch (Actiwatch), three triaxial activity 
monitors; RT3, Actigraph GT3X (Actigraph), Dynaport MiniMod (MiniMod) and one triaxial activity 
monitor combined with different sensors (multisensory); SenseWear Armband (SenseWear). More 
details about software, type, body location and outputs of these monitors can be found in Table 3.2.  
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Patients also wore a portable metabolic system (Jaeger Oxycon Mobile), an oxygen saturation finger 
probe and a Polar T31 (Polar) coded transmitter belt for heart rate monitoring. The portable metabolic 
system was attached to the upper chest with a harness and due to its low weight (950g), caused 
minimal discomfort. A face mask with a dead space of < 30mL (Hans Rudolph Inc, Kansas City 
MO/USA) was used. Location of attachment for the Oxycon Mobile together with the six activity 
monitors is shown in Figure 3.1. A two-point gas calibration was completed prior to each test. All 
monitors were time synchronised with each other and with the metabolic kit. 
 
 
. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Position of the activity monitors and metabolic kit 
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3.2.3 Expired gases method of indirect calorimetry  
 
Expired oxygen and carbon dioxide levels were measured from a tightly fitted mask, or mouthpiece 
and nose clip, minimising loss of these expired gases through leak. Room air was inspired (the 
equipment is calibrated to this prior to any test). The rate of oxygen consumption (VO2) and carbon 
dioxide elimination (VCO2) are therefore calculated as ml/min, VO2 can be expressed as metabolic 
rate in ml/kg/min, or as METs (Metabolic Equivalent of Task
4
) [28], using the subject’s body weight. 1 
MET is equivalent to 3.5ml O2/kg/min. Energy expenditure can be derived from these measurements 
using the Weir equation [198] 
 
 
In this study, VO2, VCO2, heart rate, respiratory rate and tidal volume were measured continuously 
from the metabolic cart. Breath-by-breath measurements were averaged over one-minute intervals. 
After the experiment, stored data were downloaded from the portable metabolic device to a personal 
computer. Energy expenditure estimates from the portable metabolic system (METs) were used as a 
criterion measure for energy expenditure and were compared with the following activity monitor 
outputs: Kenz- arbitrary unit (AU); Actiwatch – activity count (AC); Actigraph and RT3 – vector 
magnitude unit (VMU); MiniMod and SenseWear – METs. 
 
Patients were instructed to perform a strict schedule of activities lasting 59 minutes (Table 3.3) which 
were chosen to be representative of everyday tasks (such as walking, stair climbing and sweeping the 
floor [265]. Time was kept with both a stopwatch as well as a laptop computer clock so that activities 
were completed in whole minutes. During the activities, a manual step count was recorded with a 
clicker counter. The patient’s feet were also filmed using a handheld camcorder in order to provide a 
videoed step count. This served to verify the manual step count. Oxygen saturations and heart rate 
readings as well as Borg scores for breathlessness and fatigue were recorded at regular intervals 
during the protocol. Although the duration of the protocol was 59 minutes, occasionally it took longer 
to complete (for example if the patient needed to rest for longer in between activities). 
 
 
 
 
 
 
 
 
                                                     
4
 The Metabolic Equivalent of Task (MET) is a physiological measure expressing the energy cost of physical activities. It is 
defined as the ratio of metabolic rate and therefore rate of energy expenditure. 1MET is the metabolic rate obtained when 
sitting resting. Activity intensity typically ranges from 0.9 MET (during sleep) to 23 during fast running at 22/5km/hr.  
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Table 3.1 Patient 
characteristics 
 
Data are expressed as 
mean ± std. FEV1- forced 
expiratory volume in 1s; 
FVC- forced vital capacity; 
6 MWD - six-minute 
walking distance; MRC - 
Medical Research 
Council; CAT - COPD 
Assessment Test; SGRQ - 
St George’s Respiratory 
Questionnaire.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable COPD patients (n=39) 
Age (years) 67.9 ± 7.4 
Gender (male/female, n) 25/14 
FEV1 (L) 1.43 ± 0.60 
FEV1 (%predicted) 54 ± 18 
FVC (L) 2.97 ± 0.85 
FVC (%predicted) 90 ± 16 
GOLD stage I/II/III/IV (n) 4/18/14/3 
TLco (%predicted) 61.0 ± 25.9 
BMI (kg/m
2
) 26.2 ± 5.2 
6 MWD (m) 438 ± 115 
VO2peak (ml.min
-1
.kg
-1
) 16.9 ± 5.5 
VO2peak (%predicted) 79 ± 31 
MRC 2.6 ± 0.7 
CAT 15 ± 8 
SGRQ 
        Total Score 
        Activities 
        Impacts 
        Symptoms 
 
  42 ± 18 
  60 ± 24 
  30 ± 17 
  44 ± 23 
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Name, (Manufacturer; 
software) 
Type Location 
Measured 
output 
Estimated 
output 
Kenz Lifecorder Plus (Suzuken 
Co Ltd., Nagoya, Japan; 
Physical Activity Analysis 
Software) 
Uniaxial accelerometer 
Waist 
(left) 
Steps, 
activity score 
EE
c
, activity 
intensity level 
Actiwatch 
(MiniMitterCo,Sunriver, OR, 
USA; Respironics Actiware 5) 
Uniaxial accelerometer 
Wrist 
(left) 
AC
a
  
RT3 (Stayhealthy Inc. 
Monrovia, CA, USA; 
Stayhealthy RT3 Assist 
Version 1.0.7) 
Triaxial accelerometer 
Waist 
(right) 
AC, VMU
b
 EE 
Actigraph GT3X (Actigraph 
LLC Pensacola, FL ; Actilife 5) 
Triaxial accelerometer 
Waist 
(right) 
Steps, AC 
EE, activity 
intensity level 
DynaPort® MiniMod 
(McRoberts BV, The Hague, 
The Netherlands; 
www.gaitweb.nl) 
Triaxial accelerometer 
Waist 
(lower 
back) 
Steps, 
movement 
intensity, 
different 
body 
positions 
EE 
SenseWear Armband 
(Bodymedia, Pittsburgh, PA, 
USA; SenseWear Professional 
6.0) 
Multisensor device: 
triaxial accelerometer + 
sensors (heat flux, 
galvanic skin response 
and skin temperature) 
Upper left 
arm at 
triceps 
Steps, 
activity 
intensity 
level 
EE 
 
Table 3.2. Details of type, location and output of the six activity monitors  
(a AC – activity counts; b VMU – vector magnitude units; c EE – energy expenditure). 
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Table 3.3 Schedule of physical 
activities in the standardised 
protocol. 
 
* These walking activities were 
performed in a 30m corridor. Speeds 
were self-selected. During fast walking, 
patients were instructed to walk as fast 
as possible. ** Participants walked at 
85% of their fast walking speed, first on 
the flat and then at an incline of 4%. 
Participants were instructed not to 
support their arms during treadmill 
walking. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3 Statistical analysis 
 
Minute-by-minute data were compiled for each patient in one database and synchronisation was 
verified by inspection of the curves to ensure the best fit on a patient-by-patient basis for each of the 
monitors. The analyses were carried out as follows: 
 
Activity Duration  (minutes) 
Standing 1 
Lying 3 
Sitting 2 
Standing 2 
Slow walk* 6 
Sitting 2 
Standing 2 
Fast walk* 6 
Sitting 2 
Standing 2 
Sweeping 2 
Sitting 2 
Standing 2 
Lifting 2 
Sitting 2 
Walking/standing 1 
Stairs 1 
Sitting 5 
Walking/standing 1 
Walking on treadmill 
(flat)** 
4 
Standing 2 
Walking on treadmill 
(4% incline)** 
4 
Walking/standing 1 
Sitting 2 
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3.3.1 Primary outcomes 
 
First, a minute-by-minute correlation between METs from the portable metabolic system and each of 
the activity monitor outputs was calculated for every patient. Correlations between minute-by-minute 
VO2 and activity monitor outputs were reported as median with inter-quartile range.  
 
Second, mean METs level for the 59 minute protocol was calculated for each patient and correlated to 
the mean activity monitor output over this period. A statistically significant relationship was judged as 
indicative of validity.  
 
 
3.3.2 Secondary outcomes 
 
First, the response of monitors to slow and fast walking was assessed by evaluating the correlation 
between changes in METs and changes in activity monitor outputs at the different speeds. For this 
analysis the first minute of the walking bouts was excluded; stronger correlations were taken to 
indicate greater validity. 
 
Second, for monitors which gave a stepcount as an output, the accuracy was compared to the verified 
manual stepcounts using Bland Altman analysis. This was also analysed at slow and fast walking 
speeds to test whether walking speed affected stepcount accuracy..  
 
Third, Bland regression analyses [266] were performed to test the agreement between indirect 
calorimetry (METs) and the activity monitor outputs. The 95% predictions limits of the METs at the 
mean (of the different activity monitor outputs) were calculated.   
 
 
3.4 Results 
 
Due to technical difficulties with the RT3 monitor, only 29 patients used this monitor. An example of 
one patient’s data is provided in Figure 3.2.  
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Figure 3.2 Example of one patient’s experiment, showing indirect calorimetry data from the 
Oxycon Mobile (METs) plotted against the different activity monitor outputs. 
 
 
 
Minute by minute correlations between metabolic cost and activity monitor output are shown in Figure 
3.3. Strong correlations (R>0.7) were found with the MiniMod (0.82 (interquartile range (IQR) 0.13)), 
Actigraph (0.79 (IQR 0.11)), SenseWear (0.73 (IQR 0.18)) and RT3 (0.73 (IQR 0.15)) but not for the 
Actiwatch (0.53 (IQR 0.21)) and Kenz (0.57 (IQR 0.26)).  
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Figure 3.3. Minute-by-minute correlations (R) between activity monitor outputs and metabolic 
equivalents of task (METs) per patient (white dots).  
MM; MiniMod, AG; Actigraph, SW; SenseWear, AW; Actiwatch, VMU; vector magnitude unit, AC, 
activity count, AU; arbitrary unit. Median (inter-quartile range) correlation for each activity monitor is 
reflected by cross bars, *p<0.05." 
 
 
The mean correlation between metabolic cost (METs) and activity monitor outputs over the whole 
protocol was, from highest to lowest; SenseWear (r=0.76 [95% confidence interval (CI) 0.54-0.91]), 
Kenz (r=0.52 [95% CI 0.27-0.73]), Actigraph (r=0.49 [95% CI 0.28-0.64]), MiniMod (r=0.45 [95% CI 
0.21-0.61]), Actiwatch (r=0.37 [95% CI 0.17-0.56]), all p<0.05 and RT3 (r=0.35 [95% CI -0.04-0.48], 
p=0.06) (Figure 3.6).  
 
Patients changed their mean walking speed by 1.31km/h from the slow (3.27±0.47 km/h) to the fast 
(4.65±1.28 km/h) walking phase. As expected, the change in walking speed correlated with the 
change in VO2 determined by the metabolic equipment (r=0.65) increasing from 3.11±0.74 METs to 
3.93±1.23 METs. All monitors detected this increase in energy expenditure, via their outputs, during 
fast walking compared to slow walking. The highest correlations were reported for the MiniMod 
(r=0.94 [95% CI 0.89-0.97]) and Actigraph (r=0.88 [95% CI 0.77-0.93]) compared to the RT3 (r=0.69 
[95% CI 0.42-0.85]), Actiwatch (r=0.59 [95% CI 0.34-0.76]), Kenz (r=0.57 [95% CI 0.31-0.76]) and 
SenseWear (r=0.52 [95% CI 0.25-0.72]), all p<0.0001. Both the Actigraph and Minimod are worn at 
the hip, whereas the Sensewear is worn on the upper arm. 
 
The stepcount accuracy for the Sensewear and MiniMod was analysed against the verified stepcount 
where available, i.e. the manual stepcount verified by the video data. In some cases, a verified count 
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was not available, so only the manual count was used. However, there was a very good agreement 
between the manual and video stepcounts (as shown in the Bland Altman analysis in Figure 3.4). 
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Figure 3.4 Bland-Altman plot showing comparisons of manual step counts with Sensewear, 
Dynaport Minimod and Video step counts. 
 
The Sensewear tended to underestimate the stepcount more than the MiniMod, which actually had a 
slight tendency to overestimate the stepcount (95% confidence intervals 147.8 to -26.9 for Sensewear 
compared to 754.7 to -224.4 for Minimod)The Sensewear also underestimated at both walking 
speeds (see Figure 3.5), and more so at slow walking speeds (95% CI at slow walking 365.1 to -
103.7 and 251.8 to -56.2 at fast walking). The MiniMod performed well at both speeds (95% CI at 
slow walking 140.5 to -80.6 and 53.9 to -13.3 at fast walking). 
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Figure 3.5. Bland Altman plot showing comparison of manual step count with Sensewear an 
Dynaport Minimod monitors for slow and fast paced walking  
 
 
Bland regression analyses showed significant relationships (p<0.05) between METs derived from 
indirect calorimetry and the different activity monitor outputs, except for the RT3 (p=0.06) (Figure 
3.7). The 95% limits of prediction for  METs (derived from indirect calorimetry) at the mean (3.59 
METs) were from lowest to highest: 1.13 METs with the SenseWear, 1.15 METs with the Actigraph, 
1.17 METs with the MiniMod, 1.25 METs with the Actiwatch, 1.28 METs with the Kenz and 1.41 METs 
with the RT3. 
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Figure 3.6. Mean correlations of each activity monitor output with indirect calorimetry (METs).  
R Value shown for each monitor (all p<0.001) 
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Figure 3.7. Bland regression analysis for each activity monitor output versus indirect 
calorimetry (IC).  
95% confidence intervals are shown as dashed lines. 
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3.5 Discussion  
 
3.5.1 Significance of the findings 
 
The validity of six physical activity monitors was investigated by comparing activity monitor outputs for 
each monitor to actual VO2 measured with indirect calorimetry from a portable metabolic kit in 
controlled laboratory conditions. Triaxial activity monitors were judged to be more valid compared to 
uniaxial activity monitors according to a number of criteria. 
 
Correlations between minute-by-minute outputs and VO2 were highest with the Dynaport MiniMod, 
Actigraph GT3X, SenseWear Armband and RT3, all exceeding an r value of 0.7. The best correlations 
of mean activity monitor output with mean VO2 over the 59 minute activity protocol were again 
reported for the three triaxial activity monitors (SenseWear Armband (r=0.76), Actigraph GT3X 
(r=0.49) and Dynaport MiniMod (r=0.45)) and one uniaxial activity monitor (Kenz Lifecorder (r=0.52)).  
 
All monitors were able to detect modest changes in walking speed, but two triaxial activity monitors 
had the strongest correlations with indirect calorimetry (MiniMod (r=0.94) and SenseWear (r=0.88)). 
The ability of an activity monitor to detect a difference in walking speed of 1.31 km/hr or 0.36 m/s is 
clinically relevant. Patients with COPD do walk more slowly than healthy subjects, and this is 
reflected, for example, by their reduced six minute walking distance [267, 268]. In this study, all 
monitors were responsive enough to detect these modest changes in walking speed.  
 
Interestingly, step count accuracy varied with walking speed. Only the Sensewear and MiniMod were 
considered in this analysis. The Sensewear was much less accurate overall than the MiniMod, but 
was worse at slow walking speeds. This is probably because the Sensewear is positioned on the 
upper limb, so unless there was reasonable arm excursion during walking (part of a normal gait 
pattern), it may not always detect a step. The MiniMod’s greater accuracy is probably due to the fact it 
is positioned around the waist and would give more information about hip movement during walking.  
 All activity monitor outputs showed similar variability in predicting energy expenditure. The 95% 
prediction limits for mean METs (3.59 METs) varied between ±1.13 METs (SenseWear) and ±1.41 
METs, (RT3). This implies that, from a clinical perspective, predicting oxygen consumption directly 
from different activity monitor outputs is not accurate. However, when patients engage in activity, 
monitors do indeed detect the increase in physical activity levels within a range of 1 to 1.5 METs.  
 
This is the first multi-centre trial where several activity monitors have been validated against indirect 
calorimetry (VO2) in different stages of COPD. Until now, only the Dynaport MiniMod and SenseWear 
Armband had been validated against VO2 in patients with COPD. In these devices, similar correlation 
coefficients were previously reported between activity monitor outputs and total energy expenditure 
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(r=0.75 and r=0.93 for the SenseWear Armband [269, 270], r=0.7 for the Dynaport MiniMod) [269]. In 
a previous study, during a set of 5 daily activities, a high level of agreement between SenseWear 
Armband (22.7±7 kcal) and indirect calorimetry (21.0±7.9 kcal) was observed [271]. In a similar 
protocol, a moderate agreement between energy expenditure estimated from the SenseWear 
Armband and energy expenditure measured from indirect calorimetry was reported (mean difference 
of -0.2 METs with a limit of agreement of 1.3 METs) [272].  
 
 
3.5.2 Critique of the method 
 
In this study, validity was assessed using correlation analyses rather than a measure of agreement 
(e.g. Bland-Altman plot), as most of the outputs of the activity monitors are in different units (activity 
counts, vector magnitude units etc.) to each other, and to the VO2 data. Although several prediction 
equations are available to convert some outcomes (e.g. VMU) to energy expenditure (which can also 
be derived from the VO2 data for direct comparison), these are not available for all of the monitors 
used [273-276]
6
. Moreover, the goal of the study was to assess the validity of the devices rather than 
their prediction equations. Therefore, comparing the raw data from the activity monitor with VO2 data 
from the portable metabolic kit using correlation analysis was more appropriate than using a measure 
of agreement.  
 
Although the monitors were able to detect modest changes in walking speed, which is important for 
use in the COPD population, overall, it could be argued that the patients who participated in this study 
were perhaps not as limited as some of the more severe patients encountered clinically. For example, 
the mean six minute walk distance was 438m, and there were only 3 GOLD stage IV patients. 
Therefore the findings of validity must be interpreted in this light. Therefore it may be more accurate to 
repeat the study protocol in patients who, for example, have a six minute walk distance less than 
200m, giving a walking speed of 2km/hr, as compared to the ‘slow walk’ speed of 3.27km/hr in this 
study. In fact, Harrison et al [277] recently assessed the sensitivity of the Sensewear armband in 57 
COPD patients during the incremental shuttle walk test. In 7 patients at level 1 of the test and at a 
speed of 1.8km/h, they found that the Senswear was not able to detect any steps at all. (These 
patitents were not significantly phenotypically different to the other patients in terms of baseline 
characteristics or distance walked). However, step count was a sensitive measure with significant 
differences between levels 1 and 2 if these 7 patients were excluded. In contrast, the measure of 
energy expenditure was only significantly different as patients progressed from level 1 to level 2. Step 
count was significantly sensitive at higher levels of the test.  
                                                     
6
 Publicly available for the Actigraph (7164 model and GT1M), Actiwatch, Kenz and RT3, but not for the SenseWear and 
MiniMod as these use proprietary algorithms developed by the device manufacturers. 
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It must be highlighted that the gold standard used, energy expenditure, is driven to a large extent by a 
number of other factors. Whilst specific factors such as body weight, age, and height can be 
incorporated into prediction equations, it is more difficult with non-specific factors such as mechanical 
efficiency, especially in patients with COPD. These patients have a higher active energy expenditure 
[278], even though it is well recognised that they are moving less. This is consistent with findings of 
reduced mechanical efficiency in these patients compared to healthy controls [279, 280]. An activity 
monitor cannot be expected to detect this complex variable accurately, and thus perhaps greater 
weight should be given to direct monitor outputs (steps, activity counts, vector magnitude units). 
Activity monitors are most appropriately used for the assessment of the activities of patients in terms 
of amount and/or intensity. The derivation of energy expenditure from activity monitors is imprecise so 
therefore not necessarily the ideal gold standard for assessing monitor performance, but the only one 
available for this currently. 
 
A limitation of this study was that inter- and intra-device reliability of the different activity monitors 
were not evaluated. Inter-device reliability is essentially the accuracy or repeatability of two different 
devices (e.g. two identical Sensewear armbands) when measuring exactly the same activity (for 
example the same patient performing a particular activity wearing two identical activity monitors on 
the arm simultaneously). Ideally, there should be no differences at all between the two measures. 
Similarly, intra-device reliability is the repeatability of the measurement of the same device measuring 
exactly the same activity (e.g. monitoring a patient while walking a given distance at a given speed 
twice and comparing the two results). This is important when physical activity levels of patients are 
followed over time. Several studies have shown moderate to high inter-device reliability (intra-class 
correlation coefficient (rICC) = 0.99 for the Actigraph Model 7164 [281], rICC = 0.95 for Kenz Lifecorder 
[282] and rICC = 0.75 for the RT3 [283]) as well as intra-device reliability (rICC = 0.98 for the Actiwatch 
[284], rICC = 0.97 for the SenseWear Armband [285] and rICC = 0.86-0.99 for the Dynaport MiniMod 
[286]). Apart from the concepts of validity and reliability, other factors such as size and scope of the 
study, usability and cost of the activity monitor need to be taken into consideration when selecting an 
activity monitor for use in clinical trials. The validation of these activity monitors in a laboratory setting 
(validation against VO2) can be considered as an important step in ascertaining their validity. An 
essential next step will be to confirm their validity in a field setting. 
 
In conclusion, the present study found that three triaxial activity monitors (Dynaport MiniMod, 
Actigraph GT3X and SenseWear Armband) were the best of 6 monitors tested to assess standardised 
and common physical activities in the range of intensity conducted by patients with COPD. Changes 
in walking speed are most accurately registered by the Dynaport MiniMod and Actigraph, which are 
both worn on the hip. These results should serve as a useful guide for future choice of valid activity 
monitors for both research and clinical use in patients with chronic diseases including COPD. 
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4 Domestic validation study of physical activity monitors in COPD 
in daily life 
 
4.1 Introduction 
 
This study sought to validate a number of different physical activity monitors in COPD patients in a 
free living home environment, as opposed to the previous study, which took place under strict 
laboratory controlled conditions and which was limited to 1 hour. Whilst minute-by-minute 
performance of activity monitors is important in terms of their technical accuracy, from a practical 
perspective, patients would be required to wear activity monitors for a number of days in, for instance, 
clinical studies or as part of an exercise programme. Therefore, consistent performance over a period 
of time becomes more relevant. Another significant consideration is that monitors should be able to 
detect change or variability in physical activity; a COPD patient suffering an exacerbation is much less 
physically active, and a suitable activity monitor should be able to detect this change adequately, 
particularly if it is to be used in future interventional studies.  
 
As discussed earlier, the accepted method of validation of physical activity monitors is via calorimetry 
to measure energy expenditure. In the domestic setting, clearly it is not practical to use the expired 
gases method of indirect calorimetry used in the previous study as the reference against which to 
validate any physical activity monitors. Whole body direct calorimetry would be theoretically possible 
in free living individuals who could wear activity monitors in a room calorimeter, but whilst very 
accurate, this method would be limiting in terms of cost and time, as it would only be possible to test 
subjects one at a time. Physical activity would also be confined to what was possible within the room, 
and would not be reflective of how most patients go about their daily lives, e.g. going out of the house 
for a walk, shopping etc., as well as probably being less acceptable as a method to potential study 
participants themselves.  
 
This leaves the only other method of calorimetry which could be used for a long term validation of 
physical activity monitors; that of doubly labelled water (DLW). This has been used in several 
previous validation studies of activity monitors and is accepted as the gold standard criterion.  
As already discussed, this method relies on the fact that labelled 18-oxygen is eliminated as both 
water and carbon dioxide, whereas labelled hydrogen (deuterium) is only eliminated as water. Thus 
the difference between the two rates of elimination is a measure of CO2 flux, described by the 
following equation: 
  rCO2 =N/2 (k18-k2)  
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where rCO2 is CO2 production rate (mol/day), N is the total body water pool size (mol) and k18 and k2 
are the elimination rates of labelled 18-oxygen and deuterium respectively. 
 
Sources of error include isotope measurement, variations in background levels of isotope (both 
deuterium and 18-oxygen are naturally occurring in small concentrations) and unanticipated changes 
in the body water pool (for example due to large insensible losses or diuretic therapy) or atypical diets 
or other metabolic disorders which would significantly alter the respiratory quotient (estimated to be 
around 0.85). 
 
Carbon dioxide and water production and energy expenditure as measured with DLW was validated 
against room calorimetry by Schoeller et al, and shown to be accurate to 1 to 2% [287]. 
Reproducibility was assessed in a review by Schoeller and Hnilicka and shown to have a mean 
coefficient of variation of 8%, largely due to physiological variation of 7%, which seems to reflect 
variation in physical activity [288].  
 
Whilst this method has been used widely in validation studies in healthy populations, there has been 
very little work in disease populations, including COPD. In fact, in a systematic review by Van 
Remoortel et al as part of the PROactive project, of the 48 studies that had used doubly labelled 
water as the criterion method, only 5 studied subjects with chronic disease. Most studies used a 
single monitor, with a few using 2 simultaneously. The review showed that studies in general had 
wide heterogeneity and as such, validation studies in chronic disease are lacking [264]. Disease 
specific studies are essential as these patients tend to move more slowly than healthy subjects. 
Therefore energy expenditure will be accounted for to a greater proportion by individual patient 
characteristics such as weight and age, rather than necessarily physical activity. Baarends et al 
showed that COPD patients have a higher active energy expenditure although they are less physically 
active according to physical monitor outputs, suggesting metabolic inefficiency, i.e. they require more 
energy to achieve the same level of movement compared to healthy subjects [279].  
 
Patients in this study used 3 activity monitors simultaneously which enabled direct comparison as well 
as validation against doubly labelled water. A fourth, novel monitor, the Imperial eAR monitor was 
also added. The hypothesis tested was that the outputs of all monitors would show strong correlations 
with the total energy expenditure calculated using the doubly labelled water method over a 14 day 
period, but that energy expenditure outputs would have a better correlation, This relationship with the 
gold standard measurement of doubly labelled water would serve to validate the use of these activity 
monitors in COPD in a long term domestic setting.  
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4.1.1 The Imperial College eAR monitor 
 
This ear-worn device consists of a miniaturised computer and triaxial accelerometer, allowing the 
measurement of activity (activity index), as well as mobility and gait pattern continuously whilst the 
patient is at home. The monitor is connected to a base unit which serves as both a charger as well as 
adata storage hub. This base unit can be connected to a PC via USB connection in order to download 
the data.  
      
 
Figure 4.1  Imperial eAR monitor 
 
 
The positioning of the monitor on the ear is critical in its ability to detect information regarding posture 
and balance in a similar way to the vestibular function of the human ear [289]. The output of the 
monitor appears as raw counts in each axis of movement with 20 measurements per second 
(corresponding to a frequency of 20Hz). To get an actual activity count, the variance of each second 
in each axis is calculated to produce the eAR activity index. The raw data from each axis can also be 
plotted in a graph to give characteristic waveforms with specific features depending on the activity 
being undertaken, such as running or jumping. In one study with healthy subjects, investigators were 
blinded to the activity performed (lying down, running, sitting, cycling etc.) when analysing the raw 
data and had a 80 to 99% accuracy level when predicting the type of activity [290]. It is also possible 
to determine gait pattern as the waveform patterns vary characteristically when weight is transferred 
from one foot to the other. This has been validated against the gold standard of foot force plates 
[289]. The accessibility to the raw data counts and graphs is far superior to the commercial devices 
which have been used, whose algorithms are not disclosed and whose data are filtered by the 
software provided.  
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The eAR monitor has been used in a number of different populations for example in sportsmen and 
women, to monitor posture during rowing or for swim stroke analysis [291, 292], thereby aiding 
training and performance, as well as rehabilitation after injury.  
 
 
Figure 4.2. Example of data from eAR monitor. 
 
 
Using the eAR monitor gave the opportunity to compare it with other relatively established commercial 
devices in terms of both accuracy as well as usability to both investigator and subject alike. The eAR 
has had good results in other populations, namely healthy subjects, and in elderly patients with knee 
osteoarthritis and abdominal surgery [293-295]. It has been previously used in cystic fibrosis patients 
to measure physical activity around the time of exacerbation by this group [296]. It therefore was an 
attractive choice to validate in the COPD population.  
 
The rationale for using this device was primarily to validate it in a COPD population against doubly 
labelled water, which has not been done previously. The device has been previously validated in 
COPD patients against another device, the Sensewear armband (which was validated in the previous 
present studies) [297]. It has also been validated against indirect calorimetry using mobile metabolic 
data in a similar way to the previous study, albeit in healthy participants [290]. There was good 
agreement between predicted energy expenditure according to activity and measured energy 
expenditure from the metabolic data.   
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4.2 Materials and methods 
 
4.2.1 Study subjects 
 
20 patients with COPD were recruited. All had a clinical history compatible with COPD as well as 
evidence of chronic airflow limitation, and ranged in severity from GOLD stage II to IV [246]. They 
were all clinically stable and free from exacerbations for a minimum of 4 weeks prior to the study. 
Patients were excluded if they had other co-morbidities which would interfere with their movement, 
other than due to COPD (e.g. arthritis, neuromuscular disease) or respiratory diseases other than 
COPD (e.g. asthma), or cognitive impairment. Patients were also excluded if they were on variable 
doses of diuretics as this causes too great a fluctuation in the body water pool which would violate the 
assumptions made with the doubly labelled water method of indirect calorimetry.  Patient 
characteristics are shown in Table 4.1. All patients gave written informed consent. The study had 
ethical approval from the Lothian Regional Ethics Committee (Edinburgh, United Kingdom) and local 
site specific approval from the Research and Development department of the Royal Brompton 
Hospital. The sample size was determined (as in Chapter 3) by the PROactive consortium in terms of 
what had been previously done in the literature and what was technically possible. A calculation to 
find a specific change was not undertaken due to the observational nature of the study and also the 
fact that there was a limited quantity of doubly labelled water that could be used in this study. 
Regarding the eAR monitor, essentially, this was a pilot study, so no sample size calculation was 
performed.  
  
All patients underwent baseline testing as described above in the Methods section. 
 
4.2.2 Study design  
 
Three of the six monitors used in the laboratory validation study were also used in the field study (see 
Table 3.2), in addition to a novel device, the eAR monitor (Imperial; Figure 4.1). All six were not used 
as this would have been too uncomfortable for the patient. The AG and RT3 were chosen to compare 
two hip worn devices, along with the Sensewear as it was a multisensor device. Their outputs over 2 
weeks were compared to a gold standard of indirect calorimetry as obtained from doubly labelled 
water. This method is described in detail below. Patients wore the activity monitors for 14 consecutive 
days, but were instructed not to wear them at night or while bathing or swimming. At the end of this 
period, they also completed a usability questionnaire for each monitor, which assessed factors such 
as ease of use, comfort and obtrusiveness.  
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4.2.3 Doubly labelled water method of indirect calorimetry 
 
The total energy expenditure (TEE) over the 14 day period of monitoring was measured using doubly 
isotopically labelled water (DLW), according to the Maastricht protocol [298]. On the morning of day 0, 
body weight was recorded, and after the collection of a background urine sample, subjects drank a 
weighed amount of doubly labelled water (enriched with 
2
H2 and 
18
O such that baseline levels were 
increased by 100 ppm for 
2
H and 200 ppm for 
18
O). Urine samples were collected in the afternoon of 
day 0 approximately 6 hours post ingestion and from the second voiding. Further samples were 
collected on the mornings of day 1, day 7, and day 14, and in the evening of day 6, and day 13. 
Patients were asked to note carefully the exact time of each urine sample. 
 
4.2.4 Measurement of resting energy expenditure 
 
This was done using the ventilated hood method [197]. Patients were instructed to fast overnight and 
measurements were taken first thing in the morning of the first day of the study period. The 
calorimeter was calibrated before each patient measurement using a span gas (20% CO2, 1% O2), 
and to nitrogen for a zero calibration. Patients were asked to lie still under the canopy for 20-30 
minutes until the readings of VO2 and VCO2 had reached equilibrium. The next 10 minutes of 
readings were taken to calculate resting energy expenditure. A second measurement was taken 
during the second week of the study and a mean of the two values was used. The Weir equation was 
used to calculate resting energy expenditure (REE) from the VO2 and VCO2 values obtained [198].  
 
Predicted resting energy expenditure (REE) was also calculated using the Harris Benedict equation 
[199].  Active energy expenditure (AEE) was measured as (0.9 × TEE) − REE, assuming diet-induced 
thermogenesis to be 10% of TEE [299].  AEE was further normalized by body weight in kg and 
expressed as AEE.kg
-1
. TBW was calculated as the 
2
H dilution space from the 
2
H enrichment of the 
second voiding minus the 
2
H concentration of the sample before dose administration [300]. The 
2
H 
dilution space was divided by 1.04 to correct for isotope exchange with non-aqueous hydrogen of 
body solids [301]. 
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Table 4.1. Patient 
characteristics  
 
Data are expressed as 
mean ± std. FEV1- forced 
expiratory volume in 1s; 
6MWD - six-minute 
walking distance; MRC - 
Medical Research 
Council; CAT - COPD 
Assessment Test; SGRQ - 
St George’s Respiratory 
Questionnaire.  
 
 
 
 
4.3 Statistical analysis 
 
A priori criteria for validation of the monitors were established before any analyses were undertaken: 
 
. 
4.3.1 Primary outcomes  
 
The ability to capture day-to-day variability of physical activity levels throughout the period of 
assessment, as expressed by the coefficient of variation for each activity monitor. 
 
 
4.3.2 Secondary outcomes  
 
First, the ability to capture the lower levels of activity levels during weekends characteristic of COPD 
patients [302], at least of GOLD I-III. 
Variable COPD patients (n=20) 
Age (years) 68.5 ± 8.0 
Gender (male/female, n) 16/4 
FEV1 (L) 1.27 ± 0.62 
FEV1 (%predicted) 48.3 ± 19.2 
GOLD stage II/III/IV (n) 9/7/4 
BMI (kg/m
2
) 24.7 ± 4.8 
6MWD (m) 435 ± 111 
VO2peak (ml.min
-1
.kg
-1
) 14.2 ± 6.4 
MRC 2.8 ± 1.0 
CAT 16.4 ± 7.7 
SGRQ 
        Total Score 
        Activities 
        Impacts 
        Symptoms 
 
  43.0 ± 19.7 
  60.1 ± 29.7 
  29.2 ± 16.7 
  50.8 ± 25.7 
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Second, the relationship with parameters of exercise capacity (6 minute walk distance and peak VO2), 
as this comparison had been used in the previous laboratory based study. 
 
Third, the relationship of each activity monitor output with active energy expenditure as assessed by 
DLW, demonstrated by Pearson’s correlation; and Bland-Altman plot for those monitors giving an 
estimate of mean daily energy expenditure.  
 
Fourth, the correlation of the eAR monitor with other monitor outputs. 
 
Lastly, while not a test of monitor accuracy we took the opportunity to evaluate the patient user-
friendliness from the results of the usability questionnaire. 
 
 
4.4 Results 
 
Patients had at least 2 weekends and 6 weekdays of data for each activity monitor. Although subjects 
wore the monitor for 14 days, in some cases, technical problems resulted in incomplete data 
collection. No patient had to be entirely excluded from the analyses. However, incomplete days of 
monitoring were excluded.  
 
In some of the patients, the resting energy measurements (REE) from the ventilated hood method 
gave unexpectedly low readings, despite repeating the measurements on different days, which could 
have been due to technical problems such as from the canopy or errors in calibration, although these 
were not apparent at the time of the measurements. Therefore the analyses presented shows results 
using predicted resting energy expenditure using the Harris Benedict equation as well as those results 
obtained using the ventilated hood and the Weir method (see Methods section). 
 
The ability to capture day-to-day variability was expressed as a coefficient of variation for each 
monitor output. This reflects the intra-patient variability. The mean (SEM) for each output is plotted in 
Figure 4.3.  
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Figure 4.3. Coefficient of variation for each 
patient for each activity monitor.  
SEM as follows: SW steps 0.35-0.54; SW EE 
0.08-0.22; AG steps 0.39-0.76; AG VMU 0.26-
0.57; RT3 EE 0.05-0.11; RT3 VMU 0.32-0.47; 
eAR activity 0.44-0.58) 
 
 
 
 
 
 
 
A t-test was carried out to compare weekday with weekend activity for the various monitor outputs. 
The test was not significant for any output although a trend was noted for the Actigraph (AG) step 
count (p=0.08) and AG vector magnitude units (VMU) (p=0.06). This implied that these monitor 
outputs were different during the week versus the weekend. However some patients were actually 
more active at the weekend than during the week according to the activity monitor data in contrast to 
the hypothesis. 
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Figure 4.4. Percentage difference in mean activity between weekday and weekend for activity 
monitor output (with maximum and minimum difference plotted on error bars)  
 
Pearson’s correlations with 6 minute walking distance and mean activity output are shown in Figure 
4.5. Significant correlations were obtained for all monitor outputs evaluated except for the eAR with 
Pearson’s r as follows: AG steps 0.87 (p=0.0005), SW steps 0.84 (p<0.0001), RT3 VMU 0.77 
(p=0.0003), AG VMU 0.58 (p=0.012), RT3 EE 0.54 (p=0.025) and SW EE 0.46 (p=0.05). 
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Correlations of the various monitor outputs with active energy expenditure (AEE) as measured with 
doubly labelled water are shown in Figure 4.6. AEE was calculated using the Harris Benedict 
prediction equations due to discrepancies with some of the REE values collected with the ventilated 
hood. Significant correlations were obtained for Sensewear step count (r=0.51) and RT3 energy 
expenditure (r=0.53) only. Figure 4.7 shows the same analysis but using the AEE values obtained 
with the ventilated hood. The only significant correlation was with RT3 AEE (r=0.83). AEE was 
calculated by subtracting the REE values obtained from the hood from the TEE values obtained from 
the activity monitor to enable a more accurate comparison. The same was done for the Sensewear to 
obtain SW AEE; however this correlation was not significant (r=0.37). 
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Figure 4.5. Correlations between activity monitor outputs and 6 minute walk distance. 
r values are shown for each monitor. 95% confidence intervals of the line of best fit are indicated by 
the dashed lines. 
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Figure 4.6. Correlations between activity monitor outputs and active energy expenditure 
measured with doubly labelled water (AEE); REE calculated using Harris-Benedict predicted 
values. SW – Sensewear; AG VMU – Actigraph vector magnitude units. r values are shown for each 
monitor. 95% confidence intervals of the line of best fit are indicated by the dashed lines. 
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Figure 4.7. Correlations between monitor outputs and AEE as calculated by the Weir method 
using measured REE values from the ventilated hood. 95% confidence intervals of the line of best 
fit are indicated by the dashed lines. 
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The Sensewear and RT3 monitors gave a derived estimated energy output based on proprietary 
equations. Agreement with total energy expenditure as measured by doubly labelled water (TEE-
DLW) is shown in Figure 4.8 in a Bland-Altman plot. 
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Figure 4.8. Bland-Altman plot of Sensewear (SW) and RT3 energy expenditure (EE) versus total 
energy expenditure (TEE) as measured by the doubly labelled water method.  
The dashed lines indicate the 95% confidence intervals. 
 
 
 
 
Correlation of the eAR monitor with other monitor outputs is shown in Figure 4.9. Significant 
correlations were seen with AG step count, AG VMU and RT3 VMU. 
 
 
 
In terms of acceptability to patients as assessed by the usability questionnaire, the monitors scored 
out of a total score of 100 as follows: Sensewear 74.0, Actigraph 71.5, RT3 62.0 and eAR 56.7.  
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Figure 4.9. Correlations between eAR activity index and other activity monitor outputs 
(significant correlations shown).  
Dashed lines indicate 95% confidence levels of line of best fit. 
 
 
 
 
4.5 Discussion 
 
4.5.1 Significance of the findings 
 
The validity of three commercially available physical activity monitors and one novel device were 
evaluated against indirect calorimetry in 20 COPD patients in a home setting over a 14 day period. All 
monitor outputs evaluated had high coefficients of variation (all greater than 0.20) apart from SW-EE 
and RT3- EE (less than 0.1).  A high coefficient of variation implies that the monitor is able to detect a 
great deal of variation in physical activity within a patient, which is over and above the margin of error 
of the device. However, intradevice reliability was not formally tested in this study. The monitors (apart 
from the eAR) used have previously been reported to have high interdevice [281-283] and intradevice 
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correlations [284-286]. In the laboratory validation study (Chapter 3), we have shown there to be 
strong correlations (all r>0.7, p<0.05) between activity monitor outputs and indirect calorimetry for all 
monitors used in this subsequent study, with 95% limits of prediction of energy expenditure to be 
between 1.13 METS (SW) and 1.41 (RT3). This implies that the margin of error of the monitors (apart 
from the eAR) is sufficiently low to consider that the variation in physical activity is likely to result from 
the patient.  
 
All monitors apart from the eAR showed good correlations with 6MWD. This implies that they were 
able to capture the activity at the speed at which the patient moved during the six minute walk test 
and that the activity measured by that device parameter reflected that patient’s exercise capacity. 
However, patients do not typically move at the speed at which they perform the six minute walk test, 
during which they are encouraged to walk as fast as they can for the duration of the test. Therefore it 
is merely assumed that all movements which expend energy are captured, including those performed 
very slowly.  
 
The Sensewear step count and the RT3 energy expenditure demonstrated a statistically significant 
correlation with indirect calorimetry from doubly labelled water if predicted values for REE as 
calculated by the Harris Benedict equations were used. However, if actual measured values for REE 
from the ventilated hood were measured then only the RT3 energy expenditure output was significant. 
This could be due to fewer values as 5 subjects had to be excluded from the analysis using the 
measured REE values as data could not be obtained from them due to difficulties tolerating the test 
(unable to fast, undergoing a concurrent exacerbation, technical problems with canopy leak).  
 
 
4.5.2 Critique of the method 
 
The eAR monitor did not show any significant correlations with AEE or 6MWD, but this may be due to 
the small sample size – only 10 out of the 20 patients tested actually gave a full set of data. The eAR 
monitor has previously been shown to be a valid head-worn monitor for gait analysis [289], to predict 
energy expenditure [290] and has also been validated for use in COPD patients [297]. Good 
correlations were found between the eAR activity index and the AG step count and VMU and the RT3 
VMU. This may be because they all generate the same raw data i.e. a vector in 3 different axes.  
 
Reasons for lost data from the eAR monitor include technical problems with devices themselves 
either not recording accurately or losing data. One device suffered water damage and another was 
lost. Some patients also found the device uncomfortable to wear, particularly if they wore glasses or a 
hearing aid, due to its location behind the earlobe; it scored the lowest on the usability questionnaire 
(56.9%). Wearing glasses or hearing aids does become more common with age so is an issue which 
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needs due consideration in the design of this device going forwards. Overall, the most acceptable 
monitors were the Sensewear (74%), worn on the upper arm, and Actigraph (72%), worn on a belt 
over the right hip. 
 
The other monitor to suffer significant technical problems was the RT3, mainly because it failed to 
record for a whole week (half of the testing period) in eight patients due to poor battery life, and totally 
failed in one patient. The Sensewear also suffered from lost data of 2 to 3 days in seven patients, 
again due to battery life. Only one patient’s data was lost with the Actigraph. Technical reliability is 
crucial when considering a monitor for use in interventional studies or for long term home use. 
Moreover, if a monitor is too inconvenient or uncomfortable to wear, as seemed to be the case with 
the eAR, then it also cannot be used with any confidence in larger studies. 
 
It was not possible to use a measure of agreement for all the monitors as only the Sensewear and 
RT3 gave estimated energy expenditure values as one of their outputs. A Bland-Altman analysis for 
these two monitors showed both monitors to be prone to error, but less so with the RT3 (see Figure 
4.6).The overall trend for both monitors was to under-record energy expenditure; it is well known that 
COPD patients have higher resting energy expenditure levels, so the monitors were not able to 
estimate this accurately. However, a closer look at the individual data points seems to suggest that 
the tendency to under-record energy expenditure is greatest in the two patients with highest total 
energy expenditure as measured by DLW. This could be for one of 2 reasons – firstly, active energy 
expenditure during physical activity was under-recorded, or that resting energy expenditure was 
underestimated. In fact, in these two patients, REE as predicted by the Harris-Benedict equation was 
significantly lower than that measured by the Weir method using the ventilated hood (1468kCal vs 
1926kCal and 1754kCal vs 1840kCal). Their respective mean stepcounts as recorded by the 
Sensewear were 6903 and 3204, which were not especially high, but doesn’t exclude the possibility 
that this was inaccurate in these two patients. Such errors in a small sample size would influence the 
overall results more than in a larger cohort. 
 
Some patients in this study were actually more active during weekends than on weekdays. This 
observation does not support previous findings of lower activity of COPD patients at weekends. This 
could be due to a number of factors, such as a chance distribution of poor weather during the two 
week study period during the week as opposed to the weekend. This data was not collected in this 
study, but was investigated in the study in the next chapter. Such confounding factors are likely 
mitigated by having a larger sample size. In fact, in the whole data set of 80 patients, weekend activity 
was found to be lower than weekday [303].  
 
In terms of the gold standard of calorimetry itself, there was certainly the possibility of error in the 
measurements. The patients may have incorrectly recorded the time of their samples. A more 
accurate method of measuring total energy expenditure is to use a thermogenesis room for direct 
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calorimetry [304-306], but this method would not have been practical in this study, where the aim was 
to record patients’ usual physical activity over a number of days in a free living environment.  
 
The REE values measured with the ventilated hood were unexpectedly low for some patients (e.g. 
50% of predicted values from Harris Benedict equations). Although these problems were not apparent 
at the time of making the measurements, these low results could represent incorrect data due leak 
from the canopy. This is why the analysis has been presented using both values. (In 5 patients, 
results were not at all available either due to having an exacerbation at the time of the measurement, 
being unable to fast or being unable to tolerate lying flat under the canopy).In fact, in the wider 
multicentre EU study [307], other European centres encountered similar problems, and it seemed to 
be generally when unexpectedly low measurements were obtained from the ventilated hood than the 
values predicted by the Harris-Benedict method (these patients were excluded from the final analysis 
in the published paper). If it is assumed that the patients for whom an actual resting energy 
expenditure measurement (via ventilated hood) was not available did in fact have a high higher REE 
that predicted due to having COPD, then active energy expenditure would in fact have been lower. In 
fact, previous work in COPD patients using doubly labelled water and the ventilated hood method to 
measure total and resting energy expenditure respectively have shown consistently that resting 
energy expenditure values are higher than healthy controls [278, 308]. This seems to be independent 
of disease severity and other factors such as fat free mass (i.e. metabolically active muscle tissue). In 
a study by Sergi et al comparing elderly COPD and healthy age matched controls, fat free mass index 
was similar in both groups but hypermetabolism (REE > 110% predicted REE) was found in 60% of 
the COPD patients compared to 13.7% of controls. However the hypermetabolic COPD patients did 
not have significantly worse spirometry than the other COPD patients [308]. Other possible reasons 
include medications (beta agonists, theophyllines), and the pro-inflammatory state known to exist in 
COPD [309]. 
 
In conclusion, the Sensewear and RT3 monitors were found to be the most accurate monitors in a 
field setting in this group of patients when validated against indirect calorimetry. All monitors apart 
from the novel eAR device showed good correlation with patients’ exercise capacity in terms of 6 
minute walk distance. However, the RT3 was far more prone to technical problems leading to lost 
data. All monitors, with the exception of the eAR, were reasonably well tolerated with the Sensewear 
and Actigraph being the most popular. These results, together with the results of the laboratory 
validation study, should help to guide researchers in selection of activity monitor in future research 
studies in similar patient groups.  
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5 Change in physical activity with time and climate in COPD 
5.1 Introduction 
 
The importance of physical activity in COPD is well established. The seminal studies from Garcia-
Aymerich et al [9, 66, 67] have established the importance of physical activity in long term outcomes 
in COPD in terms of exacerbation rate, hospital admission and mortality.  However, physical activity 
was assessed in these studies using questionnaire data, which have certain limitations, including 
recall bias. There have been few studies published showing longitudinal data from physical activity 
monitoring in COPD patients, showing the effect of time on lung function parameters or health related 
quality of life measures [310], [311], The most recent and comprehensive of these was published by 
Waschki et al [312], who followed up 163 patients with COPD and chronic bronchitis over a median of 
2.8 years. Data regarding physical activity was collected prospectively over this time from the 
Sensewear armband. A decline in all measures of physical activity over the follow up period was 
found in all GOLD stages of COPD. 
 
In addition, the variability of physical activity with season or climate (and therefore geographical 
location) is an important factor to consider; climate is a non-modifiable factor but a better 
understanding of how it influences physical activity would enable strategies to mitigate any negative 
effects or enhance any beneficial effects, for example, in how patients are advised medically or 
availability of resources such as pulmonary rehabilitation at different times of the year. There would 
also be implications in further studies using physical activity as an outcome measure in COPD, in 
particular with respect to interventional studies and trial design.  
 
There is much evidence in healthy populations that physical activity is influenced by environmental 
conditions such as temperature, as already discussed earlier. For example, a large systematic review 
looking at over 30000 subjects over a 26 year period found that physical activity peaked in the 
summer months and was significantly lower in winter [235] . However, very high environmental 
temperatures can also be prohibitive; a Texan study found that high temperature (average 29°C) 
acted as a deterrent to physical activity [7]. It may be that the effect seen in healthy populations is 
more marked in COPD subjects. 
 
It is known that falls in environmental temperatures are associated with falls in FEV1 and FVC as well 
as an increase in exacerbation frequency [313], which would likely impact physical activity. Sewell et 
al [241] examined the effect of season on physical activity in 95 patients participating in a pulmonary 
rehabilitation programme. The patients were split into 4 groups according to when they enrolled in the 
programme. They found that those starting pulmonary rehabilitation in the winter had lower physical 
activity levels at baseline but also improved the most. However, there was no effect of season on the 
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other outcome measures before and after rehabilitation, namely incremental shuttle walk distance or 
quality of life measures. In addition, the number of patients in each group was relatively small (n=18 to 
34) and the same patients were not followed up throughout the seasons. Importantly, the investigators 
did not explain how they defined the seasons, for example, stating differences in temperature with 
winter being cooler, so it seems that these were decided arbitrarily depending in the month of the 
year, rather by than climatic conditions such as temperature, rainfall, sunshine or day length.  
 
Another study, published in 2012 by Moy et al [310], measured physical activity in a cohort of 102 
COPD patients using the StepWatch activity monitor at two time points ranging from 3 to 9 months 
apart [310]. This US based group found a decline in physical activity over time with a mean of 645 
fewer steps per day. There was also some evidence of seasonal variation with a greater decline in 
step count if patients were followed up in winter, over and above the mean decline over time for the 
cohort as a whole. However, the cohort was divided into 4 groups depending on which season they 
were monitored in, resulting in very small numbers in each group. This is a similar limitation to the 
Sewell study referenced above. Again, these investigators also do not state clearly how they defined 
each season as no information regarding temperature was given. In addition 98% of the patients were 
male, which is not truly representative of the COPD population.  
 
A more recent study by Alahmari et al [314] involved a London-based cohort of 73 COPD patients 
who had daily physical activity monitoring by way of the Yamax DigiWalker pedometer, for a mean of 
267 days, although the range was wide (29 to 658 days). They also recorded daily weather data in 
terms of temperature, rainfall, sunshine and wind speed, as well as pollution levels specified by levels 
of PM10. They found that step count increased with environmental temperature, but only up to 22.5 
degrees C, after which there seemed to be a negative association between step count and 
temperature. They stated a 43 steps increase for every degree increase in temperature, but the range 
was again wide (95% CI 2.14 to 84.4 steps). They also found activity to be higher on sunny or dry 
days. 
 
If it could be shown that there is a significant difference in physical activity within the same subject 
due to climatic conditions mentioned above, then this would have to be taken account in terms of 
choosing when to monitor patients as well as for how long, as this would influence outcomes in not 
only interventional studies but in clinical settings such as pulmonary rehabilitation.  
 
Against this background, we conducted a study aiming to assess the effects of time, as well as 
climatic conditions, namely temperature, sunshine, rainfall and day length, on physical activity levels 
in COPD patients over a 12 month period. We hypothesised that: 
  
1.  Physical activity would decline with time, that is be lower at the end of the 12 month study 
period 
 
106 
 
2.  Physical activity would be affected by climate, that is, would be lower in conditions of cooler 
temperature, increased rainfall and shorter day length (which acts as a surrogate for season 
with shorter day length during the winter months).  
 
 
5.2 Materials and methods 
 
5.2.1 Study subjects 
 
236 patients were recruited from 5 European centres as part of the PROactive study (Royal Brompton 
Hospital, London UK: Elegi Colt Institute, Edinburgh, UK; KU Leuven, Belgium; Thorax Institute 
Athens, Greece; Department of General Practice, University Medical Center Groningen, Netherlands). 
All had a clinical history compatible with COPD as well as evidence of chronic airflow limitation, and 
ranged in severity from GOLD stage II to IV [246]. Other than a subset of exacerbation patients 
(n=11), all were clinically stable and free from exacerbations for a minimum of 4 weeks prior to the 
study. Patients were excluded if they had co-morbidities which would interfere with their movement, 
other than COPD (e.g. arthritis, neuromuscular disease) or respiratory diseases other than COPD 
(e.g. asthma), or cognitive impairment. Patient characteristics are shown in Table 5.1. All patients 
gave written informed consent. The study had ethical approval from the respective ethics committees 
(Lothian Regional Ethics Committee, UK; UZ Leuven Medical Ethics Committee, Belgium; University 
Hospital Ethics Committee "Sotiria" Hospital Athens, Greece, University Medical Center Ethics 
Committee University of Groningen, The Netherlands) as well as local site specific approval. All 
patients underwent baseline tests as described in the Methods section, apart from incremental 
cardiopulmonary exercise testing which was optional. 
 
The patients were all recruited as part of Work Package 4 (WP4) of the PROactive project. The main 
purpose of the WP4 study was an item reduction exercise of two draft patient reported outcome tools 
to record physical activity in COPD (daily and clinic versions), in order to eliminate redundant 
questions and produce a final version of each tool, as previously published [245]. These were 
completed electronically on a personal digital assistant device (PDA). This was a multicentre study 
across the 5 European centres described. The initial phase of the study was 6 weeks, with a 
subsequent 6 and 12 month follow up visit. The study design is shown in Figure 5.1. 
 
The first 6 weeks represent a cross-over study where the patients were randomised to either Arm 1 or 
2 (to complete either the daily PRO or the Clinic PRO first), followed by a 2 week washout and then a 
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further 2 weeks with the other PRO. Each part was accompanied with 2 weeks of physical activity 
monitoring. Visit 1 (V1) occurred at the start of the study prior to randomisation, followed by Visit 2 
(V2), 2 weeks later. Visit 3 (V3) took place after the 2 week washout period with Visit 4 (V4) a further 
2 weeks later. Each of these initial 2 week blocks involved physical activity monitoring for 2 weeks, 
along with completion of one of the ePROs.  
 
 
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 
      
Visit 1    Visit 2               Visit 3              Visit 4 
     2 week washout →  
 
 
 
 
 
 
6 months  12 months 
   
Visit 5        Visit 6                         Visit 7  Visit 8 
 
 
  
Figure 5.1. WP4 study design (adapted from Gimeno-Santos et al [245]). 
 
 Follow up was conducted at 6 and 12 months from Visit 1, but with only 1 week of activity monitoring 
at 6 and 12 months (Visits 5 and 6 and Visits 7 and 8 respectively). This shorter period of monitoring 
was decided as a result of work previously published by the PROactive consortium from the domestic 
validation study of activity monitors which showed that accuracy of monitoring was not significantly 
improved with 2 weeks of activity monitoring compared to 1 week
7
 [307]. 
                                                     
7
 Data was repeatable over 2 weeks; the second week of monitoring did not change variability necessitating a change in 
sample size. 
Study design
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Sample size was calculated according to the primary objective of the study, which was the item 
reduction exercise, and based on test-retest analysis of the draft clinic PRO. It was calculated as 200 
(to give 90% power and taking into account the probability of answering to each response for each 
draft question administered. A further 50 exacerbated patients were also to be recruited to represent a 
full range of patients, to give a total of 250 subjects. The final number of 280 was agreed upon, to 
allow for approximately a 10% dropout rate.  
 
5.2.2 Physical activity monitoring 
 
As well as completing the draft questionnaires, patients were also required to wear 2 physical activity 
monitors, the Dynaport MiniMod and Actigraph GT3X simultaneously for two 2 week periods initially. 
These monitors had been previously validated in the first two studies described in previous chapters. 
Both monitors are trunk-worn triaxial accelerometers; the MiniMod is worn in the small of the back; the 
Actigraph is worn at the right hip. Patients wore the activity monitors for 14 consecutive days during 
the first part of the study, and for 7 consecutive days during follow up, but were instructed not to wear 
them at night when asleep or while bathing or swimming. 
 
5.2.3 Weather data 
 
Data specific to the time periods during which patients were studied, as well as to their location, were 
provided by the Met Office. The Met Office provided weather information for all European centres. 
These data comprised daily highest temperature and information on number of hours of sunlight and 
total rainfall per day (mm). Therefore daily weather data was available for every day of activity 
monitoring collected. Unfortunately, data on daily hours of sunshine was not available for two of the 
centres (Leuven and Groningen) so these centres could not be included in that particular analysis. 
 
 
5.3 Data handling and statistical analysis 
 
The following guidelines were used when processing the activity data: 
 
1. Incomplete days of activity monitoring were excluded – at least 10 hours of activity data for a 
day were required for that day to be included in the analysis (patients were not asked to wear 
the monitors in bed at night). 
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2. Wherever possible, activity data was used from V1-2, but if not possible (for example, due to 
technical problems), data from V3-4 was used instead. 
 
3. Patients who did not participate in all 3 time points (baseline, 6 and 12 months) were not 
included in the analysis. 
 
 
Statistical analysis was carried out using IBM SPSS Version 19. Continuous variables are presented 
as mean value ±1 standard deviation (SD) or as median values (interquartile range) depending on the 
normality or not of their distribution, while categorical variables are presented as % predicted value. 
Normality distribution was assessed utilising Shapiro-Wilk normality test, while Q-Q plots
8
 were used 
for visual confirmation of distribution of data. Comparisons of non-normally distributed physical activity 
measures across several groups and time points were conducted after they were transformed to 
natural logarithms. One-way ANOVA and Chi-square test were used to compare quantitative and 
qualitative variables across different sites at baseline. Further analysis of results, addressing 2 main 
objectives, was set out a priori as follows: 
 
 
1. Assessment of changes in physical activity levels with time  
 
Mixed repeated measures ANOVA was used to compare measurements of physical activity of the 
patients (steps, walking time etc) between baseline, 6 and 12 months (V1-2, V5-6 and V7-8) (within-
subjects factor), with site being the grouping variable (between-subjects factor). Equality of the 
variances of differences was tested utilising the Mauchly’s test of sphericity
9
 and the Huyhn-Feldt 
correction
10
 was used when assumption of sphericity was violated, because epsilon was>0.75 in all 
cases. Levene’s test was used to investigate the equality of error variances. Bonferroni Post-Hoc test 
was used for pairwise comparisons between groups. The F statistic was reported to describe effect of 
time on PA measures. 
 
 
                                                     
8
 These are plots of quantiles of the first data set against the second data set to check visually for normality. 
9
 Sphericity means that the variances of all possible pairs of groups are equal. If Mauchly’s test is violated, variance 
calculations can be distorted, leading to inflated F ratios and increasing the chance of Type I errors, i.e incorrectly 
rejecting the null hypothesis. 
10
 The Huyn-Feldt correction modifies the degrees of freedom to get a valid F ratio: the further the F ratio from 1, 
the worse the violation of sphericity. 
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2. Assessment of the effect of climate condition on physical activity changes over 
three time points (baseline, 6 months, 12 months) 
 
Multivariate analysis was conducted using mixed linear models. Separate models were built with each 
measure of physical activity (steps, walking time etc) being the dependent variable. Repeated variable 
was time period (visit), while site, FEV1, age, BMI, QMVC, RV/TLC and climate conditions 
(temperature, day length, rainfall and their interactions) entered the model as potential explanatory 
variables. The model fit was tested using the -2 Log Likelihood and the Akaike’s information criterion, 
with the smallest value indicating the test with the best fit. The estimates of fixed effects with 
corresponding 95% confidence intervals were used to describe the effect of each of the explanatory 
variables (covariates) on each physical activity measure. A level of p<0.05 was considered significant. 
 
 
5.4 Results 
 
236 patients with COPD were recruited from 5 different European centres. Their baseline 
characteristics are detailed in Table 5.1. A breakdown by centre is also given in Table 5.2 with results 
of ANOVA showing the differences between patients in each centre. However only 157 patients 
actually completed 12 month follow up successfully (i.e completing visits for baseline, 6 and 12 
months with valid data from at least one activity monitor). This significant drop out rate is discussed 
later. 
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Variable N Mean  Std. Deviation  
Age (years) 236 67.4 8.42 
BMI (kg/m2) 236 27.0 5.50 
FEV1 % predicted 235 57.0 20.5 
RV/TLC% 221 50.9 11.4 
Male:Female~ 236 160:76 - 
6MWD (m) 229 430 129 
QMVC (kg) 233 31.8 11.8 
AG mvpa* (mins) 227 7.7 16.6 
AG mvpa ln (mins) 227 1.84 1.53 
AG steps*  227 3715 3400 
AG steps ln 227 8.17 0.72 
AG VMU*  227 368000 248000 
AG VMU ln 227 12.7 0.54 
AG temperature^ (°C) 227 17.3 6.35 
AG daily sunshine (hrs) 139 4.94 2.60 
AG daily rainfall (hrs) 227 0.75 0.97 
MM walktime (mins)* 229 55.8 41.3 
MM walktime ln (mins) 229 3.94 0.68 
MM intensity* (g) 229 0.18 0.04 
MM intensity ln (g) 229 -1.72 0.34 
MM steps* 229 4290 3410 
MM steps ln 229 8.30 0.74 
MM VMU* 229 267000 239000 
MM VMU ln 229 12.4 0.70 
MM temperature^ (°C) 229 17.3 6.07 
MM daily sunshine (hrs) 139 4.80 2.660 
MM daily rainfall (mm) 229 0.74 0.96 
Daylength AG (hrs) 234 649 125 
Daylength MM (hrs) 234 648 122 
HAD A score 235 5.63 4.16 
HAD D score 235 4.98 3.44 
CAT score 226 14.4 8.12 
CCQ score 230 1.78 1.06 
 
Table 5.1. Baseline characteristics of all patients at Visit 1 
BMI – body mass index; FEV1% – forced expiratory volume in 1 second percentage predicted; RV/TLC% - ratio 
of residual volume to total lung volume percentage predicted; 6MWD –six minute walk distance; QMVC – 
quadriceps maximal voluntary contraction; AG – Actigraph GT3X monitor; MM – Dynaport MiniMod monitor; 
mvpa – moderate to vigorous physical activity; VMU – vector magnitude units; ln – natural logarithm; °C – 
degrees centigrade; HAD A – Hospital Anxiety and Depression Scale – Anxiety score; HAD D – Hospital Anxiety 
and Depression Scale – Depression score; CAT – COPD Assessment Tool; CCQ – Clinical COPD 
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Questionnaire. * These variables were non normally distributed so values shown are median an interquartile 
range. ~Male:Female presented as frequency. 
^On some days, patients had activity data available from only one of the two activity monitors (largely due to 
technical problems such as failed recording or incomplete days of monitoring). This is the reason that the mean 
temperature for the days AG data was collected was slightly different to that for the days MM data was collected, 
although there was no significant difference between the two measures of temperature. The same applies to 
rainfall, sunshine hours and day length.  
 
 
Baseline characteristics that were different between centres as demonstrated by ANOVA (see table 
5.2) are as follows: 
 
Age, FEV1% predicted, resting HR, six minute walk distance, QMVC, AG steps, AG VMU, 
temperature, hours of sunshine per day, daily rainfall, MM steps, MM walktime, MM intensity, MM 
VMU, Daylength, HAD score (A and D) and CCQ score.  
 
For example, the patients in Athens had on average a lower FEV1 than the other centres, with lower 
six minute walk distance. The patients in Leuven had higher baseline step counts and other PA 
measures with both activity monitors compared to other centres. Day length was significantly longer 
and sunshine hours greater in Athens compared to the other centres. Rainfall in Athens was much 
lower. The HAD and CCQ scores were significantly lower in Groningen (which sees a larger 
proportion of patients in primary care).  
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Variable  Athens Edinburgh Leuven London  Groningen ANOVA  
p value 
 N Mean (sd) n Mean (sd) n Mean (sd) N Mean (sd) N Mean (sd)  
Age yrs 49 66.1 (8.01) 45 71.7 (7.38) 54 66.3 (6.50) 49 68.6 (9.06) 39 64.0 (9.59) 0.00 
a
 
Male:Female~ 49 38:11 45 28:17 54 42:12 49 28:21 39 24:17 0.075 
BMI kg/m
2
 49  27.0 (6.22) 45 28.8 (5.80) 54  26.6 (5.13) 49 26.3 (5.97) 39  26.6 (3.56) 0.18 
FEV1 %  49 46.9 (15.3) 44 61.6 (20.3) 
 
54 61.9 (21.9) 
 
49 53.6 (23.2) 
 
39 62.3 (15.6) 
 
0.00
 a, b, c
 
RV/TLC% 47 51.8 (12.8) 32 48.9 (9.30) 54 51.9 (13.0) 49 53.0 (9.81) 39 47.3 (10.3) 0.13 
6MWD m 49 356 (99.1) 43 404 (125) 54 501 (136) 44 412 (128) 39 472 (91.7) 0.00
b, c
 
QMVC kg 49 27.7 (8.20) 44 37.6 (12.7) 52 34.1 (10.0) 49 27.5 (10.4) 39 32.5 (14.8) 0.00
a,d,e
 
AG steps* 48 3437 
(3225) 
44 2979 (2792) 
 
50 4736 
(1905) 
 
47 3980 (3825) 
 
38 3784 
(3496) 
 
0.02
f
 
AG steps ln 48 8.09 (0.82) 44 7.93 (0.65) 50 8.37 (0.65) 47 8.15 (0.80) 38 8.32 (0.57) 0.03
 f
 
AG mvpa (mins)* 48 17.53 
(20.2) 
44 4.61 (8.82) 50 10.1 (17.1) 47 9.38 (27.3) 38 6.77 (8.93) 0.06 
AG mvpa ln 48 1.90 (1.64) 44 1.27 (1.56) 50 2.26 (1.26) 47 1.83 (1.75) 38 1.89 (1.23) 0.04
&
 
AG VMU* 48 307457 
(210000) 
44 297143 
(164000) 
49 443000 
(246000) 
47 372927 
(301000) 
38 408210 
(235000) 
0.02
f
 
AG VMU ln 48 12.6 (0.57) 44 12.6 (0.43) 49 12.9 (0.57) 47 12.7 (0.62) 38 12.8 (0.41) 0.09 
AG temp (°C) 48 23.6 (7.05) 44 14.5 (3.19) 50 17.1 (4.63) 47 19.0 (4.10) 38 10.5 (3.29) 0.00
a,b,c,g,
h,I,j
 
AG sunshine (hrs) 48 7.07 (2.57) 44 3.22 (1.31) n/a  47 4.36 (1.98) n/a  0.00
a,d,g
 
AG rainfall cm 48 0.32 (0.89) 44 1.19 (1.00) 50 0.97 (10.8) 47 0.76 (0.90) 38 0.47 (0.62) 0.00
a,h
 
MM steps* 49 4045 
(3452) 
41 3463 (2651) 54 5476 
(3870) 
48 3732 (4301) 37 4895 
(3605) 
0.00
b,f
 
MM steps ln 49 8.16 (0.83) 41 8.06 (0.63) 54 8.60 (0.56) 48 8.15 (0.92) 37 8.47 (0.49) 0.00
 b,f
 
MM walktime* 49 53.7 (42.0) 41 42.9 (27.7) 54 71.8 (40.4) 48 48.0 (47.7) 37 59.6 (37.9) 0.00
a,f,k
 
MM walktime ln 49 3.82 (0.77) 41 3.73 (0.55) 54 4.23 (0.51) 48 3.79 (0.84) 37 4.11 (0.46) 0.00
 a,f,k
 
MMintensity (g)* 49 0.17 (0.04) 41 0.17 (0.02) 54 0.19 (0.03) 48 0.18 (0.05) 37 0.19 (0.04) 0.02
&
 
MM intensity (g) ln 49 -1.50 (0.15) 41 -1.76 (0.14) 54 -1.70 (0.15) 48 -1.76 (0.70) 37 -1.66 (0.13) 0.63 
MM VMU* 49 223569 
(251000) 
41 209730 
(137000) 
54 353717 
(258000) 
48 295948 
(240000) 
37 360802 
(193000) 
0.02
h
 
MM VMU ln 49 12.3 (0.73) 41 12.2 (0.57) 54 12.7 (0.64) 48 12.4 (0.86) 37 12.7 (0.51) 0.00
 h
 
Daylength (mins) 49 978 (71.1) 44 599 (98.7) 54 682 (167) 48 698 (129) 39 563 (49.1) 0.00
a,c,f,k,I
,j
 
HAD A
$
 49 5.98 (4.25) 45 6.71 (4.01) 53 5.08 (4.00) 49 6.47 (4.72) 39 3.67 (2.88) 0.00j 
HAD D
$
 49 5.35 (3.56) 45 5.11 (3.14) 53 5.53 (3.41) 49 5.25 (3.81) 39 3.28 (2.80) 0.02
c,i
 
CAT
$
 49 14.5 (7.46) 44 15.9 (7.77) 54 14.1 (8.39) 45 15.2 (9.21) 34 11.8 (7.29) 0.25 
CCQ
$
 49 1.87 (0.99) 45 1.96 (1.03) 54 1.59 (0.99) 46 2.00 (1.26) 36 1.43 (0.89) 0.05
&
 
Table 5.2. Baseline characteristics by centre & ANOVA  
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BMI – body mass index; FEV1% – forced expiratory volume in 1 second percentage predicted; RV/TLC% - ratio 
of residual volume to total lung volume percentage predicted; 6MWD –six minute walk distance; QMVC – 
quadriceps maximal voluntary contraction; AG – Actigraph GT3X monitor; MM – Dynaport MiniMod monitor; 
mvpa – moderate to vigorous physical activity; VMU – vector magnitude units; ln – natural logarithm; °C – 
degrees centigrade; HAD A – Hospital Anxiety and Depression Scale – Anxiety score; HAD D – Hospital Anxiety 
and Depression Scale – Depression score; CAT – COPD Assessment Tool; CCQ – Clinical COPD 
Questionnaire. . * These variables were non-normally distributed so values shown are median and interquartile 
range. ~Male:Female represented as frequencies with result of Chi squared test presented. 
Post-hoc analysis differences: a=Athens & Edinburgh; b=Athens & Leuven; c=Athens & Groningen; d=Edinburgh 
& London; e=Leuven & London; f=Edinburgh & Leuven; g=Athens & London, h= Edinburgh & Groningen; 
i=Leuven & Groningen; j=London & Groningen; k= Leuven & London; &=non-significant on post-hoc analysis 
 
 
$
Although these data are presented, there were several missing values so they were not used in the further 
analysis 
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1. Assessment of changes in physical activity levels with time  
Repeated ANOVA analysis showed that physical activity declined with time. For all the measures of 
physical activity, pairwise comparison indicated that physical activity change with time was similar 
across centres (p<0.05), although there were differences between the patients in each centre at 
baseline (Table 5.3).  
Variable Baseline 6 months 12 months ANOVA  
p value 
FEV1% 56.7 (1.69) 56.7 (1.75) 57.6 (1.76) 0.19 
6MWD (m) 440(10.7) 437(10.4) 441 (10.7) 0.57 
QMVC (kg) 32.9 (0.92) 31.9 (0.84) 32.3 (0.88) , 0.11 
RV/TLC% 50.2 (0.95) 56.7 (1.65) 57.5 (1.74) <0.05 
AG steps 4770 (2930) 4120 (2480) 4010 (2480) <0.05 
AG steps ln 8.27 (0.06) 8.13 (0.06) 8.10 (0.06) <0.05 
AG mvpa 18.5 (28.6) 16.3 (36.8) 12.0 (17.0) 0.08* 
AG mvpa ln 2.07 (0.13) 1.83 (0.13) 1.67 (0.12)  <0.05 
AG VMU 405000 
(181000) 
356000 
(163000) 
348000 
(167000) 
<0.05 
AG VMU ln 12.7 (0.04) 12.6 (0.04) 5.49 (0.02) <0.05 
MM steps 5560 (3260) 5040 (3140) 5170 (3160) <0.05 
MM steps ln 8.41 (0.06) 8.29 (0.07) 8.33 (0.06) <0.05 
MM walktime (mins) 68.6 (36.2) 62.4 (34.8) 64.2 (35.8) <0.05 
MM walktime ln (mins) 3.94 (0.04) 3.89 (0.06) 3.95 (0.05)  <0.05 
MM intensity (g) 0.19 (0.02) 0.18 (0.03) 0.18 (0.03) 0.05 
MM intensity ln (g) -1.68 (0.01) -1.71 (0.01) -1.71 (0.01) <0.05 
MM VMU 349000 
(220000) 
313000 
(199000) 
309000 
(199000) 
<0.05 
MM VMU ln 12.6 (0.06) 12.4 (0.06) 12.4 (0.06) <0.05 
 
Table 5.3. Results of repeated measures ANOVA.  FEV1% – forced expiratory volume in 1 second 
percentage predicted; RV/TLC% - ratio of residual volume to total lung volume percentage predicted; 6MWD –six 
minute walk distance; QMVC – quadriceps maximal voluntary contraction; AG – Actigraph GT3X monitor; MM – 
Dynaport MiniMod monitor; mvpa – moderate to vigorous physical activity; VMU – vector magnitude units; ln – 
natural logarithm; °C – degrees centigrade; HAD A – Hospital Anxiety and Depression Scale – Anxiety score; 
HAD D – Hospital Anxiety and Depression Scale – Depression score; CAT – COPD Assessment Tool; CCQ – 
Clinical COPD Questionnaire. *Although p 0.08, significant difference between baseline and 12 months (p=0.03) 
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2. Assessment of the effect of climate condition on physical activity changes over 
three time points (baseline, 6 months, 12 months) 
 
For each activity monitor, the following variables were tested in the mixed model method: 
 
Actigraph: Centre, age, BMI, FEV1%, RV/TLC%, QMVC, daylength, temperature, daylength x 
temperature (daylength-temperature interaction) 
 
Minimod: Centre, age, BMI, FEV1%, RV/TLC%, QMVC, temperature 
 
The mixed model results tables show F and p values and upper and lower 95% confidence levels for 
each activity monitor output. Each activity monitor variable was tested in this analysis. 95% 
confidence intervals are not shown for centre number as this was non-significant (and on subsequent 
pairwise analysis, confidence intervals were calculated for each centre). 
 
 
Variable F P value 95% confidence interval 
Intercept 40.5 0.00 3.13 – 6.23 
QMVC (kg) 14.5 0.00 0.01 – 0.04 
FEV1% 39.9 0.00 0.02 – 0.03 
BMI (kg/m2) 10.9 0.00 -0.08 - -0.02 
Age (years) 36.8 0.00 -0.08 - -0.04 
Temperature (°C) 0.90 0.35 -0.02 – 0.008 
Centre no 5.02 0.01 na^ 
 
Table 5.4 AG mvpa ln  
(^Although initially significant, this effect does not persist on pairwise comparison). 
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Variable F P value 95% confidence intervals 
Intercept 1407 0.00 12.6 – 14.0 
QMVC (kg) 6.77 0.01 0.001- 0.010 
FEV1% 54.1 0.00 0.007 – 0.012 
BMI (kg/m
2
) 13.9 0.00 -0.030 - -0.009 
Age (years) 31.5 0.00 -0.026 - -0.001 
Day length (mins) 5.44 0.02 0.0010 – 0.0011 
Temperature (°C) 9.04 0.00 0.0146 – 0.070 
RV/TLC% 1.27 0.28 -0.003 – 0.0009 
Temperature x Day 
length 
6.44 0.00 -8.23 - -1.04 
Centre no 0.33 0.86 na 
 
Table 5.5 AG VMU ln 
 
 
Variable F P value 95% confidence interval 
Intercept 1388 0.00 2.05-2.28 
QMVC (kg) 14.7 0.00 0.0007 – 0.002 
FEV1% 52.1 0.00 0.001 - 0.002 
BMI (kg/m
2
) 4.92 0.03 -0.004 - -0.0002 
Age (years) 29.2 0.00 -0.004 - -0.002 
Day length 3.67 0.06 -2.10 – 0.0002 
Temperature (°C) 6.12 0.01 0.001 – 0.010 
Temperature x Day length 4.12 0.04 -1.12 - -1.17 
Centre no 0.70 0.59 na 
RV/TLC% 1.07 0.30 -0.0005 – 0.0002 
 
Table 5.6 AG steps ln 
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Variable F P value 95% confidence interval 
Intercept 121.1 0.00 3.67 – 5.20 
Age (years) 8.70 0.00 -0.02 - -0.005 
BMI (kg/m2) 7.48 0.01 -0.03 - -0.005 
FEV1% 34.9 0.00 0.007 – 0.013 
RV/TLC% 0.312 0.58 -0.003 – 0.016 
Temperature (°C) 13.3 0.00 0.005 – 0.016 
QMVC (kg) 13.7 0.00 0.005 – 0.015 
Centre no 1.64 0.16 na  
 
Table 5.7 MMwalktime ln 
 
 
Variable F P value 95% confidence interval 
Intercept 116.3 0.00 -1.81 - -1.25 
Age (years) 10.0 0.00 -0.009 - -0.002 
BMI (kg/m2) 4.58 0.03 -0.01 - -0.0004 
FEV1% 19.4 0.00 0.002 – 0. 
Temperature (°C) 4.62 0.03 0.0003 – 0.007 
QMVC (kg) 7.79 0.01 0.001 – 0.006 
Centre no 0.21 0.93 na 
 
Table 5.8 MMintensity ln 
 
 
Variable F P value 95% confidence interval 
Intercept 414.9 0.00 8.01 – 9.98 
Age (years) 9.80 0.00 -0.026 – -0.006 
BMI (kg/m2) 5.87 0.00 -0.03 – -0.004 
FEV1% 38.4 0.00 0.008 – 0.015 
Temperature (°C) 11.5 0.00 0.004 – 0.016 
QMVC (kg) 11.1 0.00 0.004 – 0.016 
Centre no 1.20 0.31 na 
RV/TLC% 0.39 0,53 -0.003 – 0.002 
 
Table 5.9 MMsteps ln 
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Variable F P value 95% confidence interval 
Intercept 1291 0.00 13.0  – 14.5 
Age (years) 26.9 0.00 -0.032 - -0.014 
BMI (kg/m2) 13.3 0.00 -0.039 - -0.011 
FEV1% 52.8 0.00 0.009 – 0.016 
Temperature (°C) 4.81 0.03 0.0007 – 0.012 
QMVC (kg) 11.3  0.00 0.004 – 0.014 
Centre no 0.21 0.94 na 
RV/TLC% 3.26 0.07 -0.004 – 0.0002 
 
Table 5.10 MM VMU ln 
 
 
In summary, for both activity monitors, RV/TLC% and centre were never significant predictors of 
physical activity measures. For Actigraph measures, age, BMI, FEV1%, temperature, day length and 
the interaction between temperature and daylength did have a significant effect.  
 
For MiniMod measures, age, BMI, FEV1%, temperature, day length and the interaction between 
temperature and daylength did have a significant effect.  
 
 
 
3. Dropouts 
 
Across all centres, dropouts were a problem (see table 5.11) ; 236 patients were initially recruited, but 
only 157 patients had data for at least one activity monitor for all visits, representing a 33% dropout 
rate over 1 year across the whole studies.  
 
Overall, the subjects who dropped out of the study at some point throughout the 12 month follow up 
period had lower baseline physical activity levels as measured by either activity monitor. They also 
had a lower baseline six minute walk distance (mean difference 60m lower) and lower quadriceps 
strength. In addition, CCQ scores were also lower in the dropout group, suggesting lower quality of 
life, although CAT scores were not statistically significantly different at baseline. However, there was 
no difference in exacerbation frequency between the groups (Chi squared = 0.187, p=0.67) and the 
groups were well matched for age, BMI and FEV1. Weather conditions at baseline were also similar, 
although temperature was statistically significantly different between the two groups, with the mean 
difference approximately 2 degrees.   
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Variable Dropout Non dropout Difference T test p value 
Age (years) 67.8 (9.42) 67.2 (7.89) 0.63 0.626 
BMI (kg/m2) 27.7 (6.52) 26.7 (4.90) 1.04 0.172 
FEV1% 55.7 (14.4) 57.7 (22.0) 2.04 0.475 
RV/TLC% 52.4 (10.4) 50.2 (11.9) 2.17 0.193 
6MWD (m) 389 (130) 449 (124) 60.0 0.001 
QMVC (kg) 28.5 (12.2) 33.3 (11.3) 4.85 0.003 
AG mvpa ln 1.42 (1.61) 2.05 (1.45) 0.63 0.00 
AG steps ln 7.97 (0.78) 8.27 (0.67) 0.30 0.00 
AG VMU ln 12.6 (0.58) 12.8 (0.51) 0.02 0.06 
AG temp (°C) 16.0 (6.09) 17.9 (6.41) 1.85 0.040 
AG sunshine (hrs) 4.60 (2.27) 5.11 (2.75) 0.51 0.277 
AG rainfall (mm) 0.81 (0.96) 0.72 (0.97) 0.09 0.523 
MM walktime ln (mins) 3.73 (0.79) 4.05 (0.59) 0.32 0.00 
MM intensity ln -1.79 (0.55) -1.69 (0.15) 0.1 0.03 
MM steps ln 8.07 (0.85) 8.41 (0.65) 0.34 0.00 
MM VMU ln 12.3 (0.81) 12.5 (0.63) 0.02 0.00 
MM temp(°C) 15.9 (5.86) 17.9 (6.10) 2.04 0.016 
MM sunshine (hrs) 4.35 (2.24) 5.09 (2.71) 0.74 0.108 
MM rainfall (mm) 0.80 (0.98) 0.70 (0.94) 0.10 0.457 
Daylength (mins) 636 (113) 656 (130) 19.9 0.253 
HAD A 6.28 (4.58) 5.31 (3.91) 0.971 0.091 
HAD D 5.34 (3.58) 4.80 (3.37) 0.547 0.251 
CAT 15.7 (8.03) 13.8 (8.12) 1.90 0.100 
CCQ 2.00 (1.12) 1.67 (1.01) 0.318 0.032 
 
Table 5.11: Baseline characteristics in dropout subjects vs non-dropout subjects.  
FEV1% – forced expiratory volume in 1 second percentage predicted; RV/TLC% - ratio of residual volume to total 
lung volume percentage predicted; 6MWD –six minute walk distance; QMVC – quadriceps maximal voluntary 
contraction; AG – Actigraph GT3X monitor; MM – Dynaport MiniMod monitor; mvpa – moderate to vigorous 
physical activity; VMU – vector magnitude units; ln – natural logarithm; °C – degrees centigrade; HAD A – 
Hospital Anxiety and Depression Scale – Anxiety score; HAD D – Hospital Anxiety and Depression Scale – 
Depression score; CAT – COPD Assessment Tool; CCQ – Clinical COPD Questionnaire. 
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5.5 Discussion 
 
The effect of time and seasonal factors, namely temperature, rainfall, sunshine and day length, on 
physical activity in COPD as measured by two validated, commercially available physical activity 
monitors, at baseline, 6 and 12 months, was investigated.  There was a significant effect of time with 
a decline in all measures of PA over 12 months, as well as climate in the form of temperature. This 
study has many strengths: it involved a large cohort of patients across a range of disease severities 
and they were followed up over three time points during the year. In addition, this was a multicentre 
study covering different geographical areas, enabling investigation of the effect of different climates 
on physical activity in COPD.  
 
5.5.1 Significance of findings 
 
Decline in physical activity over time 
 
There was a significant effect of time with a decline in all measures of physical activity over 12 
months. This applied to all centres, despite the patients having significant differences in baseline 
characteristics, including FEV1, six minute walk distance and baseline physical activity.  
 
This is a significant finding, given the importance of physical activity as the strongest predictor of 
mortality in COPD [115] . Moreover, the finding that there was no effect of centre on this decline with 
time is a valuable one as it has positive implications for future multicentre studies in COPD patients, 
using physical activity as an outcome measure. 
 
In this study 6MWD and FEV1 did not decline significantly with time, albeit over a follow up period of 1 
year. Although Waschki et al did find a decline in FEV1 and 6MWD as well as physical activity, during 
a more long term follow up (over 3 years) and that this decline in physical activity was significantly 
associated with decline in FEV1 over time, they did not find this in those subjects who had a sustained 
low physical activity level. They also did not find an association of decline in physical activity with 
6MWD decline [312]. These findings support our conclusions that measures of physical activity in 
COPD are potentially much more sensitive measures of disease progression than FEV1 and exercise 
capacity, commonly used outcome measures.[315]; as our follow up period was only a year, it may 
not have been long enough to see significant changes in FEV1 and 6MWD.  Physical activity therefore 
should be considered as a primary outcome measure in intervention studies as well as longitudinal 
prospective studies in COPD.  
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Effect of climate on physical activity 
 
A significant effect of climate on physical activity, in the form of temperature was also found, with 
lower levels associated with cooler temperatures. This change was independent of centre; it was not 
the fact that the patients were recruited at different locations that explained the variation in activity 
levels, but the change in environmental temperature itself.  
 
A persistent effect of temperature was seen for almost all measures of physical activity. However, 
other seasonal factors were less significant. Rainfall, where available, was not a significant 
determinant of physical activity for any measures. Unfortunately, the analysis of climate was limited by 
availability of data. For example, the number of hours of sunshine per day was not available for all 
centres, and other factors such as humidity or pollution levels were not available. The effect of the 
interaction between temperature and day length as a separate variable was tested and found to be 
significant for AG VMU ln, and approached significance for AG steps ln only (and not for any MM 
measures), but it seems that most of this effect is accounted for by temperature. One would expect 
temperature to be higher in the summer than the winter, so a seasonal effect can be inferred from this 
finding, which seems to be over and above the decline seen in physical activity over time, although 
we did not specifically test for this. This has implications in choosing when to conduct studies, 
particularly multi centre studies in different countries and temperature is one of the factors that would 
need to be controlled for. A practical solution would be to do all measures in the same season to try 
and match environmental temperature as best as possible, for baseline and follow up; or to at least to 
correct for this effect during any data analysis or to randomise as patients are recruited so that the 
effect of climate is negated.  
 
Another interesting observation was that temperature was 2 degrees lower in the patients that 
dropped out of the study. Step count was approximately 1000 steps per day lower in these subjects 
compared to the non-dropouts. It is only possible to speculate as to the reason for this; lower 
environmental temperatures could be driving the lower physical activity levels and cause more drop 
outs due to increased frequency or severity of exacerbations, although we did not find a difference in 
exacerbation frequency between dropouts compared to non-dropouts. 
There are few published studies looking at the effect of climate on physical activity in COPD, and as 
already alluded to, they are not without their limitations. Moy et al’s cohort was small and made up 
mostly of male patients; there were no data regarding climatic conditions such as temperature or 
sunshine to define the seasons [310]. The recent study by Alahmari et al in 73 COPD patients 
measured physical activity daily for 12 months using pedometers, as well as daily weather data 
(temperature, rainfall, sunshine) and data for atmospheric PM10 and ozone [314]. They found step 
count to be lower on weekends and on colder and overcast days. There was also an impact on step 
count of environmental PM10 and ozone levels with higher levels of each correlating with decreased 
activity levels. However, a closer look at the data reveals quite large standard deviations of, for 
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example, the daily average step count and the step count increase that each degree in temperature 
rise produced. The physical activity data were linearly distributed in this study of only 73 patients, 
whereas in our multicentre study we had to log-transform much of the data in order to model it 
accurately. This could be explained by the multicentre nature of the study producing a wide spread of 
the data, or the fact that physical activity and other variables were only sampled at 6 month intervals, 
and not daily. However, the wide range of physical activity that is seen COPD patients needs to be 
considered carefully during data analysis in order to produce accurate results and draw valid 
conclusions.  
 
In the wider context, lower environmental temperature and the association with lower physical activity 
levels, increased exacerbation rates and lung function decline in COPD could be driving mortality in 
COPD, but causality needs to be established. It is already well established that early pulmonary 
rehabilitation following exacerbation reduces the risk of re-exacerbation [316]. If physical activity 
levels during winter were increased through therapeutic interventions, would this act as a preventative 
measure to reduce exacerbation rates, lung function decline and therefore mortality? 
 
 
5.5.2 Limitations   
 
There were some limitations to this study. The primary objective was to perform the item reduction 
task for the PRO tool and so it was powered to this endpoint and not to detect the physical activity 
changes over time. However, decline of physical activity was significant, so it is improbable that a 
larger sample size would have altered the conclusions of the study. 
 
The staggered start times of the patients proved problematic when analysing the data fro climate and 
seasonal differences. Ideally all patients should have been enrolled into the study within the summer 
in a short period to minimize the differences in climate; they would then have been followed up in 
winter at the first follow up visit at 6 months. However, in reality, patients were slowly recruited into the 
study with some entering during summer, and others in autumn with a handful in winter. Those who 
were enrolled in autumn were followed up at 6 months in spring, at which time there was not a great 
difference in temperature compared to the time of enrollment. Daylength was used as a surrogate for 
season, but again is only relevant when comparing winter and summer (as, again, daylength in 
autumn and spring is similar), and that too only in northern European countries (daylength did not 
vary as much in Athens as, for example, in Edinburgh). It could be possible to group patients 
according to the season in which they were recruited, but this would have to be done arbitrarily, as 
there is a gradual transition from one season to the next. It would also mean that patients recruited in 
autumn may end up being excluded from the analysis, which could skew results. Therefore, rather 
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than being able to look for a seasonal effect, the main variable of temperature had to be used, as this 
was deemed a more objective and robust variable.  
 
Weather data was collected retrospectively, and although these were official data from the Met Office, 
and this technique has been previously used [314, 317], it would have been more accurate to keep 
real time records of weather conditions at the time of the study. 
  
Dropouts were a problem as 33% of the initial patient population dropped out. The recent study by 
Waschki et al had a dropout rate of around 20% (single centre), which is lower than the present study, 
but still represents a significant number. In both studies, patients who dropped out had significantly 
lower physical activity levels at baseline. This seems to be a particular feature of COPD patients and 
mirrors the finding in pulmonary rehabilitation that those patients who do not complete have more to 
gain; those who drop out are more breathless, have poorer health related quality of life , lower FEV1, 
weaker quadriceps strength and higher anxiety and depression scores [20, 318]. In this study, 
patients who dropped out had lower quadriceps strength, six minute walk distance and CCQ score, as 
well as physical activity levels, but not increased exacerbation rates. However, with respect 
pulmonary rehabilitation, other socioeconomic factors such as access to transport,, living alone and 
smoking status [319]. We did not necessarily allow for these factors in this study, but is something 
that could be targeted to reduce the dropout rate in future studies. As a whole, dropout rate  
represents an important factor that clearly needs to be accounted for in any future studies 
investigating physical activity in this population. This also needs to be accounted for in future studies 
in both patient selection and sample size calculations. 
 
 
5.6 Conclusion 
 
We have demonstrated a decline in physical activity in COPD over 1 year follow up, in the absence of 
significant decline in FEV1 or 6MWD, commonly used outcome measures in this population group. We 
have also shown an effect of climate, namely that of temperature, with cooler temperatures 
associated with lower physical activity levels, independent of geographical location. 
 
These findings have important implications regarding future research in this field, particularly 
regarding trial design. As already alluded to, as temperature has been found to have a significant 
effect on physical activify levels, this variable has to be controlled for when recruiting patients into 
studies where physical activity is to be used as an outcome measure, Either patients should be 
recruited during similar climatic conditions, or sample size calculations have to allow for the effect of 
temperature. When conducting follow up, an attempt should be made to control for climatic conditions 
such as temperature, such as following up patients in the same season, or adjusting for the effect of 
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temperature in subsequent statistical analysis. Effects of interventions must be ‘real effects’, not just 
the result of following patients up in better weather. 
 
Reassuringly, we did not find an effect of centre on physical activity, and this bodes well for future 
European multicentre studies using physical activity as an outcome measure. Further research into 
how physical activity varies in COPD, as well as in other chronic diseases, in other parts of the world 
with very different climatic conditions (e.g. countries around the equator) is needed to provide a more 
comprehensive understanding of this area, in order to effectively design trials and develop new 
interventions for COPD. 
 
These findings also have significant clinical relevance. It is already known that physical activity is the 
strongest predictor of mortality, and seems to decline earlier than other clinically important measures 
such as exercise capacity or lung function. If physical inactivity could be tackled earlier with 
intervention, then there could be real promise in attenuating decline in these patients. This could 
represent a new emphasis in therapy, over and above existing pulmonary rehabilitation programmes 
and could be tested in further randomised controlled studies. Our dropout rates and lower levels of 
physical activity in those who do drop out parallels the limitations of pulmonary rehabilitation, in that it 
is those who do not complete who are those who have most to gain. More innovative ways of 
reaching this target population need to be devised in order to make a real impact on this as yet 
incurable disease. 
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6 Changes in early exercise in patients with COPD and their 
association with daily physical activity 
 
6.1 Introduction 
 
As discussed in previous chapters, exertional dyspnoea is the predominant limiting symptom in COPD 
patients, with respect to physical activity, be it exercise or activities of daily living. A number of factors 
are responsible for early termination of physical activity due to dyspnoea, but the key phenomenon is 
widely agreed to be dynamic hyperinflation. In fact, Garcia-Rio et al found in 110 patients with 
moderate to severe COPD that daily physical activity as measured with a triaxial accelerometer (RT3) 
was mainly related to the presence of dynamic hyperinflation on CPET, (as well as 6MWD), with lower 
vector magnitude units recorded in those who did develop dynamic hyperinflation (p<0.001) [320]. 
This relationship was independent of disease severity as classified by FEV1. 
 
It may be reasonably postulated that in COPD, as in many biological systems, physiological 
phenomena are responsible for behavioural adaptation to potentially unpleasant stimuli [321] i.e. 
dyspnoea. It could be argued that in COPD, dynamic hyperinflation is a consequence of a 
maladaptive breathing response to increased load on the respiratory system during exercise. 
Compared to healthy controls, patients with COPD have been observed to have a faster, more 
superficial ventilatory response to exercise, i.e. a more rapid and shallow pattern of breathing, which 
contributes to the development of dynamic hyperinflation [322, 323]. It has also been observed that 
hypercapnic patients exhibit a more rapid and shallow breathing pattern than eucapnic patients [324]. 
In addition, there is some evidence to suggest that those COPD patients displaying this pattern of 
breathing are more likely to fail a trial of weaning from mechanical ventilation [325].  
 
The usual response to breathing in healthy adults is dependent on the type of exercise and intensity. 
The response to exercise at a constant work load consists of 3 phases: an immediate abrupt increase 
in minute ventilation (VE i.e. the product of tidal volume and respiratory rate) within seconds of the 
onset of exercise, which is neurally mediated; a slower exponential rate of increase in VE; and a 
steady state (usually at around 4 minutes) where tidal volume and respiratory rate remain constant 
and VE is related to CO2 production linearly. As exercise becomes heavier, respiratory rate increases. 
At peak exercise, tidal volume is 50 to 60% of vital capacity [326] [327].  
 
Several studies have analysed the pattern of breathing in response to exercise in COPD. Casaburi et 
al studied 25 COPD patients in a pulmonary rehabilitation setting over 15 years ago [328]. The 
subjects went through an 8 week training programme consisting of 45 minute periods of cycling 3 
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times per week at 80% of peak work rate with CPETs before and after the training period. After 
training, there was a significant increase in the patients’ tidal volume, VT (11%) with a reduction in 
respiratory rate, RR (15%) and a reduction in the ratio of dead space to tidal volume (VD/VT), i.e. more 
efficient breathing and an attenuation of the ‘rapid shallow’ pattern of breathing.  
 
Gorini et al investigated the relationship between PaCO2, breathing pattern and inspiratory muscle 
strength in COPD during normal breathing at rest [324]. Pleural pressure was measured using the 
oesophageal balloon technique
11
. They found an inverse relationship between inspiratory time and 
pleural pressure swing, i.e. the shorter the inspiratory time, the greater the pressure required for 
breathing relative to inspiratory muscle strength. They also found a significant association between 
dyspnoea score, reduced inspiratory time and increased pleural pressure swing. Hypercapnic patients 
were more likely to have a reduced tidal volume and increased respiratory rate than eucapnic 
patients. It could be that by reducing tidal volume, this allows patients to reduce the pressure changes 
required during breathing relative to inspiratory muscle strength, thereby reducing breathlessness and 
avoiding inspiratory muscle fatigue. The cost of this is hypercapnia due to reduced alveolar 
ventilation. However, Polkey et al showed that diaphragm fatigue is very difficult to elicit in COPD 
[329].  
 
The results of Marin et al’s study suggest that abnormal resting pulmonary mechanics are responsible 
for the abnormal breathing pattern adopted during exercise [330]. They studied resting lung 
mechanics in 29 GOLD II to IV COPD patients using the oesophageal balloon technique to measure 
resting pleural pressure. Transpulmonary pressure was estimated as the difference between 
oesophageal and mouth pressure when flow was zero. All patients went on to have a symptom limited 
incremental CPET. At rest and at each workload, the VT/VC ratio and VT/VC over VE were calculated 
and formulated into a single exponential equation as described by Jones et al [331]: 
 VT = VC (1-e-kVE) 
They found that patients who had the highest k values had worse lung function (r=0.55 for FEV1% 
predicted), generated higher VT/VC ratios and had abnormal resting pulmonary mechanics with 
higher resting transpulmonary resistance. 
 
Neural mechanisms may also be important. Loveridge et al measured normal rest breathing in COPD 
patients and age matched controls using a dual band respiratory inductance plethysmograph [332]. 
They found there was less variability in breathing in patients with COPD compared to the controls, in 
terms of Ti, TI/TTOT and ventilation, despite similar mean tidal volumes in both groups, and suggest 
that changes in the neural control of breathing due to the disease state are responsible. This 
                                                     
11
 This technique uses two catheters connected to pressure transducers. One is passed through the nose and placed in the 
oesophagus - position is indicated by negative sniff pressure on the pressure trace – and represents intrathoracic presure. The 
other is passed further down to the stomach and represents abdominal pressure. A difference between the two measures 
represents transdiaphragmatic pressure. Other measures such as compliance can also be made. 
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assertion is supported by the results of their subsequent study in patients ranging from moderate to 
severe, and with respiratory failure [333]. Despite the severe and respiratory failure groups’ reduced 
tidal volumes and faster respiratory rates, there was no significant difference in the variability of 
breathing. This suggests that changes in the control of breathing are independent of disease severity 
and mechanical abnormalities. 
  
The findings of Wilkens et al also warrant discussion [322]. They studied the lung compartment 
volumes of three groups of lung transplant candidate patients; COPD (n=21), pulmonary fibrosis (PF; 
n=9) and cystic fibrosis (CF; n=9), as well as 10 healthy controls and 16 transplanted patients, using 
opto-electronic plethysmography (OEP) at both rest and exercise. At rest, the PF and CF patients had 
higher respiratory rates than the COPD patients (who had a mean FEV1 of 20.8% predicted) and 
healthy controls (35 and 24 breaths/minute compared to 16 and 14 breaths/minute respectively). The 
COPD patients had proportionally longer expiratory times (TE) than the other groups, resulting in a 
lower duty cycle. They found that at maximal exercise, the patients with PF and CF developed a rapid 
shallow breathing pattern, with much shorter inspiratory (TI) and expiratory times. However, the 
COPD patients actually had longer TI and TE than even the controls, with much longer TE as well as 
increases in EELV (and therefore dynamic hyperinflation) compared to the other subjects. The 
changes in the disease groups were not seen in the transplant group who behaved similarly to the 
controls, suggesting that the lungs themselves are responsible for the exercise response, rather than 
systemic disease factors.    
 
Nonetheless, rapid shallow breathing is less energy efficient in COPD (see Figure 6.1); due to loss of 
elastic recoil and airway obstruction, a slow deep pattern of breathing is optimal, taking advantage of 
low pressures needed to overcome the elastic recoil, while minimising the pressures required to 
produce airflow. This would result in less dyspnoea and better exercise tolerance. It may be that this 
is a dysfunctional pattern of breathing and it could be associated with reduced daily physical activity; 
individuals adapt their behaviour byavoiding physical exertion because of the unpleasant sensation of 
dyspnoea, resulting in reduced daily physical activity. It may also be much easier to detect this 
breathing pattern compared to dynamic hyperinflation, simply by measuring respiratory rate in clinical 
settings: dynamic hyperinflation measures must at least be done in laboratory conditions with either 
ventilatory flow meters and inspiratory capacity manoeuvres or with the use of 
optoelectroplethysmography. Both methods can be challenging to patients, so a simple method would 
be advantageous for both patient and clinician in terms of better understanding disease severity and 
limitations in daily life.  
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Figure 6.1. Lung compliance as a 
function of respiratory rate in an 
emphysema patient [334] 
 
 
 
 
 
 
 
Thus in the present study, we hypothesised that patients who disproportionately increased their 
respiratory rate compared to tidal volume (i.e. who had a rapid shallow breathing pattern) would have 
lower daily physical activity levels. We also hypothesised that the correlation between rapid shallow 
breathing and daily physical activity would be stronger than that of peak performance (VO2max) with 
daily physical activity.   
 
Patients’ responses to cardiopulmonary exercise testing were analysed. A subset of these patients’ 
responses to walking during a six minute walk test was also analysed. Daily physical activity data in 
the form of step count collected from a triaxial accelerometer was used.  
 
It was further hypothesised that there would be a stronger correlation between the breathing response 
during the early part of the six minute walk tests and daily physical activity levels than that during the 
cardiopulmonary exercise tests, as this measure of exercise capacity has been shown to correlate 
better with measures of physical activity than CPET VO2max and is therefore more representative of 
what patients actually do. 
 
 
6.2 Methods 
 
6.2.1 Cardiopulmonary exercise testing 
 
25 patients with COPD (GOLD I to IV) who were recruited at the Royal Brompton Hospital as part of 
the PROactive Work Package 4 Item Reduction study were studied. Their baseline characteristics are 
shown in Table 6.1.  All patients underwent cardiopulmonary exercise testing on a stationary bike 
using a 10W incremental protocol preceded by a 2 minute rest period and a further minute of 
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unloaded pedalling. Patients were attached to expired gas analysers via a mouthpiece and wore a 
nose clip. They were instructed to pedal at 60 revolutions per minute until exhaustion or until they 
reached 85% of their maximum predicted heart rate.  
 
 
Table 6.1.  Patient characteristics – 
cardiopulmonary exercise testing 
 
 
 
 
 
 
 
 
6.2.2 Six minute walk tests 
 
A subset of the above patients (n=8) who had also participated in the laboratory validation study of 
Work Package 2 (described earlier in Chapter 3) were studied [335]. As part of the laboratory study 
protocol, they undertook a schedule of activities including two six minute walk tests at slow and fast 
pace whilst wearing a portable metabolic kit. Both tests were preceded by at least 2 minutes of rest 
with the patient sitting quietly prior to starting the walk. During the ‘slow walk’ the patients were 
instructed to go at comfortable pace, around 50% of their maximum walking pace. During the ‘fast’ 
walk, they were instructed to go as fast as was comfortably possible in order to cover the greatest 
distance during the six minutes. The same physical activity data was used as in the first analysis. 
 
 
  
Table 6.2. Patient 
characteristics – six minute 
walk distance 
 
 
 
 
 
Variable Mean (sd) 
N 25 
Male: Female 14:11 
Age (years) 69.3 (8.6) 
FEV1% 60.1 (20.4) 
QMVC (kg) 30.1 (11.0) 
RV/TLV% 51.3 (7.2) 
6MWD (m) 467 (102) 
Mean daily step count  4396 (2730) 
Peak VO2 (ml/min/kg) 15.2 (3.5) 
Variable Mean (sd) 
N 8 
Male:Female 6:2 
Age (years) 70.9 (9.9) 
FEV1 %predicted 48.8 (24.0) 
TLco %predicted 45.9 (20.3) 
RV/TLC ratio % 56.5 (11.8) 
6MWD (m) 422 (124) 
Peak VO2 (ml/min/kg) 15.0 (3.5) 
Mean daily steps 3161 (1541) 
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6.2.3 Physical activity monitoring 
 
Physical activity monitoring was carried out using the Actigraph, a triaxial accelerometer, which the 
patients were instructed to wear for 2 weeks during all waking hours (apart from bathing or swimming) 
at the right hip, in accordance with the manufacturer’s guidelines. This was validated for use in COPD 
in the earlier chapters [303, 335] 
 
Other baseline tests were carried out as previously described in the Methods chapter.  
 
6.3 Data analysis  
 
6.3.1 Exercise data 
 
The CPET breath by breath raw data was analysed for all patients, focusing specifically at the 
initiation of exercise, which was defined as being at the onset of loaded pedalling (at 10W). For each 
parameter, a rolling 8 breath average was calculated.  The changes in tidal volume and respiratory 
rate during the first minute of loaded pedalling were analysed in the following way: 
 
Firstly, the area under the curve (AUC) for tidal volume (VT) and respiratory rate (RR) were 
calculated. VT and RR were expressed as a percentage of change from baseline. Baseline was 
calculated from an average of the tidal volume or respiratory rate during the 2 minute rest period of 
the CPET before the start of unloaded pedalling respectively. The ratio of change in AUC VT over 
change in AUC RR was calculated for each patient. The relationship between these values and 
physical activity levels were expressed using linear regression. 
 
Secondly, the rate of change of VT, as a proportion of VC, with VE was calculated using the 
exponential relationship described by Jones et al [331]:  
                                   VT = VC (1-e-kVE) 
So                               k = - [ ln (1-VT/VC) ] /VE 
The relationship of these k values with physical activity was also expressed using linear regression.  
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6.3.2  Six minute walks 
 
For each walk (slow and fast), the first minute of metabolic data was analysed using a similar method 
to above, i.e. the area under the curve for both VT and RR was calculated for the first minute of the 
walk. Baseline for each parameter was calculated from the period of rest earlier in the laboratory 
protocol. A ratio for AUC VT/AUC RR was calculated. A k value was also calculated for this minute for 
each walk as described above. Each value was related to average daily step count using linear 
regression.  
 
6.3.3 Physical activity data 
 
Physical activity data recorded with the Actigraph was available for at least 7 days for all patients. 
Incomplete days, where less than 10 hours of data were recorded, were excluded. Mean steps per 
day was calculated using all the complete days of activity data for each patient.  
 
 
6.4 Results 
 
6.4.1 Cardiopulmonary exercise testing 
Figure 6.2 shows the relationship of physical activity (steps per day) with various lung function 
parameters as well as with 6 minute walk distance. In this cohort, there is only a moderately good 
correlation with 6MWD (r=0.51) and a relatively poor correlation with RV/TLC ratio, a measure of 
dynamic hyperinflation, which is contrary to what Garcio-Rio et al found [320]. 
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Figure 6.2. Relationship of steps per day with FEV1, RV/TLC ratio, six minute walk distance and 
TLco 
 
6.4.1.1 Area under the curve 
Figure 6.3 shows an example of a patient’s data. The area under the curve for the first minute after 
loaded pedalling (and following a period of rest and 1 minute of unloaded pedalling) was calculated as 
shown in the shaded area. Interestingly, this patient does seem to demonstrate an increase in 
respiratory rate with a concomitant reduction in tidal volume immediately on initiation of exercise.  
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Figure 6.3. Example from one patient: Area under curve for tidal volume (VT) and respiratory 
rate (RR) for first minute of loaded cycling. 
 
Figure 6.4 shows the results of linear regression for all the patients of area under the curve and steps 
per day. There was no significant relationship either with AUC VT or AUC RR or with the ratio of these 
and daily steps.  
 
Figure 6.4. Graphs showing linear regression for area under curve for VT, RR and VT/RR 
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6.4.1.2 Change of VT/VC with VE 
Figure 6.5 shows the k values obtained for each patient during the first minute of loaded pedalling 
plotted against steps per day. K values at different stages of the exercise test are also shown for 
comparison. There was a moderate correlation of k value with daily steps at 10W (r=0.49), and 
similarly at unloaded pedalling (r=0.48) compared to that obtained at peak exercise (r=0.33). This is 
against the hypothesis; Marin et al found that higher k values were associated with worse lung 
function, so a negative correlation between k value and physical activity would be expected.  
 
Rest
0 5000 10000 15000
0.00
0.01
0.02
0.03
0.04
r=0.41
Steps/day
K
UL
0 5000 10000 15000
0.00
0.01
0.02
0.03
0.04
0.05
r=0.48
Steps/day
K
10W
0 5000 10000 15000
0.00
0.01
0.02
0.03
0.04
r=0.49
Steps/day
K
20W
0 5000 10000 15000
0.00
0.01
0.02
0.03
0.04
r=0.42
Steps/day
K
Peak
0 5000 10000 15000
0.00
0.01
0.02
0.03
r=0.33
Steps/day
K
 
Figure 6.5. Linear regression of K values for all patients plotted against time periods of 1 
minute for rest, unloaded cycling, 10W, 20W and at peak exercise. 
 
6.4.2 Six minute walk tests 
6.4.2.1 Area under the curve 
Figure 6.6 shows the area under the curve for tidal volume and respiratory rate plotted against daily 
steps. There is only a positive correlation between respiratory rate and daily steps, i.e. as daily 
physical activity increases, the proportional increase in respiratory rate from baseline is greater.  
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Figure 6.6. Area under curve for VT and RR against steps per day for slow and fast walks. 
 
Figure 6.7 shows the ratio of AUC VT to AUC RR for both slow and fast walks during the first minute 
of exercise. There is a positive correlation between this ratio and daily steps at slow paced walking 
(r=0.63), i.e. as daily physical activity levels increase, the proportion to which tidal volume increases 
compared to respiratory rate is greater. In other words, the more physically active a person is, the 
more they increase their depth of breathing than their respiratory rate. However, no relationship is 
found at the faster walking pace. 
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Figure 6.7. AUC VT to AUC RR for slow and fast walks during the first minute of exercise. 
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6.4.2.2 Change of VT/VC with VE 
Figure 6.8 shows the k values for each patient plotted against physical activity for both slow and fast 
walks. There is no significant correlation between k value and daily steps for either walk speeds.  
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Figure 6.8. Linear regression of k values against steps per day for slow and fast walks. 
 
 
6.5 Discussion 
 
The early response to exercise in COPD was investigated. The hypothesis that a rapid shallow 
breathing pattern (i.e. a disproportionate increase in respiratory rate to tidal volume) at the onset of 
exercise would be associated with lower daily physical activity levels and would be better related than 
measures of peak performance was tested in two modalities of exercise, (during an incremental cycle 
CPET and during the first minute of slow and fast paced walking for 6 minutes) but was not proven. 
 
6.5.1 Significance of findings 
 
The area under the curve method was used to assess the rate of change of tidal volume in relation to 
respiratory rate at the onset of exercise. It was hypothesised that there would be a positive correlation 
between the ratio of AUC VT/AUC RR and daily steps, and that this relationship would be stronger for 
walking than during cycling as walking is more representative of what patients actually do on a daily 
basis.  No significant correlation was found during for the CPET modality of exercise, or for fast 
walking, but was found for slow walking.  
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Using the exponential equation VT = VC (1-e
-kVE
) describing the rate of change of VT/VC with time to 
calculate a constant, k, during the first minute of exercise, a moderately significant relationship with 
physical activity was found during cycling both during the first minute of loaded pedalling as well as 
during unloaded cycling, (r=0.49 and 0.48 respectively) and was stronger than that found at peak 
(r=0.33). However, this was not what was expected and was not in keeping with the findings of Marin 
et al who found a higher k value associated with poor lung function.  
 
These findings could be explained because patients usually do things at their own pace throughout 
the day and not at maximal effort, hence the similarities between changes in breathing pattern during 
slow paced walking and physical activity levels. It may be that some patients have to consciously alter 
their breathing pattern to do so slowly and deeply, and may find this more difficult to do at higher 
intensities of exercise. It may explain the training effect found in Casaburi’s pulmonary rehabilitation 
study where patients’ breathing pattern during exercise was altered after 8 weeks of pulmonary 
rehabilitation. However, it may also be the case that the early response to exercise is not indicative of 
either exercise capacity or daily physical activity levels.  
 
As previously discussed, several factors contribute to whether an individual is active on any given 
day. Disease factors have already been discussed, including exertional dyspnoea, dynamic 
hyperinflation and leg fatigue. Other factors include exacerbation frequency and severity and 
adherence to medication which could help to alleviate symptoms [22] [336].  
 
Many other factors are involved. Personal factors such as motivation, cultural background, mood, 
previous experience of activity, along with environmental factors such as access to facilities and 
weather, also influence physical activity levels independent of pathophysiology, so analysing an 
aspect of one of the physiological parameters is likely overly reductive.  
 
 
6.5.2 Critique of the method 
 
There are several limitations with the current study. During the CPET, patients’ breathing during rest 
was often erratic and therefore affected the initial baseline calculations of VT and RR. It may have 
been better to extend the period of rest so that patients were fully accustomed to the mouthpiece and 
breathing in a fully relaxed way prior to the start of cycling. The phenomenon of anticipation is well 
recognised and was not controlled for in this protocol, as patients knew when they were due to start 
exercising. Tobin et al [337] demonstrated this in healthy subjects who were given verbal warnings 
every 30 seconds for 5 minutes prior to the onset of exercise. Compared to the control group, they 
increased their tidal volume and hence minute ventilation on commencing exercise (during the first 
minute). The same effect was observed in subjects who were asked to perform mental arithmetic prior 
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to starting exercise. However, this result was not seen in all the subjects in the present study. Tobin et 
al state this response likely to be cortical in nature, although the absence of a fall in end tidal CO2 
suggests mechanisms other than stimulation of the respiratory centres. It could be that cardiac factors 
are responsible; they noted a concomitant increase in heart rate and O2 pulse which could be 
catecholamine driven. This would be in keeping with the findings of Wasserman et al who 
demonstrated in anaesthetised dogs an increase in ventilation as a result of increased cardiac output, 
either with cardiac pacing or infusion of isoprenaline; the cardiogenic hyperpnea theory [338]. 
However, the patients in the present study did not seem to exhibit a similar O2 pulse response at the 
onset of exercise.  
 
Fukuba et al studied the effects of prior exercise, anticipation and breathing frequency on the 
breathing response to exercise on a static bike at workload of 75W [303]. When preceded by a period 
of rest, they found a rapid increase in tidal volume (phase 1 response) on initiation of cycling if 
exercise was anticipated by the subject. If exercise was not anticipated, this tidal volume response 
was slower if preceded by rest but not if by light exercise, i.e. there is no effect of anticipation on the 
VE response to exercise if preceded by light exercise.  
 
In this study, rest was followed by a period of unloaded cycling, which could have had a similar effect 
to the light exercise in the Fukuba protocol, thereby altering the ventilator response. Similarly, during 
the walking protocol, patients did the fast walk around 4 to 5 minutes after the slow walk, which could 
again have mimicked the light exercise condition.  
 
For some of the more severe patients, unloaded pedalling would cause greater exertion than the 
milder patients and so in these cases, the analysis of unloaded rather than loaded cycling would have 
been more accurate in terms of looking at the immediate breathing response to exercise. Overall, it 
would have been better to have asked the patients to go straight from rest to loaded pedalling to 
reduce the possibility of error here.  
 
The number of patients studied for the walking modality was very small. More patients could be 
studied to generate more data. Each patient could also be studied several times to see if the 
breathing response is reproducible in each patient, or if other factors could influence it, such as a 
training effect, anticipation, length of rest period between walks, or the effect of walking on different 
days or walking outside. For instance it is known that in a standard six minute walk test, 
encouragement increases the distance walked [326], and so might also have an effect on breathing 
pattern. In this protocol, there was a short period between the slow and fast walks of around 5 
minutes, but a longer period may be necessary in this patient group.  
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It should also be noted that the patients wore a mask during the walking tests, as opposed to a 
mouthpiece during the CPET. The experiment could be repeated with a mask during the CPET to see 
if this influenced breathing pattern, particularly during rest.  
 
A much more standardised protocol where factors such as anticipation are controlled for should have 
been employed. In terms of physical activity monitoring, this should have been done as close to the 
time of exercise testing as possible in order to draw any valid conclusions about the relationship 
between daily physical activity and early breathing response on exertion. Both quantity (total steps, 
vector magnitude etc) as well as intensity (time spent in moderate or vigorous physical activity) should 
be measured to see which measure is most closely linked, if at all, with the early breathing response.  
 
No data was collected about resting pulmonary mechanics, which would have been useful since this 
has been previously reported to be related to the ventilatory response to exercise, including by Marin 
et al. It would also be possible to measure intrathoracic pressure changes on exertion using the 
oesophageal balloon technique, and this would be valuable to do in future studies.  
 
The area under the curve method of analysis is a novel one, and may itself need to be evaluated 
under stricter controlled conditions, for example, in a simpler exercise protocol and several times in 
the same patient for reproducibility, as it is particularly susceptible to error incurred if data acquired 
during rest, which is used as baseline for the AUC calculation, is not stable.  
 
 
6.5.3 Conclusions 
 
The results of this study illustrate the complexity and variability of the breathing response to exercise 
initiation in COPD, and that much more controlled conditions are required for a meaningful analysis in 
this population. However, to link this response to actual daily physical activity may merely serve to 
introduce yet more variables into an already complex phenomenon; preliminary data at least failed to 
show a link between respiratory pattern and daily PA. Nevertheless, a greater understanding of this 
response may help to better support patients during pulmonary rehabilitation which is known to 
influence morbidity significantly, over and above drug therapy. If patients could be taught to control 
their breathing in such a way as to improve exercise performance, this would serve not only to 
increase exercise capacity, but also could improve quality of life. They key would be if any such 
intervention did increase daily physical activity. 
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7 Conclusions and future work  
 
The significance of physical activity in Chronic Obstructive Pulmonary Disease is undisputed. Physical 
inactivity is not only a consequence of disease, due to exertional dyspnoea and other factors such as 
muscle weakness and cardiovascular disease, which lead to exercise limitation, but also an emerging 
factor in the progression of COPD, even before symptoms have developed. This thesis has explored 
the importance of technical, environmental and patient factors in physical activity in COPD, to further 
our understanding in this important field. Much of the work in this thesis has its origins in the 
PROactive project, the EU wide 6 year initiative to develop a patient reported outcome tool to 
accurately reflect COPD patients’ experience of physical activity, as such a tool did not previously 
exist. Alongside the development of this PRO, each of the chapters in this thesis has sought to further 
our understanding of technical aspects of physical activity monitoring, how physical activity is 
influenced by time, climate and geographical factors, as well as exploring the possible interaction of a 
dysfunctional breathing pattern with daily physical activity levels.  
 
 
7.1 Laboratory validation of six activity monitors in COPD: a comparison with 
indirect calorimetry. 
 
7.1.1 Summary of findings 
 
The validity of six physical activity monitors was investigated by comparing activity monitor outputs for 
each monitor to the gold standard of indirect calorimetry from a portable metabolic kit in controlled 
laboratory conditions. The main rationale for conducting this study is that whilst several activity 
monitors are commercially available, very few have been validated in populations with chronic 
disease. COPD patients have been shown to move much more slowly than healthy subjects, so it was 
not known if the monitors in question would be sensitive enough to detect this slower pace of 
movement. In addition, some COPD patients have a higher rate of resting energy expenditure, and as 
such, the outputs of energy expenditure from some of the activity monitors, which have been 
previously validated in healthy subjects, could not be relied upon without first validating them in this 
population. 
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This study found triaxial activity monitors to be more valid compared to uniaxial activity monitors 
according to a number of predetermined criteria, namely correlation with energy expenditure derived 
from indirect calorimetry. 
 
Firstly, correlations between minute-by-minute outputs and VO2  (representing energy expenditure) 
were highest with the Dynaport MiniMod, Actigraph GT3X, SenseWear Armband and RT3, all triaxial 
monitors, and all exceeding an r value of 0.7. This shows that the monitors are sensitive and 
responsive to changes in physical activity, even at the small time epoch of minutes.  
 
Secondly, using cumulative energy expenditure over the whole 59 minute protocol, the best 
correlations of mean activity monitor output were again found for three of the triaxial activity monitors 
(SenseWear Armband, Actigraph GT3X and Dynaport MiniMod, as well as one uniaxial activity 
monitor (Kenz Lifecorder). This demonstrates that monitors can accurately reflect a variety of activities 
that patients may realistically do in normal life over a sustained time period, such as housework or 
shopping.  
 
Thirdly, with respect to detecting slower speeds of motion, step count accuracy was assessed and 
found to vary with walking speed, although only two monitors, the Sensewear and MiniMod, were 
considered in this analysis. The Sensewear was much less accurate overall than the MiniMod, 
particularly at slow walking speeds, likely due its positioning on the upper limb. In contrast, the 
MiniMod is positioned around the waist, giving more information about hip movement during walking 
and improving its sensitivity. 
 
Fourthly, all monitors were able to detect a modest change in walking speed of 1.31km/hr, but two 
triaxial activity monitors had the strongest correlations with indirect calorimetry (MiniMod and 
SenseWear).  
 
Fifthly, all activity monitor outputs showed similar variability in predicting energy expenditure. However 
there were fairly wide margins of error (95% prediction limits for mean METs (3.59 METs) varied 
between ±1.13 METs (SenseWear) and ±1.41 METs, (RT3)). Therefore, predicting oxygen 
consumption directly from different activity monitor outputs is not accurate but when patients engage 
in activity, monitors do detect the increase in physical activity levels within a range of 1 to 1.5 METs. 
This confirmed the assertion that the prediction equations for energy expenditure are only relevant for 
healthy subjects.  
 
This study has many strengths. It is the first multi-centre multinational trial where several activity 
monitors were validated simultaneously against indirect calorimetry in different stages of COPD. A 
complex protocol of various activities was used, to include not only walking, but others such as lifting 
and sweeping, to mirror more closely activities of daily living that COPD patients actually perform. All 
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the monitors were sensitive to changes in activity at the minute by minute level, as well as being able 
to accurately record activity over a period of an hour. Some of the triaxial monitors’ ability to detect 
slower speeds of walking was demonstrated.  
 
The protocol used in this study provides a ‘blueprint’ which can be used in future to assess other 
activity monitors, including newer versions of those used here as well as novel devices. It is a 
valuable robust approach which has been shown to be technically feasible in this group of patients. 
 
 
7.1.2 Limitations 
 
There are however, limitations to this study. Although patients from all GOLD stages were tested, the 
mean six minute walk distance was 438m, with standard deviation 115m. These patients were 
therefore functionally not as severely limited as some of our more severe patients, who for example, 
cannot walk more than 100m in six minutes. Therefore, it could be argued that the activity monitors 
were not validated in the slowest moving COPD patients. In fact, as previously discussed, a recent 
study by Harrison et al showed the Sensewear step count to be less accurate at slower speeds of 
1.8km/hr [277].  
 
The gold standard of energy expenditure, which was used to validate the activity monitors, is driven to 
a large extent by a number of other factors, namely body weight, age and height. Whilst these specific 
factors such can be incorporated into prediction equations, it is more difficult with non-specific factors 
such as mechanical efficiency, especially in patients with COPD. These patients have a higher active 
energy expenditure [278], and reduced mechanical efficiency in these patients compared to healthy 
controls [279, 280]. An activity monitor cannot be expected to detect this complex variable accurately. 
Activity monitors are most appropriately used for the assessment of the activities of patients in terms 
of amount and/or intensity, so perhaps greater weight should be given to direct monitor outputs in 
future research (steps, activity counts, vector magnitude units). The derivation of energy expenditure 
from activity monitors is imprecise so therefore not necessarily the ideal gold standard for assessing 
monitor performance, but the only one available for this currently. 
 
 
7.1.3 Future work 
 
In light of the findings of Harrison et al regarding sensitivity of the Sensewear during very slow 
walking, it is important to validate all the monitors from this study at this slower speed and the protocol 
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should be adjusted accordingly if used to validate newer monitors in future research. It is equally, if 
not more important to measure physical activity accurately in these patients, in order to accurately 
capture the little activity they do engage in. Not only would it provide a greater understanding of 
disability, but also could be used to target interventions in this severe group. 
 
In the wider context, it is unclear which aspect of physical activity is more beneficial: steps walked per 
day; amount of time spent in moderate or vigorous activity; level of intensity or frequency of intense 
periods; total energy expended in activity; activity targeting specific muscle groups to improve 
endurance; or activity to improve cardiovascular fitness. Further work is needed in this area, and 
future interventional studies should use various activity measures, such as those listed above to 
determine if improving overall activity amount is sufficient to improve prognosis, or whether a more 
specific targeted approach is beneficial (such as improved cardiovascular fitness, intensity training 
etc.).  
 
 A recent study by Demeyer et al found the minimal important difference in step count in COPD after 
completing pulmonary rehabilitation to be between 600 and 110 steps per day [339], but there are 
problems with using an absolute figure, rather than percentage improvement from baseline. 
Nonetheless, a  ‘How much is enough?’ question needs to be asked, in terms of morbidity (such as 
exacerbation frequency, hospital admission rate) and the answer may be different in different GOLD 
stages of COPD. 
 
Apart from the concepts of validity and reliability, other factors such as size and scope of the study, 
usability and cost of the activity monitor need to be taken into consideration when selecting an activity 
monitor for use in clinical trials. All the monitors used in this study require specialist software in order 
to read and download data, which adds to research expense and time. However, if a more simple 
intervention, such as increasing steps walked per day is required, then a simple pedometer will 
suffice, and be much more cost effective in the long term. 
 
Overall, we concluded that triaxial monitors are superior to unaxial monitors when measuring physical 
activity in the COPD population, and specifically those worn on the hip as opposed to the upper limb 
(namely the Dynaport and Actigraph devices). They can detect slower movement in this population 
but further validation work is needed in the slowest moving and more severely affected patients. 
These results should serve as a useful guide for future choice of valid activity monitors for both 
research and clinical use in patients with chronic diseases including COPD. 
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7.2 Domestic validation study of physical activity monitors in COPD in daily 
life 
 
This study built on the work from the previous chapter in terms of validating activity monitors in COPD, 
this time in a domestic environment, as ultimately, if these monitors are to be used in large scale 
trials, as is the aim of the PROactive project, then they must be suitable for home use in this patient 
group. The validity of four triaxial accelerometers, three of which had been studied in the previous 
chapter (RT3, Sensewear and Actigraph GT3X), as well as one novel device, the eAR, was evaluated 
against the gold standard of indirect calorimetry from the doubly labelled water (DLW) method in 20 
COPD patients in a home setting over a 14 day period. This was the first study to validate a number 
of monitors simultaneously in this patient group using the DLW method.  
 
7.2.1 Summary of findings 
 
All monitor outputs evaluated had high coefficients of variation (all greater than 0.20) apart from 
Sensewear energy expenditure per day (SW-EE) and RT3 energy expenditure per day (RT3-EE) 
(less than 0.1). This implies that the monitor is able to detect a great deal of variation in physical 
activity within a patient, which is over and above the margin of error of the device. The lack of 
variability in SW-EE and RT3-EE could be because the majority of the energy expended is due to 
high levels of resting energy expenditure because the patients are very inactive; these outputs rely on 
prediction equations incorporating factors such as age and weight, and as previously discussed, may 
not be accurate in the COPD population. However, due to problems with the measurement of resting 
energy, it is not possible to be certain on this point (see below). 
 
In the previous chapter, we have shown there to be strong correlations (all r>0.7, p<0.05) between 
activity monitor outputs and indirect calorimetry for all monitors used in the domestic study, with 95% 
limits of prediction of energy expenditure to be between 1.13 METS (SW) and 1.41 (RT3). This 
implies that the margin of error of the monitors (apart from the eAR) is sufficiently low to consider that 
the variation in physical activity is likely to result from the patient.  
 
The Sensewear step count and the RT3 energy expenditure demonstrated a statistically significant 
correlation with indirect calorimetry from doubly labelled water if predicted values for REE as 
calculated by the Harris Benedict equations were used. However, if actual measured values for REE 
from the ventilated hood were measured then only the RT3 energy expenditure output was significant. 
This could be due to underpowering as 5 subjects had to be excluded from the analysis using the 
measured REE values as data could not be obtained from them due to difficulties tolerating the test 
(unable to fast, undergoing a concurrent exacerbation, technical problems with canopy leak). Equally, 
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it could be that the Sensewear prediction equations for energy expenditure are not as valid in this 
population as the RT3 equations. 
 
Although the eAR monitor suffered technical issues (see below), good correlations were found 
between the eAR activity index and the AG step count and VMU and the RT3 VMU, perhaps because 
this was a direct comparison of the raw data i.e. a vector in 3 different axes.  
 
All monitors apart from the eAR showed good correlations with 6MWD. This implies that they were 
able to capture the activity at the speed at which the patient moved during the six minute walk test 
and that the activity measured by that device parameter reflected that patient’s exercise capacity.  
However, patients do not typically move at the speed at which they perform the six minute walk test, 
during which they are encouraged to walk as fast as they can for the duration of the test. Therefore, it 
is merely assumed that all movements which expend energy are captured, including those performed 
very slowly.  
 
 
7.2.2 Limitations 
 
A common theme with problems experienced during the study was technical failure. The eAR monitor 
did not show any significant correlations with AEE or 6MWD, but as only 10 out of the 20 patients 
tested actually gave a full set of data, the analysis could have been underpowered. (However, the 
eAR monitor has previously been shown to be a valid head-worn monitor for gait analysis [289], to 
predict energy expenditure [290] and has also been validated for use in COPD patients [297]).  
 
Reasons for lost data from the eAR monitor were due to technical problems with devices themselves, 
either not recording accurately or losing data. Some patients also found the device uncomfortable to 
wear, particularly if they wore glasses or a hearing aid, due to its location behind the earlobe; it scored 
the lowest on the usability questionnaire (56.9%). This issue warrants further consideration regarding 
the design of this device going forwards, especially in this age group, where wearing hearing aids or 
glasses is common. Overall, the most acceptable monitors were the Sensewear (74%), worn on the 
upper arm, and Actigraph (72%), worn on a belt over the right hip. 
 
The RT3 also encountered technical problems, mainly because it failed to record for a whole week 
(half of the testing period) in eight patients due to poor battery life. The Sensewear also suffered from 
lost data of 2 to 3 days in seven patients, again due to battery life. Technical reliability is crucial when 
considering a monitor for use in interventional studies or for long term home use. Moreover, if a 
monitor is too inconvenient or uncomfortable to wear, as seemed to be the case with the eAR, then it 
also cannot be used with any confidence in larger studies. 
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It was not possible to use a measure of agreement for all the monitors as only the Sensewear and 
RT3 gave estimated energy expenditure values as one of their outputs. A Bland-Altman analysis for 
these two monitors showed both monitors to be prone to error, but less so with the RT3 (see Figure 
4.6).The overall trend for both monitors was to under-record energy expenditure; it is well known that 
COPD patients have higher resting energy expenditure levels, so the monitors were not able to 
estimate this accurately.  
 
Some patients in this study were actually more active during weekends than on weekdays. This 
observation does not support previous findings of lower activity of COPD patients at weekends. This 
could be due to a number of factors, such as a chance distribution of poor weather during the two 
week study period during the week as opposed to the weekend. In fact, in the whole data set of 80 
patients, weekend activity was found to be lower than weekday [303], so this error could be due to the 
small sample size.  
 
Further significant technical problems were experienced with ventilated hood measurements for 
resting energy expenditure. The REE values measured with the ventilated hood were unexpectedly 
low for some patients (some as much as 50% of predicted values from Harris Benedict equations). 
Although these problems were not apparent at the time of making the measurements, these low 
results could represent incorrect data due leak from the canopy. In 5 patients, results were not at all 
available either due to having an exacerbation at the time of the measurement, being unable to fast or 
being unable to tolerate lying flat under the canopy. In fact, in the wider multicentre EU study [307], 
other European centres encountered similar problems, and it seemed to be generally when 
unexpectedly low measurements were obtained from the ventilated hood than the values predicted by 
the Harris-Benedict method (these patients were excluded from the final analysis in the published 
paper).  
 
Previous work in COPD patients using doubly labelled water and the ventilated hood method to 
measure total and resting energy expenditure respectively have shown consistently that resting 
energy expenditure values are higher than healthy controls [278, 308]. This seems to be independent 
of disease severity and other factors such as fat free mass. Other possible reasons for this include 
medications (beta agonists, theophyllines), and the pro-inflammatory state known to exist in COPD 
[309]. 
 
Another potential source of error was the measurement of total energy expenditure from the doubly 
labelled water method, such as incorrect labelling of the timing of the urine samples, as they were 
given by the patients at home, rather than at the study centre,  
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7.2.3 Future work 
 
Going forward, the eAR monitor should be validated again, using both this protocol as well as the 
laboratory validation protocol presented in Chapter 3. However, some design issues need to be 
addressed to make this device more acceptable to patients in the future. Technical difficulties with the 
other monitors should be fed back to the manufacturers so that improvements can be made. 
 
The problems with measuring resting energy expenditure using the ventilated hood should be 
addressed. This is an important technical method with implications for further validation of activity 
monitors. It will also improve our understanding of the systemic effects of COPD. An interesting study 
would be to perform the ventilated hood measurements before and after a physical activity 
intervention, such as an 8 week exercise programme. A sub set analysis would look at how the 
patients with higher than predicted resting energy expenditure performed and whether the intervention 
succeeded in lowering their resting energy expenditure rate.  
 
In conclusion, the Sensewear and RT3 monitors were found to be the most accurate monitors in a 
field setting in this group of patients when validated against indirect calorimetry. All monitors apart 
from the novel eAR device showed good correlation with patients’ exercise capacity in terms of 6 
minute walk distance. However, this was a technically difficult study to carry out; all monitors suffered 
technical problems in terms of lost data. Results were further compromised due major technical 
difficulties using the ventilated hood; moreover, it was not possible to quantifiy errors when collecting 
urine samples for the DLW analysis. However, all monitors, with the exception of the eAR, were 
reasonably well tolerated with the Sensewear and Actigraph being the most popular, and either of 
these could be used in larger studies in the COPD population. Preference would be for the Actigraph, 
as it is a hip worn device, which would make it more accurate in step counting than the Sensewear, 
given the findings of the previous chapter. 
 
 
7.3 Change in physical activity with time and climate in COPD 
 
This study was the first to measure physical activity in COPD longitudinally in different centres across 
different countries. The main aim of this study was item reduction of the draft PRO as part of the 
PROactive project, but we were also able to assess the effect of time and seasonal factors, that is, 
temperature, rainfall, sunshine and daylength, on physical activity as measured by two activity 
monitors at baseline, 6 and 12 months. These commercially available activity monitors had been 
previously validated in the home and laboratory settings (see Chapters 3 and 4) and selected as a 
result of this previous work.  
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7.3.1 Summary of findings 
 
There was a significant effect of time on physical activity, with a decline in all measures of physical 
activity over 12 months. This applied to all centres, despite the patients having significant differences 
in baseline characteristics, including FEV1, six minute walk distance and baseline physical activity. 
This is in keeping with the established concept of physical activity as the strongest predictor of 
mortality in COPD [115] . Moreover, the finding that there was no effect of centre on this decline with 
time is a valuable one as it has positive implications for future multicentre studies in COPD patients, 
using physical activity as an outcome measure. 
 
In this study 6MWD and FEV1 did not decline significantly with time, albeit over a follow up period of 1 
year; although this has been shown in a more recent study by Waschki et al with a longer follow up 
period of 3 years[312]. They found decline in physical activity to be associated with decline in FEV1 
(although not with 6MWD). It is possible that measures of physical activity in COPD are much more 
sensitive measures of disease progression than FEV1 and exercise capacity, commonly used 
outcome measures.[315]; as our follow up period was only a year, it may not have been long enough 
to see significant changes in FEV1 and 6MWD.  Physical activity therefore should be considered as a 
primary outcome measure in intervention studies as well as longitudinal prospective studies in COPD.  
 
A significant effect of climate on physical activity, in the form of temperature was also found, with 
lower levels associated with cooler temperatures. This change was independent of centre; it was not 
the fact that the patients were recruited at different locations that explained the variation in activity 
levels, but the change in environmental temperature itself.  
 
A persistent effect of temperature was seen for almost all measures of physical activity. However, 
other seasonal factors were less significant. Rainfall, where available, was not a significant 
determinant of physical activity for any measures. The effect of the interaction between temperature 
and day length as a separate variable was tested and found to be significant for some measures, but 
it seems that most of this effect is accounted for by temperature. One would expect temperature to be 
higher in the summer than the winter, so a seasonal effect can be inferred from this finding, which 
seems to be over and above the decline seen in physical activity over time, although we did not 
specifically test for this.  
 
This has implications in choosing when to conduct studies, particularly multi centre studies in different 
countries and temperature is one of the factors that would need to be controlled for. A practical 
solution would be to do all measures in the same season to try and match environmental temperature 
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as best as possible, for baseline and follow up; or to at least to correct for this effect during any data 
analysis, or to randomise as patients are recruited so that the effect of climate is negated.  
 
7.3.2 Limitations 
 
There were some limitations to this study. The primary objective was to perform the item reduction 
task for the PRO tool and so it was powered to this endpoint and not to detect the physical activity 
changes over time. However, decline of physical activity was significant, so it is improbable that a 
larger sample size would have altered the conclusions of the study. 
 
The staggered start times of the patients proved problematic when analysing the data for climate and 
seasonal differences. Ideally all patients should have been enrolled into the study within the summer 
in a short period to minimize the differences in climate; they would then have been followed up in 
winter at the first follow up visit at 6 months. However, in reality, patients were slowly recruited into the 
study with some entering during summer, and others in autumn with a handful in winter. Those who 
were enrolled in autumn were followed up at 6 months in spring, at which time there was not a great 
difference in temperature compared to the time of enrollment.  
 
Daylength was used as a surrogate for season, but again is only relevant when comparing winter and 
summer (as, again, daylength in autumn and spring is similar), and that too only in northern European 
countries (daylength did not vary as much in Athens as, for example, in Edinburgh). It was not 
possible to group patients according to the season in which they were recruited, as this would have 
been done arbitrarily, as there is a gradual transition from one season to the next. Therefore, rather 
than being able to look for a seasonal effect, the main variable of temperature was used, as this was 
more objective.  
 
Weather data were collected retrospectively, and although these were official data from the Met 
Office, and this technique has been previously used [314, 317], it would have been more accurate to 
keep real time records of weather conditions at the time of the study. Unfortunately, the analysis of 
climate was limited by availability of data. For example, the number of hours of sunshine per day was 
not available for all centres, and other factors such as humidity or pollution levels were not available. 
  
Dropouts were a problem as 33% of the initial patient population dropped out. Those who dropped out 
had significantly lower physical activity levels at baseline as well as lower quadriceps strength, six 
minute walk distance and CCQ score, as well as physical activity levels, but not increased 
exacerbation rates. This seems to be a particular feature of COPD patients and mirrors the finding in 
pulmonary rehabilitation that those patients who do not complete have more to gain; those who drop 
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out are more breathless, have poorer health related quality of life , lower FEV1, weaker quadriceps 
strength and higher anxiety and depression scores [20, 318]. However, with respect to pulmonary 
rehabilitation, other socioeconomic factors such as access to transport, living alone and smoking 
status are influential [319]. We did not necessarily allow for these factors in this study, but is 
something that could be targeted to reduce the dropout rate in future studies. As a whole, dropout rate 
represents an important factor that clearly needs to be accounted for in any future studies 
investigating physical activity in this population. This also needs to be accounted for in future studies 
in both patient selection and sample size calculations. 
 
7.3.3 Future work 
 
These findings have important implications regarding future research in this field, particularly 
regarding trial design. As already alluded to, as temperature has been found to have a significant 
effect on physical activity levels, this variable has to be controlled for when recruiting patients into 
studies where physical activity is to be used as an outcome measure, Either patients should be 
recruited during similar climatic conditions, or sample size calculations have to allow for the effect of 
temperature. When conducting follow up, an attempt should be made to control for climatic conditions 
such as temperature, such as following up patients in the same season, or adjusting for the effect of 
temperature in subsequent statistical analysis. Effects of interventions must be ‘real effects’, not just 
the result of following patients up in better weather.  
 
Reassuringly, we did not find an effect of centre on physical activity, and this bodes well for future 
European multicentre studies using physical activity as an outcome measure. Further research into 
how physical activity varies in COPD, as well as in other chronic diseases, in other parts of the world 
with very different climatic conditions (e.g. countries around the equator) is needed to provide a more 
comprehensive understanding of this area, in order to effectively design trials and develop new 
interventions for COPD. 
 
These findings also have significant clinical relevance. It is already known that physical activity is the 
strongest predictor of mortality, and seems to decline earlier than other clinically important measures 
such as exercise capacity or lung function. If physical inactivity could be tackled earlier with 
intervention, then there could be real promise in attenuating decline in these patients. This could 
represent a new emphasis in therapy, over and above existing pulmonary rehabilitation programmes 
and could be tested in further randomised controlled studies. Our dropout rates and lower levels of 
physical activity in those who do drop out parallels the limitations of pulmonary rehabilitation, in that it 
is those who do not complete who are those who have most to gain. More innovative ways of 
reaching this target population need to be devised in order to make a real impact on this as yet 
incurable disease. 
152 
 
7.4 Changes in early exercise in patients with COPD and their association 
with daily physical activity 
 
This study was a largely exploratory study into the possible association between breathing pattern at 
the start of exercise with daily physical activity levels. However, the hypothesis that a rapid shallow 
breathing pattern (i.e. a disproportionate increase in respiratory rate to tidal volume) at the onset of 
exercise would be associated with lower daily physical activity levels and would be better related than 
measures of peak performance was tested in two modalities of exercise, (during an incremental cycle 
CPET and during the first minute of slow and fast paced walking for 6 minutes) but was not proven.  
 
7.4.1 Summary of findings 
 
Firstly, a novel method of analysis was used to assess the rate of change of tidal volume with 
respiratory rate at the onset of exercise by looking at the area under the curve during the first minute 
of exercise, and expressing this as the ratio AUC VT/AUC RR. Ventilation data from cycling (from a 
cardiopulmonary exercise test) and walking (during a six minute walk test) recorded with a metabolic 
cart, was used in this analysis. However there was no relationship between this measure and daily 
step count.  
 
Secondly, an exponential equation previously used by Marin et al was used to describe the rate of 
change on VT/VC with time to calculate a constant k during the first minute of exercise for both 
cycling and walking. The hypothesis was that a lower k value would be associated with better daily 
physical activity levels as measured by step count, (as they had found higher k values to be 
associated with poorer lung function) but this was not found in either exercise modality.  
 
7.4.2 Limitations 
 
There were several limitations with this study, apart from it being a total novel and unproven method. 
During the CPET, patients’ breathing during rest was often erratic and therefore affected the initial 
baseline calculations of VT and RR. It may have been better to extend the period of rest so that  
patients were fully accustomed to the mouthpiece and breathing in a fully relaxed way prior to the 
start of cycling. The phenomenon of anticipation is well recognised and was not controlled for in this 
protocol, as patients knew when they were due to start exercising.  
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In this study, rest was followed by a period of unloaded cycling, which could have had a similar effect 
to light exercise, thereby altering the ventilatory response. Similarly, during the walking protocol, 
patients did the fast walk around 4 to 5 minutes after the slow walk, which could again have mimicked 
the light exercise condition.  
 
For some of the more severe patients, unloaded pedalling would cause greater exertion than the 
milder patients and so in these cases, the analysis of unloaded rather than loaded cycling would have 
been more accurate in terms of looking at the immediate breathing response to exercise. Overall, it 
would have been better to have asked the patients to go straight from rest to loaded pedalling to 
reduce the possibility of error here.  
 
The number of patients studied for the walking modality was very small. More patients could be 
studied to generate more data. Each patient could also be studied several times to see if the 
breathing response is reproducible in each patient, or if other factors could influence it, such as a 
training effect, anticipation, length of rest period between walks, or the effect of walking on different 
days or walking outside. For instance it is known that in a standard six minute walk test, 
encouragement increases the distance walked [326], and so might also have an effect on breathing 
pattern. In this protocol, there was a short period between the slow and fast walks of around 5 
minutes, but a longer period may be necessary in this patient group.  
 
It should also be noted that the patients wore a mask during the walking tests, as opposed to a 
mouthpiece during the CPET. The experiment could be repeated with a mask during the CPET to see 
if this influenced breathing pattern, particularly during rest.  
 
A much more standardised protocol where factors such as anticipation are controlled for should have 
been employed. In terms of physical activity monitoring, this should have been done as close to the 
time of exercise testing as possible in order to draw any valid conclusions about the relationship 
between daily physical activity and early breathing response on exertion. Both quantity (total steps, 
vector magnitude etc) as well as intensity (time spent in moderate or vigorous physical activity) should 
be measured to see which measure is most closely linked, if at all, with the early breathing response.  
 
No data was collected about resting pulmonary mechanics, which would have been useful since this 
has been previously reported to be related to the ventilatory response to exercise, including by Marin 
et al. Employing the oesophageal balloon technique to measure intrathoracic pressure changes on 
exertion would be valuable to do in future studies, and again, to investige any link with daily physical 
activity levels.  
 
The results of this study illustrate the complexity and variability of the breathing response to exercise 
initiation in COPD, and that much more controlled conditions are required for a meaningful analysis in 
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this population. However, to link this response to actual daily physical activity may merely serve to 
introduce yet more variables into an already complex phenomenon; preliminary data at least failed to 
show a link between respiratory pattern and daily PA. Nevertheless, a greater understanding of this 
response may help to better support patients during pulmonary rehabilitation which is known to 
influence morbidity significantly, over and above drug therapy. If patients could be taught to control 
their breathing in such a way as to improve exercise performance, this would serve not only to 
increase exercise capacity, but also could improve quality of life. They key would be if any such 
intervention did increase daily physical activity. 
 
 
7.5 Future research 
 
7.5.1 Change in PRO over time 
 
The next major work that needs to be completed is analysis of how the scores of the final versions of 
both PROs change over the 1 year follow up period, and whether the results are similar to those 
obtained with the activity monitor data alone. If the PROs are responsive to change over time, this 
would strengthen them as a tool for further use in COPD in both research and clinical contexts.  
 
7.5.2 Physical activity as an interventional therapy 
 
There is now a comprehensive understanding of the importance of physical activity in the course of 
COPD, but interventions remain sparse. Although pulmonary rehabilitation is an effective intervention 
in COPD in terms of improving self-efficacy and symptoms, there is little evidence that it can produce 
sustained increases in daily physical activity levels. There is a need for an effective alternative which 
serves both to replace pulmonary rehabilitation for patients unable to access a local programme, and 
as an additional therapy which enables patients to increase their daily physical activity levels in the 
long term. Future research must therefore be targeted at novel interventional therapies aiming to do 
just this. 
 
To that end, and building on the work already accomplished by the PROactive project with validation 
of physical activity monitors and formulation of draft patient reported outcome tools in COPD, the last 
study in the 6 year project is an interventional study (National Clinical Trials number NCT02158065). 
The intervention is a semi-automated home activity coaching tool delivered to patients via a tablet or 
smart phone in conjunction with a simple pedometer. Participants receive daily feedback regarding 
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the number of steps walked and whether they have achieved their daily goal. Physical activity before 
and after the intervention will be measured using two of the previously validated activity monitors 
(Actigraph and Dynaport); the daily PRO tool will also be validated during the study. If successful, the 
semi-automated activity intervention could be used as a therapeutic measure for patients following 
pulmonary rehabilitation (PR) as an adjunct to improve the duration of the beneficial effect of PR; or 
as an alternative to PR for those patients unable to easily access services, either due to resource 
issues or for clinical reasons, for example, following exacerbation, where a home based activity 
programme would be easier.   
 
7.5.3 Wider use of activity monitors – implications in public health 
 
Accuracy of measurement of physical activity in COPD is important as physical activity is a strong 
predictor of mortality [115]. However the devices used in the studies in this thesis cannot give real 
time feedback to patients regarding their daily physical activity. Feedback is important: several studies 
have shown that subjects receiving feedback from, for example, simple pedometers, are more 
successful in increasing their step counts and therefore physical activity, than those receiving only 
encouragement from investigators [340-342]. Therefore, when considering employing activity 
monitors on a larger scale, such as in public health initiatives to increase physical activity in certain 
target patient groups, including COPD, a more pragmatic approach may be needed. This would be to 
opt for a less complex device such as a simple pedometer which is easier to use and more cost 
effective on a larger scale. The more complex devices may be better suited to a research context.  
 
In fact, consumer technology is far ahead of research in terms of developing devices which are 
pitched at an affordable price point, are user friendly, able to give real-time feedback in terms of step 
count or calories burnt, and can be paired with one’s smartphone with free or cheap software. 
Examples include the Fitbit range of devices, the Microsoft Band activity tracker as well as numerous 
GPS-ready sports watches and other simple pedometers. Most current smartphones themselves now 
have integrated accelerometers and are able to track step counts and calories burnt, again through 
free or relatively cheap software.  A future direction of research would be to validate one or more of 
these commercially available devices in COPD and to then use them either in intervention studies or 
as an alternative to pulmonary rehabilitation.  
 
In a wider context, if validated, such technology could be used in other disease groups, and in public 
health initiatives to promote physical activity in the population as a whole. This would follow on from 
the findings of the recent WHO review which sites physical inactivity as a major modifiable risk factor 
in non-communicable disease throughout the developed world.  
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7.5.4 Further study of the ventilator response to exercise in COPD 
 
As already alluded to, this area warrants further work. In the study in this thesis, no relationship was 
found between breathing pattern in early exercise and physical activity. However a recent paper has 
followed up breathing pattern in COPD over a 4 year period and found that a more rapid shallow 
pattern of breathing developed over this time. This was defined by a reduced tidal volume for a given 
minute ventilation and was related to an increase in hyperinflation, a fall in FEV1 and persistent 
smoking over this period [343].  
 
Breathlessness is well recognised to be multifactorial in aetiology, including not only physiological 
factors such as dynamic hyperinflation, but also psychological aspects and increased neural drive and 
may explain the differing results of these two studies. 
 
The initial response to exercise must be studied during a stricter exercise protocol and should include 
measurement of intrapulmonary pressure. The kinetics of the VO2 response could also be analysed if 
a slightly different cycle exercise protocol was used with a shorter warm-up or unloaded pedalling 
phase. This gives an estimation of the rate of oxygen delivery against utilisation when moving from 
rest to exercise. Our group has shown accelerated exercise oxygen kinetics in COPD patients who 
have successfully undergone bronchoscopic lung volume reduction surgery and was associated with 
improved cardiovascular response to exercise [344]. A similar analysis could be done before and after 
the above interventional study discussed above to test for improvements in the exercise response 
after the intervention, and how this relates to daily physical activity. This may help to explain the 
incongruity between patients’ exercise capacity and actual physical activity levels.  
 
Breathlessness is multifaceted and all aspects must be addressed, including physiological and 
psychological components. Effective treatment of breathlessness in COPD (as well as in other chronic 
conditions such as interstitial lung disease, cardiac failure) is important to well being and quality of life 
as it the single most reported symptom of patients who want to be able to do more and feel less 
breathless. Simple measures such as applying a hand held fan to the face during exercise have been 
shown to be effective in reducing dyspnoea scores and improving exercise performance [345]. More 
recently, an integrated breathlessness service has been shown to improve quality of life scores and 
have an impact on mortality [346]. If patients can feel less breathless when being physically active, 
this is a potential mechanism to moderating disease progression in terms of improved muscle 
strength, reduced exacerbation frequency and reduced systemic inflammation.  
 
In conclusion, this thesis has explored several aspects of physical activity in COPD, from accurate 
measurement using various activity monitors, to changes in physical activity with time and climate, 
and an as yet unproven relationship between physical activity levels and changes in breathing in early 
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exercise. The importance of physical activity in the course of COPD is undisputed. They key issue of 
how to increase activity in COPD in sustained and meaningful way remains unresolved. Future 
research should be targeted at understanding how to overcome the barriers to physical activity, and at 
interventions which increase physical activity in patients with established COPD, as well as in the 
wider public as part of disease prevention.  
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